Experimental design of a novel target to isolate HCV monoclonal antibodies by Brice, Sophie
Brice, Sophie (2014) Experimental design of a novel 
target to isolate HCV monoclonal antibodies. PhD 
thesis, University of Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/14180/1/ThesisBrice.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
i 
 
 
 
 
 
EXPERI MENTAL DESI GN OF A NOVEL 
TARGET TO I SOLATE HCV 
MONOCLONAL ANTI BODI ES 
 
 
Sophie Brice 
BMedSci 
MSc 
 
 
School of Molecular Medical Sciences 
 
Thesis subm it ted to the University of Not t ingham for the 
degree of Doctor of Philosophy 
Septem ber 2 0 1 3  
ii 
 
Abstract  
 
Hepatitis C Virus currently affects up to 3% of the world’s population. 
There is no effective vaccine yet available and the natural immune 
response to infection is largely inefficient. Progress has been made in 
isolating several broad-acting neutralizing antibodies that target the 
viral envelope protein E2. However, a dominant element of the epitopes 
targeted is an overlap with the highly conserved CD81 binding sites. 
Various E2 constructs were investigated as possible targets to be used in  
phage display panning of a combinatorial library of the phagemid vector 
pComb3H. HVR2 deletion showed optimal exposure of the CD81 
binding sites and D535A disrupted known CD81 epitopes. A selection 
technique was designed to improve exposure of conserved sites on an 
E2 construct target molecule that disrupts CD81 epitopes while 
remaining conformationally correct. Optimisation of the screening 
methodology was used to assess the quality of enrichment of the library 
panning along with more efficient selection of specific clones. The 
approach adopted in this project isolated Fab clones specifically reactive 
to the protein target, one of which also showed preferential binding in 
acidic environments. Taken together, the information gathered on E2 
and the implementation of the phage display method described will 
contribute to more effective ways of isolating novel antibodies.  
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1 . I nt roduct ion 
1 .1 . Hepat it is C Virus 
There are at least nine different recognised hepatitis viruses: 8  human 
viruses designated as Hepatitis A-G and a Non-Primate Hepacivirus 
designated as NPHV. Despite the common nomenclature of the human 
viruses, they do not share common origins or phylogenies. The 
Hepatitis C Virus (HCV) belongs to the family Flaviviridae, which also 
contains the Dengue virus, Tick-Borne Encephalitis Virus (TBEV), and 
West Nile Virus (WNV). The term “flavi” comes from the Latin term for 
yellow. The prototypical member of the genus Flavivirus, the largest 
genus within the family Flaviviridae, is the Yellow fever virus. Many 
flaviviruses are insect or tick borne; HCV, however, is not. HCV was 
once the sole member of the genus Hepacivirus, until improved 
screening methods led to the discovery of more HCV-related viruses, 
expanding the genus. HCV is now the prototypical member of the genus 
Hepacivirus (Bukh 2011; Kapoor, Simmonds et al. 2011), which also 
contains the Hepatitis G Virus (HGV) (Simons, Pilot-Matias et al. 1995; 
Linnen, Wages et al. 1996) and the newly discovered Canine 
HepaciVirus [(CHV), recently reattributed as Non-Primate HepaciVirus 
(NPHV)] (Kapoor, Simmonds et al. 2011). Serological screening 
methods recently identified a novel equine hepacivirus that is very 
closely related to NPHV, shedding new light on the possible origins of 
the genus Hepacivirus and the historical host shifts by which the 
15 
 
hepaciviruses have crossed species barriers (Burbelo, Dubovi et al. 
2012).  
 
HCV is a human-tropic, single-stranded RNA virus comprising seven 
genotypic groups (1-7 with subtypes therein). Genotypes 1-3 are the 
most prevalent genotypes across the world, whereas genotypes 4-7 are 
restricted to smaller populations in Africa, the Middle East and East 
Asia (see Figure 1.2). The HCV genome is 9.6 kb, containing 10  genes 
encoding three structural proteins; core, E1, and E2; at least six non-
structural proteins; NS2, NS3, NS4A, NS4B, NS5A, and NS5B; and one 
protein, p7, which is not yet confirmed as being either structural or non-
structural (Figure 1.1). All HCV genotypes contain the same genes. 
Protein-sequence variation, however, can be as high as 30% among 
different genotypes (Okamoto, Kurai et al. 1992). 
 
Figure 1 .1  Hepat it is C Virus genom e and gene products ( Coln 2 0 1 2 ) . 
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All of the viruses in the family Flaviviridae are members of group-IV in 
the Baltimore classification system: they have a single-stranded, 
positive-sense RNA genome encoding a single polyprotein, which host 
and viral proteases cleave sequentially, producing functional proteins. 
The two HCV envelope proteins, E1 and E2, are homologous to the prM 
and E proteins in the TBEV and Dengue virus (Kuhns, Zhang et al. 
2002; Zhang, Chipman et al. 2003). HCV has an error-prone RNA 
polymerase that, combined with a high rate of viral replication, 
produces a great amount of sequence variation within parts of the 
genome. HCV is phenotypically robust to genetic variation, resulting in 
genetically heterogeneous within-host populations known as 
quasispecies. Despite the high degree of genetic variability, HCV 
proteins contain many highly conserved regions, suggesting functional 
constraints. The E1 and E2 proteins, for example, contain highly 
conserved regions as well as highly variable regions. The variable 
regions may help the virus to evade host immune responses (see Section 
1.6)(von Hahn, Yoon et al. 2007; Dowd 2009). 
 
1 .1 .1 . Epidem iology 
Prior to being identified as a new virus in  1989 (Choo, Kuo et al. 1989), 
HCV was implicated as an icteric virus exclusive of the previously 
identified hepatitis A and B viruses. Researchers created a cDNA library 
using Non-A Non-B Hepatitis (NANBH)-infected sera and 
reconstructed a novel RNA genome distinct from the host genetic 
17 
 
material and similar to the genomes of the flaviviruses. The newly 
characterised HCV virus (Houghton 2009) accounted for up to 90% of 
the NANBH virus group, which currently affects 3% of the global 
population and almost 200  million chronically infected individuals 
worldwide (WHO 2011). The main routes of HCV transmission today 
are intravenous drug use in the developed world and unsafe medical 
procedures in the developing world (Maheshwari and Thuluvath 2010).  
 
The source of infection is unidentified in up to 40% of HCV cases. 
Possible sources of HCV infection include needle-stick injuries and 
mother-to-child transmission during pregnancy or childbirth; 
infrequently, HCV can be transmitted sexually or through the sharing of 
personal items such as razors or toothbrushes (Prevention 2012). 
Widespread antischistosomal treatments carried out in Egypt from the 
1960s through the 1980s inadvertently spread HCV through the use 
inadequately sterilised needles (Pybus, Drummond et al. 2003; Mezban 
and Wakil 2006). The HCV infection rate in  Egypt climbed as high as 
28% in 1991 (Saeed, al-Admawi et al. 1991); more than 10  years later in  
2004, however, it had fallen to 10-13% (Mohamed 2004). The iatrogenic 
spread of HCV infection in Egypt resulted in the expansion of a 
previously rare variant, HCV genotype 4. Indeed, over the same period, 
iatrogenic transmission led to the expansion of HCV genotype 1b in  
J apan (Tanaka, Hanada et al. 2005) and HCV genotype 5b in South 
Africa (Tanaka, Kurbanov et al. 2006). Today, HCV genotypes 1-3 are 
18 
 
the most prevalent HCV variants worldwide; with genetically distinct 
populations dominating different regions (see Figure 1.2) 
 
Figure 1 .2  Global dist r ibut ion of HCV genotypes. 
The global dist r ibut ion of HCV genotypes is not  uniform . The genotype-specific 
challenges presented by different  HCV variants m ake t reatm ent  difficult . 
 
 
1 .1 .2 . Diagnosis 
HCV diagnosis comprises a number of different assay formats. A blood 
test for HCV developed in 1992 almost completely eliminated HCV 
transmission by blood transfusion (Wilkins, Malcolm et al. 2010). The 
most basic HCV diagnostic assay is the Enzyme Linked-Immunosorbent 
Assay (ELISA), which detects the presence of anti-HCV antibodies in 
blood serum. The ELISA is prone to false-positive results (AACC 2010), 
however, for individuals who have suffered an acute infection and 
subsequently cleared the virus, often sero-converting in the process, 
gaining HCV-specific antibodies. The antibodies persist in the sera of 
19 
 
seroconverted individuals, even if the virus is no longer present, 
resulting in false-positive ELISA results. An analysis of the ELISA 
signal-to-cut-off ratio can help determine if the presence of HCV 
antibodies is caused by an active infection or by a previously resolved 
exposure or an erroneous result (National Center for HIV/ AIDS 2013). 
False-negative results can result from low antibody titres or low 
sensitivity or specificity of the diagnostic test. The Recombinant 
Immuno-Blot Assay (RIBA) is a more expensive and specific test that 
has a lower false-negative rate than the ELISA-based tests. Despite its 
higher specificity, the RIBA still relies on the presence of antibodies and 
therefore cannot detect infections in individuals who have not 
seroconverted, representing up to 7% of acute infections (Heller and 
Rehermann 2005), nor can it distinguish with any certainty between 
current or past infections.  
 
The HCV Core-antigen test detects the presence of the viral Core protein 
in the serum (Lee, Peterson et al. 2001; Muerhoff, J iang et al. 2002). 
The Core antigen can be detected within days of the initial infection, 
unlike HCV-specific antibodies, which often take several weeks or 
months to appear in the serum. The Core antigen test can be combined 
with antibody-based tests to provide a more detailed assessment of the 
stage of the HCV infection (Shah, Chang et al. 2003; Laperche, 
Elghouzzi et al. 2005). 
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Once an infection is confirmed, it is important to assess the viral 
genotype and the amount of virus present in the patient (viral load). The 
viral genotype can affect the effectiveness of different treatments. For 
example, interferon and Ribavirin therapy successfully clears ~55% of 
HCV genotype-1b infections, whereas it clears ~85% of HCV genotype-2 
infections and HCV genotype-3 infections (Sy and J amal 2006). If a 
patient is known to be infected by HCV genotype 1, the treatment can be 
amended to include the drug Telaprevir, which increases the HCV 
genotype-1 clearance rate to ~75% in treatment-naive individuals 
(J acobson, McHutchinson et al. 2011). 
 
To assess the treatment effectiveness and the clearance of infection, it is 
important to know the change in viral load over time. Assays such as the 
real-time Polymerase Chain Reaction (qPCR) can directly detect HCV 
RNAs and, more importantly, can be used to estimate the amount of 
virus present in a sample. Viral RNAs in a sample indicate actively 
replicating viruses and thus confirm an active or on-going infection. 
Measurements of the viral load taken before, during, and after a 
treatment can show the effectiveness of the treatment, allowing timely 
decisions to be made about whether to continue, extend, or amend the 
prescribed drug regimen, saving unnecessary expenditures on drugs, 
related healthcare, and treating side effects. If the viral load becomes 
undetectable in a patient for 6 months or more following the cessation 
of treatment, the individual is said to have achieved a Sustained 
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Virological Response (SVR), at which point the relapse rate is below 1% 
(Pearlman and Traub 2011). 
 
1 .1 .3 . Prognosis 
HCV infections can be either acute or chronic. An acute infection may 
not manifest symptoms; however, failure to resolve an acute infection 
can lead to decades of chronic asymptomatic disease, progressing to 
cirrhosis, hepatocellular carcinoma (HCC), and extra-hepatic 
manifestations such as Sjörgen’s disease (Haddad, Trinchet et al. 1992) 
and mixed cryoglobulinaemia (Dammacco, Sansonno et al. 1993). The 
viral genotype interacts with many other factors to influence likely 
clinical outcome of an HCV infection, making it impossible to predict 
the clinical outcomes of HCV infections with any certainty. 
 
Less than a quarter of new HCV infections are estimated to resolve 
naturally (Nelson, Mathers et al. 2011), with the remaining infections 
becoming chronic. HCC develops in 1-3% of individuals sustaining a 
chronic HCV infection for more than 30  years (Goodgame, Shaheen et 
al. 2003), along with risk of liver failure and the need for a liver 
transplant (Wilkins, Malcolm et al. 2010; Rosen 2011). HCV infection 
increases the risk of HCC by promoting fibrosis, which can lead to 
cirrhosis. Once cirrhosis occurs, individuals have about a 1-4% chance 
annually of developing HCC (El-Serag 2002). With no HCV vaccine yet 
available, the costs associated with HCV are mostly related to the 
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treatment of infections and the secondary conditions resulting from 
infections.  
 
1 .1 .4 . Acute infect ion 
In-depth study of the viral population dynamics and host immune 
responses during acute HCV infection is limited by the difficulties 
inherent in  identifying patients during the acute phase of the infection. 
Early onsets of broad-acting and specific humoral and cellular immune 
responses are associated with the clearance of acute HCV infections 
(Lavillette, Morice et al. 2005; Pestka J . M., Ziesel et al. 2007). High 
viral serum titres generally appear a week or so after the initial 
infection, followed by a delay in the appearance of immune responses. 
Cellular responses appear approximately 1 month after the initial 
infection, whereas humoral responses appear as late as 2 months after 
the initial infection (Thimme, Oldach et al. 2001; Thimme, Bukh et al. 
2002; Major, Dahari et al. 2004). HCV titers begin to decline 8-12 
weeks after the initial infection, as the host antibodies start to become 
detectable (Figure 1.4) (Rehermann and Nascimbeni 2005). Many 
factors contribute to the delayed, and sometimes diminished, host 
response to HCV, with more yet to be identified. The delay in  the HCV-
specific immune response contributes to the high rate of HCV 
persistence after the acute-infection stage; the viral titre is very high and 
the viral population is very diverse by the time the host response 
becomes fully established, confounding the efficacy of the response. 
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Another characteristic impeding the resolution of HCV infections is the 
ability of HCV to replicate at different sites within the host. HCV can 
infect non-hepatic cells, raising the potential for viral reservoirs to 
persist after clinical clearance of the infection. Peripheral dendritic cells, 
granulocytes, B lymphocytes, and monocytes/ macrophages are some of 
the cell types known to harbour HCV. Lymphocytes have been shown to 
be permissive to infection in vivo and in vitro (Lerat, Shimizu et al. 
2000; Goutagny, Fatmi et al. 2003; Nowicki, Laskus et al. 2005; 
Radkowski, Gallegos-Orozco et al. 2005). Different HCV genotypes 
distribute non-randomly among hepatic and extra-hepatic 
compartments, supporting the hypothesis that HCV genetic diversity 
impacts on cell tropism (Kato 1998; Forton, Karayiannis et al. 2004; 
Roque-Afonso, Ducoulombier et al. 2005; Zehender, Maddalena et al. 
2005). Replicative forms of HCV RNA have been found in  the 
Peripheral Blood Mononuclear Cells (PBMCs) of patients whose liver or 
serum appears to be clear of the virus (Castillo, Rodriguez-Inigo et al. 
2005), allowing the HCV infection to persist in subsets of PBMCs long 
after clinical resolution of the infection. Thus, non-hepatic cells can act 
as true HCV reservoirs, confounding efforts to prevent the resurgence of 
viral titres in chronically infected patients and in patients receiving liver 
transplants (Pham, MacParland et al. 2004). 
 
Unabated, HCV replicates with a population doubling time of about 12 h 
(Dahari, Major et al. 2005), before slowing down significantly over 
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many weeks as host immune responses gain control of the viral titres 
(Figure 1.4). HCV can usually be detected in the blood by quantitative 
PCR about 1 week after the initial exposure (Group. 1999; Seeff 2002). 
The innate responses of hepatocytes slow the viral population-doubling 
time to about 7.5 days, reducing the rate of viral titre increase during 
the initial phase of the infection. Interferon I, plasmacytoid dendritic 
cells, and natural killer cells all act to slow the increase in viral titre 
during the first several weeks of the infection (Rehermann 2009). HCV, 
however, has multiple mechanisms to interfere with the signalling 
pathways of the innate-immune response (Polyak, Khabar et al. 2001; 
Ait-Goughoulte, Banerjee et al. 2010; Arnaud, Dabo et al. 2011). The 
best-known mechanism of HCV interference in  the innate-immune 
response is the cleavage of host MAVS or TRIF by viral NS3-4A to 
counteract the host signalling of RIG-I or TLR3, respectively, following 
the intracellular detection of viral dsRNA (Li, Foy et al. 2005; Meylan, 
Curran et al. 2005). HCV proteins can also phosphorylate the 
interferon-induced Protein Kinase R (PKR), inactivating translation 
factor eIF2ɲ, which normally facilitates the translation of antiviral 
Interferon Stimulated Gene (ISG) mRNAs (Garaigorta and Chisari 
2009). 
 
HCV has additional mechanisms to escape the adaptive-immune 
responses that occur later. HCV-specific T cells can be detected 5-9 
weeks after the initial infection (Thimme, Oldach et al. 2001; Thimme, 
Bukh et al. 2002; Cox, Mosbruger et al. 2005); however, it takes at least 
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8  to 14 weeks for serum Alanine Transaminase (ALT) levels, an 
indicator of liver damage, to peak and up to 6 months for enhanced 
cross-reactivity antibodies and increased neutralisation titres to appear 
(Logvinoff, Major et al. 2004). The combined innate and adaptive 
immune responses bring down the viral titres in acute infections by 
several orders of magnitude after 10  to 15 weeks (Figure 1.3A). Viral 
interference mechanisms such as E2 suppression of NK cells 
(Rehermann and Nascimbeni 2005) along with escape mechanisms 
such as surface exposed highly variable regions of the envelope proteins 
allow viral titres to persist by preventing the host immune mechanisms 
from effectively clearing the virus. Patients who fail to clear HCV 
infections have been shown to have a weak or functionally impaired T-
cell response (Thimme, Binder et al. 2012), possibly caused by 
regulatory T-cell suppression, lack of CD4+ T-cell cooperation, and viral 
escape. Persistent or chronic infection is a disease state in which the 
viral titre resurges periodically over many years, causing secondary 
conditions or remaining subclinical for decades. Consequently, 
prevention is much more effective in managing HCV infection than cure 
alone.  
26 
 
 
Figure 1 .3  Viral k inet ics in acute and chronic HCV infect ions 
The init ial 6-8 weeks following infect ion are often unnot iced, with m any factors 
cont r ibut ing to the developm ent  of an acute infect ion (A)  or  a persistent  
infect ion (B) , determ ined by the presence of HCV RNA despite ant i-HCV 
im m une responses. 
1 .1 .5 . Treatm ent  
The HCV genome is highly variable. There are, however, many highly 
conserved regions of the HCV genome, suggesting the potential for a 
universal HCV treatment. The large amount of genetic variation within 
and among HCV populations makes it difficult to manage and treat 
HCV infections. For example, patients infected by HCV genotype 2 or 
HCV genotype 3 are twice as likely as those infected by HCV genotype 1 
to achieve SVR following pegylated interferon and Ribavirin therapy 
(Simmonds 2004; Zeuzem 2004). The current HCV treatment options 
are expensive and have varying efficacies against the different HCV 
genotypes. Recently, the standard treatment for HCV genotype-1 
A 
B  
27 
 
infection was changed to a three-drug regimen of pegylated interferon, 
Ribavirin, and Telaprevir. The addition of Telaprevir compensates for 
the genotype-specific resistance of HCV genotype 1 to pegylated 
interferon and Ribavirin alone.  
 
1.1.5.1. Pegylated I nterferon 
The standard therapy for HCV infection over the past 10  years has been 
pegylated interferon and Ribavirin administered for a period of 24 or 48  
weeks. Interferon is a natural antiviral cytokine which exhibits 
improved biological activity when pegylated. Pegylation, the addition of 
a PolyEthylene-Glycol (PEG) moiety to a protein, allows the protein to 
associate with two or three additional water molecules, making the 
compound function as though it is 5 to 10  times larger than other 
soluble proteins of the same mass (Kozlowski and Charles S. 2001). 
Interferon ɲ has a mass of 19 kDa; the addition of a PEG moiety 
increases the actual mass to 31 kDa (Liang, Rehermann et al. 2000). 
The water shield around the pegylated compound helps protect the 
compound against enzymatic degradation, interactions with cell-surface 
proteins, renal clearance, and immunogenicity. The pegylated 
compound is thus more stable, especially across pH and temperature 
ranges (Monfardini, Schiavon et al. 1995). Clinically, pegylation 
increases the half life of the compound in the body about five fold, 
helping to increase and sustain serum concentrations, generating 
improved viral suppression, ultimately providing improved convenience 
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and better treatment outcomes for the patient (Kozlowski and Charles S. 
2001) (Glue, Fang et al. 1999). 
 
1.1.5.2. Ribavir in 
Ribavirin is an antiviral drug commonly used against the major cause of 
lower respiratory tract infections; the Param yxovirus: severe 
Respiratory Syncitial Virus (sRSV). Ribavirin, however, does not appear 
to have any direct effects on HCV. Moreover, when Ribavirin  is 
administered alone to patients with HCV infections, only the adverse 
side effects of the drug occur (Brok, Gluud et al. 2006). Ribavirin  
benefits HCV therapy when it is combined with pegylated interferon, in 
which case it reduces HCV reproduction in a dose-dependant manner, 
improving liver histology and quality of life for the patient (Davis, 
Esteban-Mur et al. 1998; Chander, Sulkowski et al. 2002; Fried, 
Shiffman et al. 2002; Flamm and Chopra 2012). The mechanism of 
Ribavirin action is unknown, although multiple hypotheses have been 
proposed. Ribavirin  is a nucleoside analogue hypothesised to inhibit 
Inosine-Monophosphate-DeHydrogenase, which causes a reduction in 
intracellular GTP concentration in vitro. The reduction in intracellular 
GTP concentration is thought to inhibit viral protein synthesis and 
replication (Streeter, Witkowski et al. 1973).  
 
Ribavirin also has immunomodulatory and mutagenic effects (Crotty, 
Maag et al. 2000 ; Tam, Ramasamy et al. 2000). Indeed, Ribavirin was 
previously thought to act as a chain terminator, but studies using Polio 
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virus proved otherwise. Crotty (2000) found that the mutagenic activity 
of Ribavirin correlates directly with the antiviral activity, leading to the 
catastrophe hypothesis of Ribavirin action (Crotty, Maag et al. 2000). 
RNA viruses generally tolerate a great amount of genetic variability, 
allowing them to exist as quasispecies. There is an intrinsic limit, 
however, to the amount of genetic variability that a viral population can 
sustain and still remain infective (Eigen 1971; Eigen and Biebricher 
1988). The loss of genetic fidelity eventually allows non-functional 
genetic sequences to accumulate within the viral genomes, and the 
virions lose the ability to successfully replicate and infect new host cells. 
The catastrophe hypothesis states that by acting as a mutagen, Ribavirin 
promotes the accumulation of deleterious mutations in the viral gene 
pool to the point where the viral particles can no longer successfully 
complete their replication cycle (Eigen and Biebricher 1988; Domingo 
and Holland 1994). 
 
Ribavirin has also been associated with the induction of ISGs, which is 
correlated with the speed of the virological response to subsequent 
combination therapy (Feld, Nanda et al. 2007; Rotman, Noureddin et 
al. 2013). A high level of baseline ISG expression in the patient 
correlated with a slow virological response to combination therapy. 
Ribavirin pre-treatment increased the change in ISG expression level 
induced by combination therapy when the baseline ISG expression level 
was low, leading to a more rapid virological response. Ribavirin  also 
induced interferon-inhibitory pathways more strongly when the 
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virological response was slow. Recently Ribavirin pre-treatment was 
shown to increase the induction of ISGs by pegylated interferon-
combination therapy, although there was no associated change in the 
virological response (Rotman, Noureddin et al. 2013). Altogether, many 
more details about the mechanism of Ribavirin action remain to be 
elucidated. 
 
1.1.5.3. Telaprevir  
Telaprevir improves the efficacy of combined Ribavirin and pegylated 
interferon therapy in patients infected by HCV genotype 1. In clinical 
trials, 72-74% of treatment-naive patients receiving Telaprevir alongside 
pegylated interferon and Ribavirin did not have detectable levels of 
HCV RNAs after 24 weeks of treatment, compared to only 55% 
undetectable viral RNA for those not receiving Telaprevir in the same 
drug regimen (J acobson, McHutchinson et al. 2011; Sherman, Flamm et 
al. 2011). Telaprevir is currently being tested further in phase-IV trials. 
Telaprevir demonstrated efficacy against HCV genotype 1 in a study of 
patients who either previously failed to respond, or responded only 
partially, to treatment or relapsed following the cessation of pegylated 
interferon and Ribavirin therapy (Melnikova 2008; Zeuzem, Andreone 
et al. 2011). The study consisted of two treatment regimens: 48 weeks of 
pegylated interferon and Ribavirin alone and 48 weeks of pegylated 
interferon and Ribavirin with the addition of Telaprevir for the initial 12 
weeks. Treatment with Telaprevir resulted in 6 times more positive 
virological responses in the previously null responders (31% versus 5%), 
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an increase of almost 3 fold for the previously partial responders (57% 
versus 15%) and more than 3 times more positive responses in  the 
relapsers (86% versus 24%). Taken together, this data shows strong 
support for the use of Telaprevir in  those for whom treatment has 
previously failed. 
 
The mechanism of Telaprevir action is thought to involve the inhibition 
of the HCV NS3/ NS4A protease, which is crucial for the viral life cycle. 
So far, the success of Telaprevir in treating HCV has been limited to 
HCV genotype 1. Telaprevir treatment outcomes are also influenced by 
host factors such as age (Sasaki, Matsui et al. 1997; Alter, Kruszon-
Moran et al. 1999; Bellentani and Tribelli 2001), ethnicity (Howell, 
J effers et al. 2000; J effers, Cassidy et al. 2004; Nguyen, Whittemore et 
al. 2004), and genetic polymorphisms near the IL28B gene (Clark, 
Thompson et al. 2010; Clark, Thompson et al. 2011). 
 
1.1.5.4. Drugs in development  
Boceprevir is a protease inhibitor that has undergone phase-III clinical 
trials (Bacon, Gordon et al. 2011; Poordad, McCone et al. 2011). SVR 
rates in  treatment-naive patients receiving pegylated interferon and 
Ribavirin for 28 or 48 weeks were improved by 28% when Boceprevir 
was added to the drug regimen (67-68% versus 40%) (Poordad, McCone 
et al. 2011). Boceprevir combined with pegylated interferon and 
Ribavirin  is also being studied in previously treatment-naive patients 
co-infected by HCV genotype 1 and HIV. Interim results at 24 weeks 
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showed twice as many patients were HCV RNA negative when also 
receiving Boceprevir (70% versus 34%), thus strongly demonstrating 
the effectiveness of adding Boceprevir to the treatment regimen for such 
individuals (Franciscus 2012). In another study of partially responded 
or relapsed patients infected by HCV genotype 1 (Bacon, Gordon et al. 
2011), those who received Boceprevir alongside pegylated interferon 
and Ribavirin  had SVR rates 3 times higher than without the addition of 
Boceprevir (59% & 66% versus 21%).  
 
Asunaprevir is a protease inhibitor currently in phase-II trials for the 
treatment of HCV (BMS 650032). HCV genotype-1 RNA levels dropped 
by more than three orders of magnitude in chronically infected, 
treatment-naive patients receiving Asunaprevir alone for 3 days 
(Pasquinelli, Eley et al. 2009; Pasquinelli 2012).  
 
Daclatasvir is an NS5A inhibitor currently in phase-III trials 
(BMS790052). Interim results at week 12 from a phase-II trial among 
treatment-naive patients receiving pegylated interferon and Ribavirin 
with or without Daclatasvir (20  mg or 60  mg) showed that of the 
genotype 1 infected patients, almost 4 times as many patients receiving 
Daclatasvir had undetectable HCV RNA than those not receiving the 
drug as part of their treatment regimen (54% versus 14%). Genotype 4 
infected patients however, showed either undetectable HCV RNA in 
58% of those receiving a low dose (20mg) of Daclatasvir compared to all 
of those receiving a high dose (60mg) thus highlighting the importance 
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of dose as well as drug combination (Hezode, Hirschfield et al. AASLD 
2011).  
 
In one study, Daclatasvir and Asunaprevir are being tested in  multiple 
combinations with other drugs and with one another in patients 
infected with HCV genotype 1 prior non-responders. Approximately 
90% of the study participants have an unfavourable IL28B allele. After 
24 weeks, all of the patients receiving Daclatasvir and Asunaprevir as a 
double therapy showed at least a four-orders-of-magnitude drop in 
HCV-RNA level, with 64% of the patients having no detectable HCV-
RNA level at the end of the treatment and 36% who showed SVR at 
week 12, maintaining SVR through to week 24. All of the patients 
receiving a quadruple therapy of Daclatasvir, Asunaprevir, pegylated 
interferon, and Ribavirin achieved SVR at week 12, with 94% 
maintaining SVR through to week 24. High HCV-RNA levels eventually 
returned, however, in  55% of all the patients receiving the double 
therapy, whereas high HCV-RNA levels did not return in any of the 
patients receiving the quadruple therapy (Lok, Gardiner et al. 2012). 
 
Sofosbuvir, a nucleoside analogue inhibitor of the NS5B RNA-
dependant RNA polymerase, is a very promising anti-HCV drug being 
tested in multiple phase-III trials (GS-7977). At least two studies looked 
at the efficacy of Sofosbuvir administered alongside pegylated 
interferon and Ribavirin, and at least two more studies looked at 
Sofosbuvir administered alongside Ribavirin alone. As part of the 
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Proton study undertaken in  2011, treatment-naive patients infected with 
HCV genotype 1 received a combination of Sofosbuvir, Ribavirin, and 
pegylated interferon for 12 weeks, followed by Ribavirin and pegylated 
interferon alone for another 12 weeks. At the end of the study, 91% of 
the patients had achieved SVR (Lawitz, Gane et al. 2012). A similar 
study looked at treatment-naive patients infected by HCV genotype 2 or 
HCV genotype 3, receiving Sofosbuvir alongside Ribavirin and 
pegylated interferon for 24 weeks. All of the patients in the study 
achieved SVR after 24 weeks (Kowdley, Lawitz et al. 2012). 
 
Drug monotherapies and combinations that do not include interferon 
are being investigated in the interest of reducing unwanted side effects 
while maintaining treatment efficacy. Sofosbuvir is a candidate for such 
studies, and some interim results have been published for its use with 
Ribavirin. In one study, 100% of treatment-naive patients infected with 
HCV genotype 2 or HCV genotype 3 who took Sofosbuvir alongside 
Ribavirin for 12 weeks achieved SVR without the blood abnormalities 
that can occur with other drug regimens (Franciscus 2012). In  one arm 
of the ELECTRON study, prior non-responder patients infected by HCV 
genotype 1 were administered Sofosbuvir alongside Ribavirin, but not 
pegylated interferon, for 12 weeks. Unfortunately, eight of the nine 
patients who initially achieved SVR at 12 weeks relapsed within another 
4 weeks (Gane, Stedman et al. 2012).  
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Altogether, the new drugs and treatment strategies currently in clinical 
trials hold much promise, although many difficulties and challenges 
remain. As the results of more trials are released in the coming months, 
a better outlook on which therapies hold the most promise will be 
possible. 
 
1 .2 . HCV life  cycle 
Since 2005, cell culture based methods have allowed the study of the 
full life cycle of HCV (Lindenbach, Evans et al. 2005; Lindenbach, 
Meuleman et al. 2005). From this, the life cycle of HCV has been 
described in the following steps summarised in the Figure 1.2: 
 
 1) Bin din g: non-specific followed by specific interactions 
between viral coat and host proteins allow attachment of the virus into 
the host cell surface (discussed in more detail later in section 1.2 . 
 2) En try/ Un co atin g: virion contents are released into the 
host cell cytosol. 
 3) Tran s latio n : HCV genome acts directly as an mRNA in 
its positive strand form, acting as a template to allow translation of a 
single long polyprotein initiated through an internal ribosomal entry 
site in the 5’ untranslated region. 
 5) Re plicatio n : Cytoplasmic membrane-associated 
replication complexes form in a perinulcear membranous web. In these 
complexes, transcription of negative strand RNA intermediates are 
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catalysed to then generate positive strand progeny RNA molecules (Rice 
2001; Egger, Wölk et al. 2002). 
 6) Asse m bly: intracellular membranes bud into the ER 
lumen to form cytoplasmic vesicles/ particles containing genomic RNA 
and capsid proteins. 
 7) Buddin g: the newly formed particles migrate through 
the lipoprotein secretion pathway. 
 8) Re le ase : the HCV particles are then transported to the 
plasma membrane, possible via an exosome or sorting body, before 
fusing with the plasma membrane to ultimately become an enveloped 
virion expressing viral and host coat proteins. 
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Figure 1 .4  Stages of the HCV life cycle  ( Chevaliez and Paw lotsky 
2 0 0 6 ) . 
.  
1 .3 . Entry 
HCV’s two envelope proteins; E1 and E2, form a non covalent 
heterodimer involved in binding and entry with target cells (Lavie, 
Goffard et al. 2007; Vieyres, Thomas et al. 2010). Across the 
Flaviviridae family, the larger envelope protein of a pair such as for 
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Dengue virus and TBEV: the corresponding E(2) protein, is larger in  
size and appears to have a more dominant role over prM (E1) in entry 
(Smit, Moesker et al. 2011). Indeed E2 is thought to be 
immunodominant over E1 for HCV (Youn, Park et al. 2005).  E2 of HCV 
has not been crystallised but a model has been proposed based on 
disulphide bridging and the related crystallised proteins prM and E 
(Krey, d'Alayer et al. 2010).  
 
Figure 1 .5  Schem at ic representat ion of the proposed st ructure of HCV 
E2  ( Krey, d'Alayer et  al.  2 0 1 0 ) .  
A)  The am ino acid sequence m odel depict ing the three dom ains as filled circles 
coloured:  yellow (Dom ain I I ) ,  red (Dom ain I ) , or blue (Dom ain I I I ) .  Disulphide 
bonds are also m arked as black links, green circles m arked as “N”  are the 
locat ions of the glycans and yellow filled circles of Dom ain I I  that  have red r im s 
m ark the proposed fusion pept ide. B)  A m ore recent  update of this m odel as a 
cartoon showing the general st ructure of the sam e 3 Dom ain colour coding 
(Keck, Xia et  al. 2012) . The three hypervariable sequence regions (HVR1, 2, & 
3)  are highlighted with blue r im m ed green circles and the C term inus is m arked 
with a purple star where the t ransm em brane dom ain would then begin. 
 
Envelope proteins serve to identify and bind with specific target 
receptors on a host cell membrane so that a coordinated entry process 
can follow. Flaviviridae envelope proteins E2 (HCV) and E (Dengue) are 
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glycoproteins that possess a 3 domain structure containing important 
binding sites. E2 is proposed to comprise of 3 domains followed by a 
transmembrane domain anchoring the protein into the viral envelope. 
Across the E2 protein are binding sites for various host cell receptors, 
some identified, and others not yet located. Host receptors CD81 and 
SRB1 are two such E2 targets that have at least part of the binding sites 
characterized as being discontinuous across the E2 protein (Bartosch, 
Vitelli et al. 2003; Owsianka, Timms et al. 2006). The CD81 binding site 
has been characterized to involve up to four regions, though one is 
debated, all across the central first domain (Owsianka, Timms et al. 
2006; Rothwangl, Manicassamy et al. 2008). SRB1 has also been shown 
to use conserved residues that are in close proximity to and also within 
a highly variable region that is located at the N terminus of the primary 
amino acid sequence of E2 (Bartosch, Verney et al. 2005). With more 
binding sites unknown, all of the E2 glycoprotein and E1 are still 
considered to be potentially involved in the process of binding and 
entry. 
 
 
Figure 1 .6  Linear  sequence representat ion of E2  
Start ing from  the N term inus residue 384 at  the left  hand side going to the C 
term inus at  the r ight  hand side. The Hyper-variable regions are depicted as 
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green boxes, CD81 binding sites as red boxes and the area containing SRB1 
binding determ inants m arked with an orange box.  
 
There are many details about the HCV entry process that have not yet 
been fully elucidated. Other flaviviruses such as Dengue virus (Modis, 
Ogata et al. 2004), WNV (Nybakken, Nelson et al. 2006), and TBEV 
(Rey, Heinz et al. 1995), however, with the aid of crystallized envelope 
proteins, have a fully characterized entry process and so are good 
references for likely mechanisms to be found in HCV. There are 9 main 
steps to flaviviral entry as reviewed by Smit  (Smit, Moesker et al. 2011) 
outlined below: 
1) Circu latio n : HCV virions are transported around the host 
in the bloodstream either as Lipo-Viro-Particles (LVP) 
or as empty nucleocapsid free sub-viral particles 
associated with apoB and complexed with antibodies to 
the envelope proteins of HCV. The LVPs  consist of 
triglyceride rich lipoproteins (LDL and VLDL), 
associated with fully infectious virions (Bassedine, 
Sheridan et al. 2012) 
2) Adhe s io n : When the viral particle first comes into 
proximity with a target cell there are weak interactions 
with the negatively charged glycosaminoglycans, such as 
heparin sulphate, that are abundantly expressed on 
cells. These low affinity attachments allow virus to 
concentrate at a cell surface. 
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3) Bin din g: Specific interactions can then occur between the 
envelope proteins of the virus and co-receptors found 
on the cell e.g. Laminin Receptor binding to Dengue 
Virus E protein (Thepparit and Smith 2004). 
4) En do cyto s is : Formation of a receptor complex triggers 
the formation of a clathrin coated vesicle by endocytosis 
to internalize the virus into the cell. 
5) De live ry: The virus-containing endocytic vesicle migrates 
to deliver the virus to an early endosome. 
6) En do so m e  Maturatio n : It must be noted that the 
subcellular compartment in which fusion occurs is most 
likely reliant on the pH-dependant membrane fusion 
properties of the virus in question. The early endosome 
carrying the virus can at this point mature into a late 
endosome. 
7) En ve lo pe  pro te in  m o le cu lar chan ge s : Reaching a pH 
of 5-5.5 in the endosome triggers multiple effects in the 
viral envelope protein including dissociation, and 
energy releasing conformational changes that allow 
exposure of the fusion loop. 
8) Fus io n  lo o p in se rtio n : Fusion is initiated by the 
insertion of the fusion loop in the viral glycoprotein into 
the outer leaflet of the endosome membrane. 
9) Po re  fo rm atio n : A fusion pore is formed which can then 
enlarge to allow- 
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10) Nucle o caps id re le ase : The virion contents can now 
enter the cytosol of the target cell to initiate replication. 
 
The entry process of HCV is thought to occur via a similar order of 
events to the other flaviviruses described, however some distinct 
differences have already been identified as HCV is functionally different. 
Firstly, unlike other flaviviruses HCV is transported through the 
circulation of the host by association with apolipoproteins. Once HCV 
reaches a target cell it can adhere to Low-Density-Lipoprotein-
Receptors or the glycosaminoglycan chains of cell surface proteoglycans 
(Helle and Dubuisson 2007). Once the virus has reached a target cell, it 
is in closer proximity to cell surface expressed receptors with which 
specific interactions can occur. The first receptor to become involved 
with the HCV envelope proteins is Scavenger Receptor class B-1 (SRB1), 
followed by addition of the host tetraspanin receptor CD81 which both 
bind to E2 to form a receptor complex (Ziesel, Fofana et al. 2011). Two 
more receptors Occludin and Claudin-1 are also recruited. This is 
followed by the formation of a clathrin coated pit (Evans, von Hahn et 
al. 2007; Ploss, Evans et al. 2009).  Entry determinants have so far been 
indentified for CD81 with particular focus on residues G530 and D535 
(Drummer, Boo et al. 2006; Owsianka, Timms et al. 2006). Indeed the 
importance of residues 530  and 535 of E2 are highlighted by their 
critical role in the epitopes of several broad acting anti-E2 antibodies. 
Formation of a vesicle by endocytosis and a drop in pH to around 5 is 
finally followed by fusion of the host and viral membrane to release the 
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virus particle contents into the cytoplasm of the cell where replication 
then occurs (Blanchard, Belouzard et al. 2006). 
Conformational changes are thought to occur in the envelope proteins 
of HCV in the entry process (Tscherne, J ones et al. 2006), in a similar 
fashion to that which occurs for HIV and Dengue virus (Smit, Moesker 
et al. 2011) (Sattentau and Moore 1991). The purpose of such alterations 
in conformation is to aid proximity of functional regions to their targets 
e.g., Dengue virus bending within the E protein to draw the viral and 
host membrane into contact for fusion. Conformational changes in 
envelope proteins can result in exposure of functionally important sites. 
An example of this is the interaction of HIV gp120 and host CD4 
receptors, after which the binding site for CCR5 is unveiled  from 
behind variable loops of viral gp120 to allow binding (Sattentau and 
Moore 1991). 
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Figure 1 .7  Cartoon depict ing the steps involved in HCV entry. 
Beginning at  stage 1 where virus is t ransported associated to LDL, adhesion to 
GAG and LDLR that  allow stage 2 to occur where specific cell receptors interact  
with E2. Stage 3 is the recruitm ent  of further cell surface receptors leading to 
form at ion of the endocyt ic vesicle result ing in stage 4 where vir ion contents are 
released into the host  cell cytosol (Edwards, Tarr et  al. 2012) . 
 
1 .4 . I m m une Evasion 
Viruses often conceal important binding sites on the envelope proteins 
to shield and protect them from antibody targeting. Solvent exposed 
regions of envelope proteins can possess important mechanisms of 
immune evasion such as glycan shielding (Helle, Vieyres et al. 2010) 
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(also reviewed in  (Helle, Duverlie et al. 2011)) and sequence diversity 
(von Hahn, Yoon et al. 2007; Dowd 2009). To aid the concealment of 
central and functionally important regions of the envelope proteins, 
HCV is thought to use the glycan coat to physically obstruct anti viral 
access to precious regions. This mechanism is also adopted by other 
viruses like HIV and Influenza (Vigerust and Shepherd 2007). Initial 
work looking specifically at the function of the HCV E1E2 glycan coat 
has shown an improvement in immune response to E1 in the absence of 
glycosylation, thus supporting the notion that the glycan coat of HCV 
envelope proteins served as a shield (Fournillier, Wychowski et al. 2001; 
Liu, Chen et al. 2007). An additional mechanism in HCV immune 
escape is that the exposed parts of the envelope proteins consist of 
variable primary structure, resulting in variable secondary structure so 
that antibodies raised against these variable regions will be ineffective at 
clearing the mixed virus population that for HCV exists as a 
quasispecies. 
 
The nature of an RNA polymerase means it is often error-prone, 
especially in the absence of proof-reading activity, and thus promotes 
sequence variation in the proteins it transcribes. In the E2 glycoprotein 
of HCV there have been 3 regions of hyper-variability identified that aid 
escape from immune targeting (see Figure 1.2 ). These regions 
designated Hyper-Variable Region 1, 2 (HVR1 & HVR2), and 
Intergenotypic Variable Region/ IgVR (HVR3) reside in  domain 1, 
domain 2, and between domain 2 and 3, respectively (Wiener, Brauer et 
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al. 1991; Kato, Oostuyama et al. 1992; McCaffrey, Boo et al. 2007). 
HVR1 is a strong inducer of antibodies thus drawing the focus of an 
antibody response away from more conserved regions (Zibert, Schreier 
et al. 1995). Though antibodies raised against HVR1 can be neutralizing, 
their limited breadth means they are mostly ineffective against a 
heterologous species (Zhou, Shimizu et al. 2000). Clinical effectiveness 
of antibodies is reliant on cross-neutralizing activity to allow targeting 
of the mixed viral population existing in patients. The antigenic 
variation displayed in  the envelope proteins of the virus is a passive 
mechanism of immune escape. Another evasive mechanism exhibited by 
HCV is to spread the infection by cell-cell transmission through tight 
junctions thus avoiding circulating freely between cells where more 
antibodies roam (Timpe, Stamataki et al. 2008; Brimacombe, Grove et 
al. 2011). Consequently it has been shown that CD81 is not involved in 
cell to cell transmission of virus after an infection has been initiated 
highlighting that through this secondary route of transmission, virus 
evades extracellular exposure (Witteveldt, Evans et al. 2009; Jones, 
Catanese et al. 2010). This raises the importance of intracellular 
targeting of virus once an infection is already established to 
complement a given vaccine model. 
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1 .5 . I nt racellular  Target ing of HCV 
The first immune phase following infection with HCV is dominated by 
innate responses. This immediate phase is considered the period of time 
up to 12 weeks post infection in which large amounts of type 1 
interferon’s are normally produced by hepatocytes and dendritic cells 
(Hiroishi, Ito et al. 2008). The production of interferon’s in hepatocytes 
is initially induced as a consequence of detecting viral RNA. Briefly, 
pattern recognition receptors RIG-I and TLR 3 of hepatocytes recognise 
a polyuridine motif of the 3’ untranslated region of the HCV genome in 
the cytoplasm (Saito, Owen et al. 2008), and double stranded RNA in 
endosomes (Kawai and Akira 2008) respectively. Via adaptor molecules 
a signalling cascade is initiated that uses IPS-1, TRIF and allows the 
phosphorylation of NFʃB, IKKɸ & TNFR. These events lead to 
dimerisation of the transcription factor IRF3 which then translocates to 
the nucleus to activate transcription of interferon ɴ in synergy with 
NFʃB (thereby creating a positive feedback loop) (Rehermann 2009). 
HCV however has evolved mechanisms to obstruct this pathway as the 
viral proteins NS3/ 4A cleave TRIF and ISP-1 thereby blocking TLR3 
and RIG-I signalling (Foy, Li et al. 2005). 
 
Production of type 1 interferon’s from neighbouring uninfected 
hepatocytes subsequently occurs in response to IFN ɴ͘ Signalling via 
J AK/ STAT  pathways leads to production of PKR which inhibits 
translation of viral and host RNA, and production of IRF 7 which 
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induces IFN ɲ͕ collectively creating an antiviral state and thus 
preventing infection from HCV (Pflugheber, Frederickson et al. 2002). 
Yet again HCV proteins have evolved mechanisms of interference. HCV 
core protein inhibits STAT1 phosphorylation thus inhibiting signalling 
that leads to IFN ɲ production (Lin, Kim et al. 2006). Other cell types 
are also involved in  the production of type 1 interferon’s. Among 
dendritic cells there is a subset named plasmacytoid dendritic cells 
(pDC) which rapidly produce high amounts type 1 interferon’s in  
response to viral infection. Recognition of viral components and nucleic 
acids in these cells occurs via pattern recognition receptors TLR 7 & 9 
(Siegal, Kadowaki et al. 1999; Matsui, Connolly et al. 2009). Indeed the 
importance of pDCs and interferon production in viral infection is 
highlighted by a reduced frequency of pDCs and impaired interferon 
production by pDCs observed in the peripheral blood of chronic HCV 
patients (Kanto, Hayashi et al. 1999; Kanto, Inoue et al. 2004; 
Dolganiuc, Chang et al. 2006). Equally, an increased amount of 
conventional dendritic cells in acute infection is linked to clearance 
whereas loss in number of dendritic cells may increase risk of 
developing chronic infection (Wertheimer, Bakke et al. 2004). 
Responsiveness to pegylated interferon and Ribavirin  treatment in  HCV 
infection has been linked to expression of specific genes by gene 
profiling thus highlighting the importance of effective innate responses 
in clearing HCV infection (Chen, Borozan et al. 2005). Indeed DNA 
vaccines allow the induction of PKR to instigate cascades of interferon 
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inducible genes as little as two days post infection (Bigger, Brasky et al. 
2001). 
 
The production of cytokines following viral infection also allows cross 
talk between the innate and adaptive  system as cytokines such as 
interferons contribute to priming of T cells. Cells presenting viral 
peptide antigens in their MHC I molecules such as hepatocytes, can 
interact with CD8+ T cells, stimulates them  to produce IFN ɶ, 
stimulating neighbouring cells to inhibit HCV replication as part of an 
anti-viral state, or to lyse the infected cells via release of granzymes and 
perforins. 
 
The T cell response has been considered critical for clearance of HCV 
infection (Lechner, Wong et al. 2000; Thimme, Oldach et al. 2001). 
Indeed depletion of CD4+ T (Grakoui, Shoukry et al. 2003) or CD8+ T 
cells (Shoukry, Grakoui et al. 2003) has been linked to viral persistence.  
The detection of fully functional virus specific  CD4+ T cell responses 
that allow priming of CD8+ cells has also been linked to clearance of 
virus (Missale, Bertoni et al. 1996; Gerlach, Diepolder et al. 1999). More 
importantly, a temporal link has been made between the appearance of 
such T cell responses and the likelihood of achieving viral clearance 
(Cooper, Erickson et al. 1999; Lechner, Wong et al. 2000 ; Thimme, 
Oldach et al. 2001; Thimme, Bukh et al. 2002). Virus specific CD4+ T 
cells have been found up to 20  years after documented infection 
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(Takaki, Wiese et al. 2000), highlighting that it is not only B cell 
responses that are capable of being long lasting.  
 
There has been mounting evidence that B cell responses also contribute 
to HCV clearance and protection. Characterisation of one particular 
cohort of patients exposed to the same HCV inoculum showed a direct 
correlation between rapid induction of neutralising antibodies and 
clearance during the acute infection (Lavillette, Morice et al. 2005; 
Pestka J . M., Ziesel et al. 2007).  
Antibodies can also be used for intracellular targeting of virus. This has 
been successfully adopted for multiple viruses including the related 
West Nile Virus which has an entry pathway thought to reflect that of 
HCV (Irnai 1998; Zwick, Labrijn et al. 2001; Thompson 2009). Such 
antibodies target epitopes that are only exposed following 
conformational changes in  the viral envelope proteins that occur in the 
endosome. The same approach has recently allowed identification of a 
peptide inhibitor of the HCV related Dengue Virus that also binds the 
envelope protein specifically following molecular changes as a result of  
internalization into the endosome (Schmidt , Yang et al. 2010). With 
proof that antibodies can be used to target virus intracellularly for 
various viruses including related viruses to HCV, it could be a promising 
avenue of research for HCV. However, the molecular differences 
between these viruses and their entry pathways will need to be 
considered before applying methods successful for Dengue and WNV to 
HCV. For example, Dengue virus infects cells via surface expressed Fc 
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receptors which are not present on hepatocytes. Also, repeated infection 
with Dengue allows enhancement of infection due to the involvement of 
Fc receptors as an entry factor. Such a mechanism has not been 
observed for HCV and so intracellular factors to be targeted for HCV 
infection will need to be specifically involved in HCV activity. 
 
1 .6 . Kinet ics of the ant ibody response 
The dynamics of viral and host immune activity upon viral challenge 
can influence the progression and clearance of an infection. Normally 
the infection process consists of a burst of viral replication in the new 
host followed by a large production of specific antibodies that hopefully 
sequester the high viral titers. As the majority of HCV infections do not 
resolve, this scenario is not often the case. It has been observed that in  
acute infections of HCV, an early antibody response is mounted in some 
infected individuals that allows a more effective targeting of HCV in the 
host whilst the viral titers are low (Shimizu, Hijikata et al. 1994; Zibert, 
Schreier et al. 1995; Rosa, Campagnoli et al. 1996; Dowd 2009). 
Infections that become chronic can be characterized by a delayed 
antibody response (Ishii, Rosa et al. 1998; Pestka J . M., Ziesel et al. 
2007). The consequence of neutralizing antibodies only being produced 
when the viral titer has become high is that there is also a greater 
diversity in the heterogeneous viral population thus making any 
antibodies produced less able to broadly target the quasispecies present. 
Given the challenges that face the mounting of an effective immune 
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response to HCV infection, treatment with potently cross neutralizing 
antibodies would be more likely to succeed if administered before 
exposure to virus rather than after infection was established 
(Meuleman, Bukh et al. 2011). 
 
The administration of antibodies for managing viral infection is termed 
passive immunization and is used most commonly for the prevention of 
Hepatitis B, Tetanus, Varicella Zoster and Rabies following or preceding 
possible exposure (Keller and Stiehm 2000). The indication of 
protection from HCV infection using passive immunization was first 
observed retrospectively in 1987 following a double blind randomized 
study of the use of immune serum globulin between 1967 and 1970  
(Conrad and Lemon 1987). This study revealed that prophylactic 
administration of immune serum globulin (ISG) allowed a significant 
drop in incidence of clinical hepatitis. When looking specifically at non-
A, non-B hepatitis that is today known to consist of mostly Hepatitis C, 
there was still a significant difference between the test and placebo 
groups thus promoting the use of ISG prior to exposure. The same result 
was also demonstrated more recently following a retrospective study of 
the administration of human hepatitis B Immunoglobulin (Feray, Gigou 
et al. 1998). Research elsewhere has also demonstrated the ability of 
sera containing HCV-specific antibody to neutralize, prevent and clear 
infection in vivo (Choo, Kuo et al. 1994; Farci, Shimoda et al. 1996; 
Rosa, Campagnoli et al. 1996; Ishii, Rosa et al. 1998).  
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More recently, protection from HCV infection by passive 
immunotherapy has successfully been demonstrated in two animal 
models. Firstly, chimpanzees were given immunoglobulin preparations 
either containing or depleted of anti-HCV antibodies and then 
challenged with viral inoculum. Only the animal that was administered 
anti-HCV containing immunoglobulin demonstrated protection from 
infection by absence of detectable HCV RNA  over the full 58 week test 
period following challenge (Yu, Bartosch et al. 2004). The two control 
animals however demonstrated infection, with seroconversion 
occurring at weeks 9 and 11 post challenge. Similarly, an infection study 
with passive immunotherapy in human liver-chimeric mice 
demonstrated protection in 55% (5/ 9) of mice that received HCV 
immunoglobulin compared to 0% in the control group (Law, Maruyama 
et al. 2008). While presence of HCV RNA was initially detected shortly 
after challenge, these animals demonstrated successful clearance of 
infection despite being an immune-compromised animal model, thus 
owing the successful outcome to the administration of HCV IgG. Taken 
together, the demonstration of complete protection in the chimpanzee 
and clearance in the immune-compromised mouse indicates potential 
for success with passive immunotherapy in humans to prevent re-
infection following a liver transplant. 
 
Active immunisation however, involves the administration of viral 
material to induce a response in  the host. In 2005 a study distinctly 
showed the presence and involvement of induced neutralising sera in  
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the response to an accidental infection where the immune response, 
recovery and control of the HCV infection in humans was analysed in  
real time (Lavillette, Tarr et al. 2005). This study followed a nosocomial 
outbreak of HCV and thus was able to identify the normally hard to find 
spontaneous clearers along with tracing the immunological events for 
patients who did and didn’t resolve their infection. A key finding from 
this study was that the HCV specific sera were able to neutralise/ inhibit 
or facilitate in vivo HCV infection assays depending on whether the 
patient displayed an acute or unresolved infection by the end of the 6 
month test period. Correlation of the neutralising sera with patients 
who spontaneously cleared their infection demonstrated the 
neutralising capability of human sera in vitro as well as indicating the in 
vivo potential. The other important indication from this study was the 
kinetics of the neutralising responses in relation to the outcome of the 
infection. In agreement with Pestka 2007 and Dowd 2009 (Pestka J . M., 
Ziesel et al. 2007; Dowd 2009), the appearance of an early neutralising 
response following infection strongly correlated with the clearance of 
the virus whereas patients showing a delayed antibody response were 
much more likely to remain chronically infected. So, the natural course 
of disease in  humans promotes the need for neutralising antibodies 
immediately following (or prior to) infection to be able to effectively 
clear the virus. 
 
Disease management can involve the use of human specific sera 
administered as passive immunotherapy as a preventative measure 
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against possible infection. Two studies have employed this rationale for 
HCV and shown the potential for use of human HCV specific sera in  
preventing infection (Davis, Nelson et al. 2005; Schiano, Charlton et al. 
2006). Using purified antibody or polyclonal sera, these studies 
demonstrated the ability to reduce HCV RNA levels and induce high 
levels of serum antibodies following liver transplantation for chronically 
infected patients. Whilst the results weren’t absolute, they do reveal 
further potential for the application of antibodies in controlling HCV 
infection outcome. The natural need for antibodies in clearing HCV 
infection can be seen in humans unable to mount normal antibody 
responses such as the condition hypogammaglobulinaemia in which 
there is a deficiency of all classes of immunoglobulins (Bjoro, Froland et 
al. 1994). In these individuals it has been shown that the incidence of 
chronic HCV infection following exposure is much greater than in  
healthy subjects and the disease progression much more severe. From 
this background of studies and data, efforts have been employed to 
search for and identify several broad acting potently neutralizing 
antibodies that have potential for use in preventative passive 
immunization. 
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1 .7 . Neutralising Ant ibodies and epitopes 
Various methods and approaches have been employed in the search for 
neutralising HCV antibodies. The use of infected sera demonstrated the 
neutralising capacity of naturally induced antibodies in humans in  the 
response to infection (Lavillette, Tarr et al. 2005). Examples of potent 
broadly neutralising antibodies are the mouse derived AP33 and human 
antibodies AR3A, A8 and 1:7 which are all capable of acting against at 
least 5 of 6 genotypic groups tested (Owsianka, Tarr et al. 2005; 
J ohansson, Voisset et al. 2007; Law, Maruyama et al. 2008). The 
neutralising capacity of these antibodies has not been compared though 
they each have a varied activity profile, mostly showing the strongest 
neutralising potency against the world dominant genotypes 1, 2 and 3. 
All of these antibodies target the HCV envelope glycoprotein E2 with 
epitopes involving various discontinuous parts of the protein. This panel 
of antibodies shares a dependence on key residues for the binding of the 
important co-receptor for viral entry: CD81. The key involvement of 
CD81 in entry means the residues it binds to are thus highly conserved 
across all genotypes making antibodies that have these residues (G530  
and D535) in their epitope more likely to be broad acting. 
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Figure 1 .8  Linear representat ion of E2 , m arking the locat ion of 
epitopes for neut ra lising ant ibodies 1 :7 , A8 , AP3 3  and AR1 A. 
The dashed vert ical lines depict  the locat ion of the highly conserved residues 
G530 and D535 crucial for CD81 binding. 
 
CD81 is a key entry factor for HCV found on many cell types including 
human hepatocytes and some other cell types. During the entry process 
CD81 becomes part of the receptor complex with E2. The binding 
regions for the interaction between CD81 and E2 have been defined on 
both proteins. CD81 acts more precisely as a post attachment co-
receptor and so its involvement precedes fusion and any conformational 
changes in  E2 that might occur for it. The CD81 binding sites on the E2 
protein are comprised of a collection of residues spread across the 
central domain I grouped into three main regions designated as 
residues 474-492, 522-551 and 612-619 being CD81 binding regions I, II 
and III respectively (Roccasecca, Ansuini et al. 2003; Tarr, Owsianka et 
al. 2006) (see Figure 1.3 & Figure 1.5 ).  More recently however, it has 
been shown that it is only regions II and III that appear to be crucial for 
CD81 binding even though antibodies with epitopes involving the  first 
region compete with CD81 (Owsianka, Tarr et al. 2005; Rothwangl, 
Manicassamy et al. 2008). Linked to its importance in  entry, the CD81 
binding regions have been the most studied highly conserved region of 
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E2 and have produced the predominant portion of the broad acting 
neutralising epitopes. 
 
Current research has shown a predominance of broadly acting 
neutralising antibody to target CD81 binding regions. However this is 
not exclusive as there has been a most recent trend in research focusing 
on non-CD81 epitopes. Three groups have recently characterized novel 
broadly acting neutralising antibodies recognising novel epitopes (Sabo, 
Luca et al. 2011; Giang, Dorner et al. 2012; Keck, Xia et al. 2012). One 
study produced a set of these antibodies that did not block E1E2-CD81 
interaction but could potently neutralise virus in vitro (Giang, Dorner et 
al. 2012). Another group produced an antibody that could block soluble 
E2 binding to CD81 and SRB1 in a cross reactive manner whilst not 
being mapped to any of the binding residues for these receptors (Sabo, 
Luca et al. 2011). The antibodies studied were derived from phage 
display biopanning and myeloma-splenocyte fusions and so these data 
support the search for further novel non-CD81 binding site cross-
neutralising antibodies. 
 
1 .8 . Hyper- variable regions 
The conserved nature of the CD81 binding regions makes them ideal 
targets for antibody mediated neutralization. To help protect against 
this, the key CD81 binding residues are kept central to the E2 protein 
rather than being exposed on the most accessible surface reaches of the 
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upper domain II. According to the current proposed model of HCV E2, 
the most solvent exposed region of E2 is the second region of 
hypervariability (HVR2) representing residues 474-482 (Kato, 
Oostuyama et al. 1992). The first hypervariable region (HVR1), residues 
384-410, is mapped to the start of the E2 sequence where it forms the 
beginning of Domain I (Wiener, Brauer et al. 1991) (see Figure 1.2 ). The 
third hypervariable region which is also known as Intergenotypic 
Variable Region (HVR3/ IgVR) comprises residues 570-580 modelled to 
sit between domain I and III (McCaffrey, Boo et al. 2007). The location 
of these regions means they are easily accessible on the surface and thus 
are much more likely to be able to induce an antibody response than 
residues that are hidden in the core of the E2 protein.  
 
 Multiple viruses use the ploy of variable sequences to evade an effective 
antibody response or to draw away focus from important functional 
regions (Sattentau and Moore 1991; Wyatt, Sullivan et al. 1993; Gzyl, 
Bolesta et al. 2004).  HVR1 on the HCV E2 protein lies close to and 
among highly conserved residues that are involved in the binding of 
entry receptor SRB1 (Bartosch, Verney et al. 2005). Another functional 
region identified on the surface of the E2 protein is the fusion motif that 
is suggested to be residues 502-520  (Albecka, Montserret et al. 2011) 
and so hypothetically, in the tertiary structure is thought to lie in very 
close proximity to the HVR2, collectively forming the uppermost tip of 
domain II of E2 (see Figure 1.5). HVR3/ IgVR however has not been 
directly linked to any functional regions though neutralizing epitopes 
60 
 
have been identified in close proximity on either side of it in domain I 
and III. HVR3 also lies between the second and fourth putative CD81 
binding sites found in  Domain I and III respectively (Yagnik, Lahm et 
al. 2000; Roccasecca, Ansuini et al. 2003; Owsianka, Timms et al. 
2006) (see Figure 1.3 ). Bridging domain I and III, IgVR also lies close 
to a loop of the domain I that holds one of the Antigenic Region-3 
epitope containing areas (Law, Maruyama et al. 2008). On the other 
side of IgVR/ HVR3 is a section of domain III where the highly 
conserved cross neutralising linear epitope for antibody ALP98 can be 
found (Owsianka, Clayton et al. 2001; Clayton, Owsianka et al. 2002). 
Whilst neutralizing epitopes can also be found within these hyper 
variable regions, they are mostly if not all unable to cross neutralize 
efficiently compromising the likelihood of raising an effective immune 
response in vivo. 
 
One approach adopted in vaccine design is to remove/ delete obstructive 
non-functional parts of an immunogen to increase the chances of 
mounting antibodies against crucial conserved regions.  This approach 
has been tried out in HIV with various results. The use of recombinant 
HIV glycoproteins as a vaccine has shown some success in protecting 
against heterologous challenge in chimpanzees (Berman, Gregory et al. 
1990; El-Amad, Murthy et al. 1995; Berman, Murthy et al. 1996). 
Removal of specific variable loops of the HIV envelope protein gp120 
did not diminish virus function whilst also allowing an improvement in 
the induction of cell mediated responses, eliciting neutralising 
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antibodies, and improving exposure of neutralising epitopes/ conserved 
regions (Wyatt, Sullivan et al. 1993; Barnett, Srivastava et al. 2001; 
Gzyl, Bolesta et al. 2004). Though HCV and HIV are of different virus 
groups and families, they share the same problem of having highly 
glycosylated envelope glycoproteins that house multiple highly variable 
sequence segments that occlude functional conserved regions (Wyatt, 
Sullivan et al. 1993; Prentoe, J ensen et al. 2011). So, the results for HIV 
provide supporting evidence to the possibility of there being a similar 
result in HCV. So far, variable region deleted HCV envelope 
glycoproteins haven’t been tested for their function as immunogens in  
humans but their functional characteristics have begun to be looked at 
in recent years. 
 
Within the structure of HCV E2, the HVR’s are a candidate for removal 
to allow exposure of more central conserved regions such as the CD81 
binding regions. Few groups have removed the HVR’s in combination 
and singly to demonstrate that expression, secretion and antigenic 
profile are retained (Op De Beeck, Voisset et al. 2004; McCaffrey, Boo et 
al. 2007). Using a panel of cross domain conformational antibodies, 
wild type and triple deleted E2 (lacking HVR1, 2 & 3), showed minimal 
change in  the global and core structure with a slight improvement of 
binding noted for some antibodies used. Functional ability was assessed 
to not be changed by HVR removal after demonstrating no loss or great 
change in the ability to bind to the key host receptor used in entry; CD81 
(Roccasecca, Ansuini et al. 2003). The notion that deletion of HVR has 
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no or minimal detrimental effect on E2 structure or function has also 
been upheld elsewhere and thus has been an accepted conclusion (Op 
De Beeck, Voisset et al. 2004; Bankwitz, Steinmann et al. 2010). 
 
The full function of E2 however is not limited to its binding to CD81 as 
at least three other receptors are also involved in the entry process. 
SRB1 is another E2 binding receptor for which deletion of only HVR1 
has been tested. Testing of SRB-1 function has not been investigated as 
extensively as CD81 partly due to practical difficulties of producing 
soluble forms of SRB-1 that do not apply to CD81; which can readily be 
produced in a soluble form. The use of soluble SRB1 would allow more 
flexibility in the assays that can be used and also a quicker advancement 
of research into factors affecting SRB-1 and HCV E2 binding. Even so, 
without having tested any relationship with HVR2 or 3, only the 
relevance of HVR1 has thus been associated with SRB-1. Within HVR1 
on E2 are highly conserved single residues; some of which have been 
identified as being involved in SRB1 binding (Bartosch, Verney et al. 
2005). Initial research showed an inability of SRB-1 to bind E2 lacking 
HVR1 (Scarselli, Ansuini et al. 2002). More recently however,  in vitro 
produced pseudo HCV virus lacking HVR1 from E2 was able to bind 
SRB-1 expressed on cultured cell lines and the deletion of HVR1 did not 
affect the ability of virus to infect cells (Bartosch, Verney et al. 2005; 
Voisset, Callens et al. 2005). In the absence of HVR1, the rate of entry of 
pseudo particle virus was however reduced implying a secondary 
manner in which HVR1 might affect entry (Bartosch, Verney et al. 
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2005). Whilst HVR1 is not thought to be essential for  entry, it is 
influential in binding and the neutralising response in a genotype 
specific manner (Prentoe, J ensen et al. 2011) and so its effects on the 
rest of the protein still need further investigation. 
 
In a similar fashion, it cannot be ruled out that the remaining HVR’s of 
E2 could still exhibit direct or indirect effects on the protein or the entry 
process. Using genotype 2a virus cultured in vitro, HCV lacking HVR1 
was seen to be able to infect normally, however a lack of HVR2 or 3 
greatly reduced the virus’ infectivity (McCaffrey, Gouklani et al. 2011). 
To try and understand this difference, a comparison has been made 
between initial cell entry that is dependent on CD81 not requiring any 
HVRs, and a cell to cell route via tight junctions that bypasses the need 
for CD81 (Timpe, Stamataki et al. 2008; Brimacombe, Grove et al. 
2011). Data suggests cell to cell transmission of HCV is largely able to 
avoid antibody mediated neutralization that is otherwise effective before 
initial infection has occurred (Meuleman, Hesselgesser et al. 2008). So, 
whilst binding to CD81 or SRB-1 may not be greatly compromised by 
the removal of HVR’s, binding to other receptors involved in entry could 
be.  
 
1 .9 . Vaccine approaches 
 In the last 10  years there have been many clinical trials of preventative 
and therapeutic HCV vaccines. Therapeutic vaccines aim to 
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improve/ induce immune activity of an infected host to enable clearing 
of an infection or reduction of viral load to a sustained virological 
response. Recombinant-E1E2, expressed in Chinese Hamster Ovary 
(CHO) cells in MF59 adjuvant, is a vaccine candidate from Chiron Corp, 
which has been developed as both a preventative and later as a 
therapeutic vaccine when administered in combination with existing 
drug regimens (Colombatto, Brunetto et al. 2009). In a recent phase 1b 
clinical trial, the therapeutic vaccine E1E2-MF59 was shown to have 
minimal adverse effects and second phase viral load decay was 
improved in  those receiving the vaccine plus standard treatment with a 
viral median half life, measured from days 4-48, of 5.6 days compared 
to a half life of 10  days for those receiving standard treatment only. 
There were also  concomitant increases in neutralising antibody titers, 
in subjects receiving standard treatment plus the vaccine compared to 
standard treatment alone (Colombatto, Brunetto et al. 2009; Frey, 
Houghton et al. 2010). Alvarez-Lajoncheres group used a DNA plasmid 
vaccine encoding HCV structural genes, and a recombinant core gene 
named (CIGB-230), administered therapeutically to patients who had 
previously not responded to drug therapy (Alvarez-Lajonchere, Shoukry 
et al. 2009). Neutralising antibody and T cell responses were present in 
the majority of patients along with an improvement in liver histology 
and fibrosis. Although viraemia persisted, the positive results are 
encouraging as a method to improve the host’s ability/ chances of 
clearing infection. Intercell produced a vaccine IC41 consisting of 
synthetic peptides encoding various highly conserved T cell epitopes 
65 
 
(Klade, Wedemeyer et al. 2008). Initially this vaccine model tested 
therapeutically showed promise at phase 2 trials by inducing T cell 
responses but without reductions in viral loads the trials did not go 
further. So, the vaccine schedule was optimized and then a significant 
drop in  viral load was observed after only 4 months of treatment 
(Firbas, Boehm et al. 2010). Thus the vaccine IC41 provided proof of 
concept of using therapeutic vaccines specifically targeting T cell 
responses to contribute to the control of HCV infection.  
 
 
There have also been multiple preventative vaccines tested with varying 
degrees of success.  Stamatakis group also tested a recombinant HCV 
E1E2 vaccine for prophylactic use (Stamataki, Coates et al. 2007). They 
tested their vaccine in  guinea pigs and saw substantial production of 
antibody titers that could neutralise pseudoparticle infectivity as well as 
heterologous strains of cell cultured HCV at low levels. Chiron/ Novartis 
have also developed other prophylactic vaccine models based on 
ISCOMATRIX adjuvanted recombinant HCV proteins. In healthy 
humans a recombinant core protein vaccine induced anti-core 
antibodies and T-cell proliferative responses indicating good 
immunogenicity (Drane, Maraskovsky et al. 2009; Houghton 2011). 
Their other prophylactic vaccine model is a yeast derived fusion HCV 
polypeptide containing core and NS3-5 adjuvanted with ISCOMATRIX 
and was tested in  chimpanzees showing vigorous multi-specific T-cell 
responses but no clearance was observed (Houghton 2011). 
66 
 
 
Neither the B nor T cell response to HCV infection has been proven to 
be solely and independently deterministic of viral clearance. So, to 
complement the focus on antibody mediated clearance, multiple vaccine 
candidates have been developed that focus on the T cell response. 
Folgoris group developed a prophylactic T-cell genetic vaccine 
comprising the DNA of genotype 1 HCV non-structural genes NS3-5B 
(Folgori, Capone et al. 2006). This vaccine was tested on chimpanzees, 
which are known to resolve HCV more easily than humans, and were 
given replication-defective adenoviral-vector vaccine injections, 
followed by application of a brief electrical field to the site of injection 
(electroporation) to encourage uptake of plasmid DNA into cells. All but 
1 of the 5 vaccinated chimpanzees developed HCV specific CD4+ and 
CD8+ T-cell immune responses, and showed protection from acute 
infection from heterologous challenge. Whilst these findings are 
encouraging for the basis of priming T cell responses to aid clearance of 
acute infection in chimpanzees, they need to be supported in humans. 
 
Vaccine delivery by infectious agents has been an approach employed 
successfully for combating infectious diseases (Paglia, Medina et al. 
1998; Koesling, Lucas et al. 2001; Xie, He et al. 2007) and recently 
including HCV. Recently, a prophylactic prime boost strategy has been 
tested to induce both humoral and cellular responses in mice and 
macaques (Garrone, Fluckinger et al. 2011). The initial prime consisted 
of E1E2 containing recombinant adenovirus, following by a boost 
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consisting of virus-like particles pseudotyped with E2 and/ or E1. Multi-
specific T-cell responses and cross-neutralising antibodies were found 
in the test subjects. As with all data collected in non humans, further 
investigation would be needed in humans. Initial attempts at using 
attenuated Salm onella typhim urium  containing an expression plasmid 
for delivery of HCV core protein as a prophylactic vaccine approach saw 
immune responses to the expressed protein but not the viral DNA (Lia, 
Ren et al. 2007). Optimisation of the vaccine involved the inclusion of 
the envelope protein E2 gene in a separate expression cassette of the 
plasmid to allow immune responses and antibodies in response to the 
translation of both core and E2 genes (Cao, Chen et al. 2011). Purified 
immunoglobulin collected from the infected mice used in the study, 
were able to neutralise the infectivity of HCV pseudoparticles of 
autologous and heterologous cell cultured virus in vitro. To address the 
potency of the viral vector to be used in a prophylactic vaccine, Colloca 
and his group assessed more than 1000 adenoviral vectors for use in  
humans as a vaccine delivery model according to immunogenicity and 
potency (Colloca, Barnes et al. 2012). From this selection pool, two 
vectors were tested as HCV vaccine models containing non structural 
proteins  with the aims of priming the immune system in healthy 
human volunteers in a phase I trial  (Barnes, Folgori et al. 2012). The 
vectors induced HCV-specific T cell responses targeting multiple 
proteins as well as different genotypes that were sustained for at least 1 
year after vaccination. With these promising results, the ability to 
protect against HCV in vivo would be the next crucial challenge. 
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1 .1 0 . Glycoproteins as an I m m unogen 
Many vaccine models have been proposed for HCV including DNA 
vaccines, recombinant adenoviral vaccines and modified subunit 
vaccines. Each of these models show varying strengths for their 
potential in the human host (reviewed in (Torresi, J ohnson et al. 2011)). 
Initial data that provided support for the use of modified envelope 
protein as part of a vaccine formulation was provided by Choos group in 
1994 and Farcis group in 1996, who demonstrated that immunization of 
chimpanzees with a peptide vaccine based on the variable regions of 
envelope glycoprotein E2 could elicit neutralizing antibodies that 
prevented infection on subsequent challenge with autologous virus 
(Choo, Kuo et al. 1994; Farci, Shimoda et al. 1996). A multi-epitope 
immunogen based on the HVR1 region of E2 successfully demonstrated 
high titer antibody responses that could bind and inhibit HCV E1 and 
E2 of different genotypes (Torresi, Stock et al. 2007). Recently HVR1 
has been shown to provide a secondary immune evasive function. 
Having already observed the ability to induce antibodies inherently 
limited in breadth, HVR1 also shields cross neutralising epitopes in  the 
E2 glycoprotein (Bankwitz, Steinmann et al. 2010; Prentoe, J ensen et al. 
2011). Importantly, it has also been recently published that deletion of 
HVR1 from E2 increases the susceptibility to neutralization (Bankwitz, 
Steinmann et al. 2010). The implication of this latest research is that E2 
lacking HVR1 therefore has potential to induce greater antibody 
responses that will also be primed against more conserved neutralising 
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epitopes that might not be induced in the natural response to infection. 
The resulting antibody repertoire will thus have more chance of being 
able to potently cross neutralise and clear natural infection with HCV. 
With more research elaborating the role and influence of the HVR’s to 
be done and more results from the various clinical trials of vaccine 
candidates to be released, vaccine research for HCV is far from finished. 
Indeed a model of HCV E2 lacking all three hypervariable regions has 
already been patented for use as an immunogen vaccine(Burton and 
Law 2010) . 
 
1 .1 1 . Role of pH in entry 
Envelope proteins like E1 and E2 of HCV are often the mediators of 
fusion between viral and endosome membranes. Various studies have 
provided evidence for specific regions of E1E2 having distinct roles in 
entry: such as receptor-co receptor binding and fusion (Pileri, Uematsu 
et al. 1998; Drummer, Wilson et al. 2002; Rothwangl, Manicassamy et 
al. 2008; Haid, Pietschmann et al. 2009). Production of functional HCV 
glycoproteins has been shown to be dependent on both proteins as they 
act as chaperones for each other along the processing pathway 
(Choukhi, Wychoski et al. 1998; Bartosch, Dubuisson et al. 2003; 
Brazzoli, Helenius et al. 2005).  Fusion determinants have been 
identified on both E1 and E2 indicating a specific role for each of these 
envelope proteins within the fusion process (Drummer, Boo et al. 2007; 
Lavillette, Pecheur et al. 2007). The interdependence of E1 and E2 also 
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translates functionally as investigation of the relationship of E1 and E2 
in fusion indicates that E2 is essential for fusion to occur (Haid, 
Pietschmann et al. 2009), with E1 acting as  a companion protein 
(Yagnik, Lahm et al. 2000). Mutation of certain residues on E2 alters 
the kinetics of fusion with the effects differing according to whether 
residues are altered to a neutral or acidic amino acid (Haid, 
Pietschmann et al. 2009). This result supports two important notions. 
Firstly the importance highly conserved residues can have as the 
residues investigated by Haids group  for their involvement in fusion are 
highly conserved and centrally located within the E2 protein just like 
the key residues of the many neutralising epitopes in CD81 binding sites 
have been so far (Rothwangl, Manicassamy et al. 2008; Haid, 
Pietschmann et al. 2009). The second notion is that the effect of the 
polarity of residues involved in fusion illustrates a role for pH/ charge 
during or preceding fusion. Indeed it has been speculated that local 
hydrophobicity might induce rearrangements that have functional 
importance. So, just as receptor interaction can induce conformational 
effects in viral envelope proteins, alterations in pH/ charge could also 
induce functionally important effects. 
 
The entry process of HCV into the host cell involves the formation of a 
clathrin coated pit for endocytosis. It is the early endosome that HCV 
fuses with to release the contents of the virion into the host cell 
cytoplasm (Blanchard, Belouzard et al. 2006; Meertens, Bertaux et al. 
2006). Fusion for HCV has been shown to be pH dependant (Tscherne, 
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J ones et al. 2006; Haid, Pietschmann et al. 2009). Using the in  vitro 
pseudo particle model of HCV, pH change in  the endosome was shown 
to be crucial for fusion as preventing the acidification with drugs such as 
bafilomycin consequently blocked infection/ entry (Tscherne, J ones et 
al. 2006). In this setup the optimum pH for fusion has been observed to 
be pH 5.5 with a threshold of 6.3 (Lavillette, Bartosch et al. 2006). This 
finding is in line with other literature (Bartosch, Dubuisson et al. 2003; 
Hsu, Zhang et al. 2003; Lavillette, Morice et al. 2005) and pH 
dependant fusion events observed for related viruses in which pH 5-6 is 
also the optimum (Despres, Frenkiel et al. 1993; Corver, Ortiz et al. 
2000; Mukhopadhyay, Kim et al. 2003; Lavillette, Bartosch et al. 2006). 
In enveloped viruses exposure to acidic pH results in inactivation of the 
virus due to induction of irreversible conformation changes in  the 
envelope proteins. The structural changes imposed are normally 
necessary for the fusion of viral and endosomal membranes and so the 
timing of this conformational effect is thus important for the 
coordinated fusion process. Extracellular virions are resistant to low pH 
inactivation as HCV glycoproteins expressed on pseudo virions pre-
incubated in acid pH before application to cell culture showed no 
irreversible changes  or downstream effects in viral function (Meertens, 
Bertaux et al. 2006; Tscherne, J ones et al. 2006). From this, it is 
evident that more factors are involved for fusion. 
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1 .1 2 . E2  act ivat ion 
Viral envelope protein activation has been observed for viruses other 
than HCV for example the related Pestivirus: Bovine Viral Diarrhoea 
Virus (BVDV), which requires an activation step such as disulphide 
shuffling to become acid sensitive (Krey, Thiel et al. 2005). Indeed it has 
been postulated that a prolonged incubation at 37oC may be an 
activating step for HCV (Tscherne, J ones et al. 2006) as this is a 
necessary trigger that has been observed for the retrovirus ALV and 
Alphavirus SFV (Marsh and Bron 1997; Mothes, Boerger et al. 2000). 
Recently HCV neutralization has been shown to be affected by 
temperature and time-dependant binding (Sabo, Luca et al. 2012). The 
altered neutralising capabilities by antibodies following different 
binding incubations was seen to be a reflection of altered epitope 
exposure such that the incubation at 37oC for a prolonged amount of 
time allowed “virus breathing” to occur in  which differential exposure of 
epitopes can be seen. The concept of virus breathing is observed in other 
flaviviruses also in response to temperature incubations prior to 
infection (Lok, Kostyuchenko et al. 2008; Dowd, J ost et al. 2011). These 
data thus support that HCV E2 can be responsive to factors other than 
pH. Cholesterol and particle density are factors that have also been 
directly linked to HCV fusion (Lavillette, Bartosch et al. 2006; Haid, 
Pietschmann et al. 2009). Whether factors such as these would 
contribute as complimentary variables or as the missing sensitizing 
trigger for fusion pre-activation in HCV cannot yet be answered. 
73 
 
The full relationship between E2 conformation, pH and fusion is not yet 
fully elucidated as has been achieved for other viruses (Sattentau and 
Moore 1991; Modis, Ogata et al. 2004). Evidence for conformation 
changes in E2 in response to acid exposure has been found but no 
indication of the duration or any other conditions required was shown 
(Op De Beeck, Voisset et al. 2004; Keck, Li et al. 2005). E2 exposed to 
low pH prior to immunoprecipitation underwent drastic changes in 
global structure as the binding profile from a panel of conformation 
dependant antibodies was almost abolished. The association of E1E2 
was also affected by the low pH condition as almost 75% appeared to 
have dissociated (Op De Beeck, Voisset et al. 2004). These data showed 
definite conformational changes in at least E2 due to treatment with 
acidic pH. In these experiments E1E2 was acidified for 20  minutes at 37 
degrees Celsius and then neutralised to pH 7.5 from 5.5 before the 
immunoprecipitation indicating a permanent change occurred. 
Lavillette and Tschernes groups, both in  2006, supported this data by 
also showing temporary exposure of E1E2 to pH 5.5 with an incubation 
at 37oC allowed the necessary activation for fusion to occur which was 
not observed at 4oC (Lavillette, Bartosch et al. 2006; Tscherne, J ones et 
al. 2006). Tschernes study also showed extracellular HCV virion 
resistance to low pH despite the use of a 37oC incubation. An important 
difference between their two main observations however can be noted in  
the duration of the warm incubation at low pH for and prior to fusion. 
The apparent resistance to low pH was noted following a 10  minute 
incubation at 4 oC as opposed to a full hour at 37 oC where fusion did 
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occur raising the question of whether the results would have been the 
same had both incubations lasted a full hour or if a 10  minute 
incubation at 37 oC would also have allowed fusion to occur (Evans, von 
Hahn et al. 2007). If HCV were to be similar to SFV and ALV, than the 
activation trigger for low pH sensitivity may not be observed in such a 
short period as 10  minutes, whereas over 20  minutes at 37oC could 
allow it occur. Thus the time dependence observed in their study could 
be the duration of temperature incubation needed for activating HCV 
into a pH sensitive state. 
 
In summary, entry of HCV into the host cell is a pathway of which 
fusion is just one step. Fusion itself requires multiple 
conditions/ elements that haven’t all been identified yet. Temperature, 
time, low pH and conformational changes in E2 are elements already 
investigated as a prerequisite for fusion of the virus and endosome 
membrane. More research on these factors could allow development of 
new antiviral strategies as has been applied elsewhere. 
 
1 .1 3 . Target ing Fusion 
Many viruses undergo conformational changes in their envelope 
proteins as part of the entry process (Sattentau and Moore 1991; Smit, 
Moesker et al. 2011). This can allow exposure of functional regions such 
as binding sites or fusion motifs. Fusion determinants and motifs have 
been identified on E1 and E2 (Drummer, Boo et al. 2007; Lavillette, 
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Pecheur et al. 2007), and there is evidence for a pH responsive 
conformational change in the HCV glycoproteins (Op De Beeck, Voisset 
et al. 2004; Keck, Li et al. 2005). The identification of new conserved 
and functionally important regions of E2 should be considered for 
containing new epitopes that can be targeted as part of an anti-viral 
strategy. When the envelope glycoprotein of HIV, gp120, binds to the 
host CD4 receptor, conformational changes are induced that allow 
exposure of the highly conserved binding site for CCR5 (Sattentau and 
Moore 1991). In a similar fashion, conformational changes in HCV E2 
during the fusion process could allow exposure of conserved epitopes 
not normally accessible on the proteins surface. This concept has 
successfully provided a basis for anti-viral targeting where antibodies 
bind to the epitopes exposed after acidification and receptor binding 
induced conformational changes in the envelope proteins. These 
antibodies have successfully demonstrated the prevention of 
continuation to fusion in HIV (Zwick, Labrijn et al. 2001; Burton, 
Desrosiers et al. 2004) and the flavivirus West Nile virus (Thompson 
2009). These scenarios are thus proof of principle for the use of 
antibodies targeting epitopes linked to the fusion process as an anti-
viral strategy. So, in principle, antibody mediated inhibition of fusion 
for HCV could also be possible. Targeting epitopes that are involved in  
fusion or related conformational changes for HCV E2 could therefore 
provide an effective anti-viral strategy. 
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1 .1 4 . Ant ibody search m ethods 
Edward J enner first demonstrated the concept of vaccination by 
administering cowpox as a vaccine to prevent smallpox infection in a 
new individual. Today, advances in science and technology make it 
possible to produce and purify specific antibodies to use directly as 
passive immunotherapy. Immunologically competent mice can be 
induced to produce antibodies to HCV immunogens without 
succumbing to infection as murine hepatocytes are not permissive to 
HCV. Serum can then be collected and used experimentally to show the 
presence of antibodies from mice just as with sera samples from human 
infected individuals. This has been demonstrated by Lavillettes group in 
2005. Following a nosocomial HCV outbreak they were able to track 
where they observed the prevention of infection in cell culture due to 
the neutralising properties of the antibodies present in the sera 
(Lavillette, Morice et al. 2005). This set up however presents a limited 
source of unpurified and uncharacterized antibody. In 1975 the 
technology to create immortalized antibody producing B cells called 
Hybridomas was developed by Kohler and Milstein who went on to 
receive a Nobel prize for it in 1984. In this set up spleen or blood 
derived from mouse B cells are extracted  and treated with chemicals to 
encourage their “fusion” with myeloma cells to become immortal 
antibody producing cells/ factories (see Figure 1.6A).  With an eternal 
source of antibody it is then feasible to use binding assays to 
characterize the epitopes for such antibodies, test their neutralising 
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capacity and eventually clone the immunoglobulin genes using PCR 
technology to determine the genotype of these antibodies. Hybridoma 
technology has allowed the isolation and identification of murine 
antibodies H53, AP33 and ALP98: each of which are potently cross 
neutralising (Cocquerel, Meunier et al. 1998; Clayton, Owsianka et al. 
2002; Owsianka, Tarr et al. 2005). Non-human antibodies however 
need to be humanized to reduce their immunogenicity when 
administered to humans and so beginning with human antibodies 
avoids this complication. 
 
To overcome the need for species specific antibodies, adaptations have 
been developed to circumvent the need for human test subjects. Isolated 
murine immunoglobulin genes can be humanized by cloning so that the 
specific complementarity determining regions derived from mice 
immunoglobulin genes can be grafted into acceptor human antibody 
frameworks. This allows retention of the binding affinity and specificity. 
In the U.S nearly half of all Food and Drug Administration approved 
therapeutic monoclonal antibodies are humanized antibodies thus 
illustrating their safety and tolerance by humans (Marasco and Sui 
2007). Otherwise, transgenic mice that have their immunoglobulin 
genes replaced by a human locus can be immunised to express human 
specific antibody and so extraction of their antibody producing cells will 
naturally produce human antibody. This approach has indeed been 
successfully adopted for generating human antibodies against Severe 
Acute Respiratory Syndrome Coronavirus (SARS-CoV) and rabies 
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(Coughlin, Lou et al. 2007; Sloan, Hanlon et al. 2007). Another 
technique is the use of human antibody producing B cells that can be 
derived from infected patients and chemically transformed to be 
immortalized allowing the potential for an infinite source of human 
antibody: similar in principle to the traditional hybridoma but with less 
technical difficulty and time required. Single B cells can be isolated 
using blood samples, from which antibody containing supernatants can 
be tested for reactivity against a given target. From this, the B cell can 
be cultured to be immortalized, or the immunoglobulin genes can be 
cloned by extraction of RNA and reverting to cDNA so that genes can be 
introduced into new expression vectors. This approach has been 
adopted for HIV and Influenza to yield potently neutralising human 
monoclonal antibodies (Simmons, Bernasconi et al. 2007; Scheid, 
Mocquet et al. 2009). 
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Biopanning methods have also been developed that allow screening of 
large numbers of antibodies at the same time to isolate highly specific 
antibodies of high affinity to a given target such as an envelope protein 
of a virus (applicable as library selection/ screening as seen in Figure 
1.9). A great advantage of biopanning is the ability to “screen”/ check the 
binding of up to billions of different antibody variants at the same time 
and so this is a much more efficient set up for isolating specific 
antibodies. Several groups have used display technologies/ biopanning 
to isolate broad acting and potently neutralising antibodies against the 
HCV E2 protein in the last 10  years thereby supporting its potential 
(J ohansson, Voisset et al. 2007; Law, Maruyama et al. 2008; Perotti, 
Mancini et al. 2008; Giang, Dorner et al. 2012). 
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Figure  1 .9  I n vit ro m ethods of generat ing m onoclonal ant ibodies. 
A)  Ant ibody producing B cells can be derived from  im m unologically naïve or 
m ature individuals to generate a library for display plat form s such as phage 
display. The library is used to screen for ant ibodies specific to a given ant igen. 
B)  Otherwise B cells can be collected from  im m unized m ice ( t ransgenic or 
otherwise)  to form  hybr idom as to screen for product ion of specific ant ibodies. 
Likewise cells from  a naïve or infected individual can be cultured to produce 
m yelom a fusions to be screened just  as hybridom as. C)  Sera from  infected 
individuals can be t reated and screened to ident ify specific ant ibody producing 
B cells that  can be further used to isolate ant ibodies. D)  Non-hum an species 
specific ant ibody genes need hum anizing by cloning (Marasco and Sui 2007) .  
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1 .1 5 . Biopanning 
Biopanning is the process of affinity selection of peptides based on their 
ability to bind to a specific target. The technology to create libraries of 
peptides to select from allowed an advance in efficient screening en 
masse in different formats. In 1989 cloning of antibody genes allowed 
cloning directly from lymphocytes such that combinatorial or single 
domain libraries of variable heavy and light chain genes could be 
constructed (Orlandi, Gusow et al. 1989). At this point libraries of 
millions of different antibody clones could be made. These antibody 
clones can then be expressed on the surface of bacteria as antigen based 
fragment (Fab) and probed with radiolabelled antigen (Huse, Sastry et 
al. 1989). This set up allowed Fab to be selected and identified according 
to their ability to bind to a given target such as a viral protein. Display 
technologies superseded the previously traditional hybridoma for 
production and selection of antibodies by coupling screening of 
genotype with phenotype. This then avoided the need to be able to 
produce a fully functional antibody which was time consuming, 
expensive and not guaranteed to work, before then needing to assess the 
characteristics of all antibodies that were successfully produced. 
 
Possible platforms for the display of a given library of protein 
candidates can be; the surface of phage particles, complexed to 
ribosomes associated with mRNA, and cellular expression on microbial 
cells such as yeast (reviewed in (Hoogenboom 2005)). The different 
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platforms allow flexibility in the format of the proteins tested due to 
differences in presentation: phage particles for example display 
recombinant proteins as the protein displayed is fused with its own 
structural proteins. Microbial cell display however allows the use of 
native protein due to its expression on membrane surfaces. For 
screening and selection of antibody fragments, phage display is the most 
widespread as it is robust, simple to use and highly versatile. The 
selection process also holds high flexibility thus being advantageous 
over most other display platforms. A further advantage of using phage 
particles is that following biopanning, elution of the bound phage 
particle with its recombinant protein that contains the Fab can 
immediately infect new bacteria to begin a new cycle of expression. The 
first successful demonstration of this system to produce specific 
antibody was published in 1990 by McCaffertys group (McCafferty, 
Griffiths et al. 1990), and was quickly followed by more examples of the 
isolation of specific antibodies from different libraries (Barbas, Kang et 
al. 1991; Barbas, Björling et al. 1992; Barbas and Wagner 1995; 
Samuelsson, Yari et al. 1996; Tout and Lam 1997; Rader, Cheresh et al. 
1998).  
 
1 .1 6 . Phage Display 
Since the first application of phage display in 1990, it has remained a 
popular method, having been further developed and adapted. Recently 
the phage display platform of biopanning has been used to develop a 
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disulphide stabilized variable fragment (dsFv) as an improvement on 
Fab (J ia, Yu et al. 2008). The phage platform allows multi- or mono-
valent display, a large library size (10 10 to 1011), versatile scope and the 
ability to use the most formats e.g. scFv, Fab, dAbFab’2 and even the 
recently developed dimerized scFv known as a diabody. Thus, phage has 
remained the main choice of platform for biopanning (reviewed in  
(Hoogenboom 2005)). 
 
In the world of HCV antibodies, the majority of the prominent 
monoclonal broad acting neutralising antibodies have been derived by 
phage display biopanning in  a Fab format (J ohansson, Voisset et al. 
2007; Law, Maruyama et al. 2008; Perotti, Mancini et al. 2008; 
Mancini, Diotti et al. 2009). Until recently these phage display derived 
antibodies all had a common link of having epitopes focused on the 
CD81 binding sites with residues 530  and 535. Recently however one of 
these groups has successfully extended the application of phage display 
to pull out novel non-CD81 neutralising antibodies by optimizing the 
selection/ panning set up to favour epitopes in new areas of the E2 
protein (Giang, Dorner et al. 2012). Like the other studies, a purified 
glycoprotein was still the target for the panning. However, the available 
binding space on the surface of the target was specifically shaped by 
epitope masking as has been demonstrated elsewhere for isolating novel 
antibodies of defined specificities (Ditzel 2002; Tsui, Tornetta et al. 
2002). By capturing and masking the E1E2 target with antibodies of 
defined specificities, Giang and his group were able to ensure only 
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antibodies bound to the remaining “novel” space would be selected. 
Indeed novel antibodies were identified that did not compete with the 
previously identified and CD81 binding site residing epitopes that also 
demonstrated broad neutralising activity (Giang, Dorner et al. 2012). 
Whilst not blocking E1E2-CD81 interaction, the antibodies were 
potently neutralising at a pre and post attachment stage with the 
epitopes likely to reside in the third domain of E2, away from the 
identified binding sites for CD81 and SRB1. This recent data thus 
supports the use of the phage display platform for selection of novel 
cross neutralising epitopes on HCV E2. Indeed the groups that 
produced AR1-5 antibodies, 1:7, A8, L1 and the Fabs e137 and e20  all 
were derived using the phagemid vector set pComb3 (Barbas, Kang et 
al. 1991) of the M13 phage system. 
 
1 .1 7 . M1 3  
The most widely used phage vector for biopanning is the filamentous 
bacteriophage comprising fd, f1 and M13. These three phage species are 
so similar that they can be regarded as mutations of a single 
bacteriophage and so are often collectively referred to with the generic 
term M13 (Rasched and Oberer 1986), as will be done here. M13 
belongs to the Inoviridae family of viruses and has a 6407 base pair 
DNA genome in a single stranded covalently bound circle that encodes 
11 proteins (see Figure 1.7 & Table 1.1) (Day and Berlowitz 1977). 
Filamentous phage M13 is 7 nm wide and can be up to 2000 nm in 
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length. It has 11 different genes encoding proteins, each with a different 
role in the assembly and replication of the phage particle. 
 
 
Figure 1 .1 0  Schem at ic representat ion of the st ructure  of the M1 3  
phage part icle  st ructure  
Depicted are the various capsid proteins and the circular DNA genom e (adapted 
from  (Gao, Mao et  al. 1999) ) .   
 
 
Table 1 .1  Table list ing the 1 1  genes of M1 3  phage and the funct ion of 
the encoded protein.  
(adapted from  (Sm ith and Pet renko 1997)  
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The phage particle consists of a long shaft comprised of a helical array 
of up to 2800 monomers of the major capsid/ coat protein pVIII that 
encloses the circular single stranded DNA genome (see Figure 1.7) 
(Marvin 1998). The minor capsid proteins are clustered into two groups: 
one found at each end of the phage particle. Five copies of protein III 
and VI (pIII & pVI) are found at one end of the phage filament with the 
remaining capsid proteins pVII and pIX at the other (Grant and 
Webster 1984; Endemann and Model 1995). All other encoded proteins 
are involved in replication and assembly and so are the non structural 
accessory proteins such as pI and pIV which facilitate packaging and 
extrusion of the phage particle in co-operation with bacterial proteins. 
M13 phage infects male strains of Escherichia coli by pIII binding to the 
F’ pilus, resulting in retraction of pilus allowing translocation of the 
phage genome into the bacterial cell cytoplasm (Henry and Pratt 1969; 
Stengele, Bross et al. 1990). Replication then begins with bacterial 
enzymes synthesizing the complementary strand of the phage genome 
to form a double stranded supercoiled replicative form (RF) to act as a 
template for transcription. Translated capsid proteins migrate and 
integrate into the cell membrane while further ssDNA is formed for 
conversion to more RF. The cycle of replication and translation 
continues until the concentration of pV and phage specific ssDNA has 
become equimolar so that all the new molecules of ssDNA are 
associated with a monomer of pV. At this point formation of a new 
phage particle can start with the help of accessory proteins like pI and 
pIV. Mature capsid proteins displace pV and accompany the ssDNA out 
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of the bacterial cell enclosing the genome as the phage filament forms 
from the cell membrane outwards. Once the end of the ssDNA molecule 
has been reached the progeny phage particle terminates and separates 
from the bacterial host cell to be released into medium. This replication 
cycle thus provides multiple advantageous elements for use of M13 as a 
vector for cloned DNA. 
 
One such advantage conferred by the life cycle of the M13 bacteriophage 
is that the release of progeny phage is through the host’s membrane 
rather than disrupting it and so M13 is non-lytic phage. The 
consequence of a non-lytic life cycle is simplification of the isolation 
process of purified phage and preparations from supernatants being 
relatively free from contaminating proteins (Russel and Model 1988). 
Also, the lysogenic infection cycle allows each infecting bacteriophage to 
produce up to 1000 progeny from a single cell cycle thus very high titers 
of phage can be recovered from small cultures: up to 10 12 pfu/ ml. The 
replicative process and structural aspects of the progeny phage are 
dictated by the ssDNA phenotypically as well as genotypically. The 
capsid proteins do not dictate the morphology of the phage particle but 
instead their association with the genome means that it is the genome 
itself that dictates the shape and size of the phage. Consequently, the 
length of the genome determines the length of the phage filament as the 
length is a variable factor reflected by insertions of cloned DNA 
experimentally (Zacher, Stock et al. 1980). Furthermore, the capsid 
genes can tolerate insertion of DNA to still correctly express the protein, 
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and most importantly insertion into the N terminus of pIII or pVIII 
(McConnell, Uveges et al. 1996; Smith and Petrenko 1997). These 
protein regions are hydrophilic, located on the exterior of the phage 
particle and so as a result of this, recombinant proteins are displayed at 
the extremity of the phage surface ideal for affinity selection 
(Minenkova, Ilyichev et al. 1993). 
 
1 .1 8 . Phage library form ats 
Taken together, the features of the M13 bacteriophage life cycle have 
been used to display recombinant peptides fused to pIII (Bass, Greene 
et al. 1990; Cwirla, Peters et al. 1990; McCafferty, Griffiths et al. 1990; 
Barbas, Kang et al. 1991) or pVIII (Greenwood, Willis et al. 1991; Kang, 
Barbas et al. 1991) as a platform in affinity selection. The valency of pIII 
and pVIII on the bacteriophage particle confers restrictions on the 
application of M13 for affinity selection. A lower representation of pIII 
and thus any recombinant protein to be displayed allows affinity to be 
the property that is being selected for rather than avidity, which can be 
better selected with using the high valency representation of a 
recombinant protein VIII. So, with regards to biopanning in search for 
antibodies, gene III based libraries are the preferred choice over gene 
VIII peptide libraries that could be used for epitope mapping. Indeed 
the biopanning projects that produced the main HCV E2 neutralising 
antibodies mentioned previously all used gene III based libraries for 
their phage display (J ohansson, Voisset et al. 2007; Law, Maruyama et 
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al. 2008; Mancini, Diotti et al. 2009). However, in using phage display 
libraries containing relatively large recombinant antibody proteins 
hundreds of amino acids in size, rather than libraries of the much 
smaller peptides around 8 amino acids, a physical restraint has been 
met as large DNA inserts into gIII result in reduced infectivity and in  
gene VIII packaging is disrupted (Kang, Barbas et al. 1991; Iannolo, 
Minenkova et al. 1995). This has led to library format adaptations; 
double gene or phagemid libraries (see Figure 1.8). 
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Figure  1 .1 1  Classes of display vectors based in M1 3  
( adapted from  ( Sm ith and Scot t  1 9 9 3 )  and ( Gao, Mao et  a l. 1 9 9 9 ) .  All phage vectors contain funct ional genes I  and I I I -XI . Only the 
helper phage has a m utated gene I I  im pair ing its abilit y to replicate efficient ly. The inner yellow circle represents the genom e with relevant  
genes m arked out  in coloured boxes (blue:  gene I I I ,  green:  gene VI I I ,  pink:  fusion gene, grey:  gene I I )  and pink shapes as the fusion 
pept ides. All other sym bols are illust rated in Table 1.1.
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The double gene set up can be applied to gene III or gene VIII based 
libraries and are referred to as 33 or 88 respectively (see Figure 1.8). For 
these systems the expression plasmid encodes both the wild type phage 
gene 3 or 8 , along with another recombinant gene to express the desired 
fusion protein 3 or 8 . The advantage of there being a wild type gene 
alongside the recombinant version is to compensate for the loss of 
function observed when only the recombinant version is present. 
Having the two versions of the capsid gene present independently in the 
plasmid allows a degree of control over the induced expression of each 
depending on the promoter. The second approach to constructing an 
M13 library for large proteins is to use a second phage known as helper 
phage. This setup is also applicable to gene 3 or 8  libraries and is 
referred to as 3+3 or 8+8. In this setup the plasmid is known as a 
phagemid and encodes only one gene 3/ 8 that includes the protein gene 
to be displayed fused to the chosen phage capsid protein. To 
compensate for loss of function due to the large insert size, the fully 
functional wild type capsid gene is supplied via super infection with 
helper phage that is replicative impaired. The phagemid is thus unable 
to produce infective progeny in the absence of the helper phage, and the 
helper phage is unable to replicate efficiently resulting in preferential 
packaging of the phagemid genes. On the surface of the progeny phage 
particle will therefore be a mixture of wild type capsid proteins as well 
as the fusion protein. The advantage to the phagemid set up is that it is 
possible to culture, isolate and make bacterial stocks of the phage 
genome without producing fully infective phage. In 1991 a vector set for 
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3+3 phagemid called pComb was developed by Barbas’ lab (Barbas, 
Kang et al. 1991). Indeed the main neutralising HCV antibodies derived 
from phage display were using the pComb phagemid vector for display 
of Fab fused to capsid protein III (Allander 2000; Law, Maruyama et al. 
2008; Mancini, Diotti et al. 2009; Giang, Dorner et al. 2012). 
 
1 .1 9 . Directed select ion in biopanning 
The high through put nature of biopanning is merely one of many 
advantages over in vivo methods for the isolation of antibodies. The 
choice of reagents as well as the conditions imposed can also shape the 
attributes of the antibodies derived from biopanning. The repertoire of 
the library to be used in biopanning can vary according to whether it 
was constructed from an immunologically naïve individual or not, along 
with whether it was created from bone marrow or peripheral blood 
mononuclear cells. These factors will determine the prevalence of 
antigen specific antibody clones that can be retrieved from the library. 
One study constructed phage display libraries from donors who had 
been vaccinated against a “plethora of different bio-threat agents” to 
specifically enhance production of antibodies against otherwise 
uncommon antigens (Wild, Maruyama et al. 2003; Bradbury, Sidhu et 
al. 2011). Antibodies able to recognise epitopes on proteins from 
multiple  species have been isolated from a library derived from an 
immunologically naïve subject (Fellouse, Wiesmann et al. 2004; Liang, 
Wu et al. 2006). Conversely antibodies that distinguish between species 
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variants of antigens that differ by only one amino acid have also been 
derived from biopanning methodologies highlighting the functional 
flexibility (Ayriss, Woods et al. 2007). The affinity of antibodies can also 
be tailored by appropriate selection and screening protocols. 
Immunization of animals will typically produce antibodies via activation 
of B cells of limited affinity around 100 pM. The affinities of antibodies 
derived from in vitro display technologies however can reach as low as 
picomolar and femtomolar levels of antigen affinity (Boder, Midelfort et 
al. 2000; Hanes, Schaffitzel et al. 2000; Lee, Liang et al. 2004). 
 
The conditions of the selection process can define the requisite antigen 
conformation thus also affecting the possible antibodies that can be 
derived. Conditions that can be used for this are alteration of pH, salt 
concentration, modulators and presence of competitors (Bradbury, 
Sidhu et al. 2011). Competitors have been used by Parsons and her 
group in 1996 to specifically deplete an antigen pool of haemoglobin 
using high affinity antibodies to the adult form so that only fetal 
haemoglobin remained for the selection of fetal haemoglobin specific 
antibodies (Parsons, Earnshaw et al. 1996). Similarly, Giangs group 
most recently used competitive inhibition of their HCV E1E2 antigen 
target to focus the selection towards antibodies targeting novel areas 
(Giang, Dorner et al. 2012; Keck, Xia et al. 2012). Site directed 
mutagenesis of the antigen target to be used as bait during the selection 
process has also allowed antibodies to be isolated that specifically do 
not have problematic residues in the epitope they target. Most recently 
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this was demonstrated by Keck who used HCV E2 protein as the target 
antigen protein in which the Aspartic acid at residue 535 had been 
mutated to Alanine thus abolishing many previously identified 
neutralising epitopes containing this residue (Keck, Xia et al. 2012). 
 
 
The conformation of the chosen target antigen used in biopanning can 
also be modulated for a functional advantage. One study used small 
molecules to covalently lock a cell surface receptor specifically into the 
active/ on form to use as the antigen target in biopanning thereby 
allowing selection of antibodies highly specific for the active/ on form 
(Gao, Sidhu et al. 2009). The consequence for the antibodies selected 
was translated into the ability to probe cell surfaces for responses to 
various stimuli in the form of cell signalling. Likewise Watanabe was 
able to take advantage of limited conformational movement in the 
target antigen to confer a functional advantage in the antibodies that 
were isolated such that a specific dye fluorescence could be increased by 
up to 15,000  times upon antibody binding (Watanabe, Nakanishi et al. 
2008). 
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1 .2 0 . Aim s and approach 
HCV is a medical burden of the modern world. Limitations in the ability 
to identify and treat infection create a great need for novel preventative 
measures and treatments. There is still great potential in the current 
methods that have generated broad acting potently neutralising 
monoclonal antibodies. Adaptations to the choice of antigen target and 
screening protocol were investigated to use in phage display biopanning 
with the aim of identifying a novel neutralising antibody against HCV 
E2. A broad acting neutralising antibody against HCV would be most 
valuable for use as passive immunotherapy in liver transplant patients, 
in which there is a high re-infection rate (Charlton 2003; Brown 2005). 
Pre and post-exposure prophylaxis would also benefit from effective 
antibodies as the current HCV drug regimen especially following liver 
transplant can be poorly tolerated (Crippin, McCashland et al. 2002; 
Schiano, Charlton et al. 2006).  The main objectives of this project 
therefore were to; 
1) Produce stable, monomeric and antigenically correct E2 protein of 
various selective conformers. 
2) To assess the E2 form that could best allow selection of antibodies 
reactive to novel conserved epitopes in a biopanning format. 
3) Investigate pH status of E2 as a pre-requisite condition for any 
conformational effects in E2. 
4) Use the chosen E2 protein and defined conditions in phage display to 
isolate a novel specific neutralising antibody. 
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2 . Materia ls and m ethods    
2 .1 . Plasm ids 
A panel of 8  pMT plasmids containing a variety of codon optimized 
HCV isolate UKN2B2.8 glycoprotein constructs were kindly provided by 
Dr Thomas Krey and Dr Felix Rey (Institut Pasteur, Paris) (see Table 
2.1). Each E1E2 construct was terminated at residue 715 thus lacking the 
E2 transmembrane domain allowing secretion into culture supernatant 
following production. E1 was retained in the construct to allow optimal 
production and folding of E2 as E1 and E2 are thought to act as 
chaperones to each other during protein synthesis. In addition, each 
construct contained a C-terminal one strep tag for purification. 
 
In addition, a pMT construct corresponding to the HCV isolate 
UKN1A20.8 E2, truncated at residue 715 was provided by Dr Alex Tarr 
(University of Nottingham). Alanine replacement substitutions at 
positions G530 and D535 were made in  this plasmid. 
 
Table 2 .1  Panel of E2  constructs der ived from  tw o genotype st rains 
assessed as biopanning targets. 
 
UKN 1 A2 0 .8  UKN 2 B2 .8  
W ild Type E1 E2 - 7 1 5  Wild Type E1E2-715 Ʃ+95 
G5 3 0 A Ʃ+95 Ʃ+95 
D5 3 5 A Ʃ+95 Ʃ+95 
G5 3 0 A- D5 3 5 A Ʃ+95 Ʃ+95 
 
97 
 
 
Figure 2 .1 Diagram m at ic representat ion of the pMT plasm id form at  
conta ining the E1 E2 - 7 1 5  inserts of st rain UKN1 A2 0 .8  or  UKN 2 B3 .8 . 
The locat ion of the three hypervariable regions are illust rated along with the C 
term inal region and the st rep tag used for  affinity purificat ion. 
 
2 .2 . Site- Directed Mutagenesis 
Residues 530  and 535 of HCV E2 are crucial for the binding of CD81 
and pivotal for many neutralising epitopes previously identified. To 
allow selection of antibodies targeting non-CD81 region epitopes, these 
residues were mutated to alanine by site directed mutagenesis to 
disrupt any epitopes involving these residues. The commercial kit 
QuickChange site-directed mutagenesis (Strategene, The Netherlands) 
was used according to the manufacturer’s protocol. The E2 clone of 
genotype 1A20.8 was thus used to create a G530A clone, a D535A clone 
as well as a G530D535AA clone in addition to the original wild type 
plasmid using the respective mutagenesis primer described in  Table 2.3.  
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Table 2 .2  Site  directed m utagenesis prim ers used.  
All prim ers used were sense st rand reading. 
Prim er  Sequence ( 5 ’- 3 ’)  Nucleot ide 
posit ion 1  
1 - D5 3 5 As GGGTGAGAATGAAACGGCTGTTTTCGTCCTGAACAA 1928-1963 
2 - G5 3 5 As GGCGCGCCTACCTACAGATGGGCTGAGAATGAAACGGACGTT 1908-1949 
3 - G5 3 0 A- D5 3 5 As GGCGCGCCTACCTACAGATGGGCTGAGAATGAAACGGCTGTT 1908-1949 
1
 pr im er posit ion num bered according to H77 genome coordinates 
 
 
Figure 2 .2  Schem at ic representat ion of prim er locat ions ( according to H7 7  coordinates)  for  pr im ers presented in Table 2 .3 . 
Marked by red arrow within the H77 genom e fram ework.  
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Mutagenesis primers were synthesised by Eurofins MWG Operon* 
(Ebersberg, Germany) or DNA Technology A/ S (Denmark). Cycling 
parameters for the mutagenesis reaction were 95oC for 1 min, then 30  
cycles of 95oC for 1 min, followed by 55oC for 1 minute, and 65oC for 8 .5 
mins. The mutation reaction of G530A used both forward and reverse 
primers whilst mutation of D535A was successful using only one primer 
(*).  The creation of G530-D535A used the G530A plasmid and further 
mutagenesis using the single primer for mutating D535A. Resulting 
mutant clones were sequenced across the entire E2 insert using dye 
terminator sequencing methods (Amersham Bioscience) to verify the 
correct mutation and no others had been incorporated into the clone. 
 
2 .3 . S2  Cell culture 
The various pMT soluble E2 constructs were expressed in Drosophila 
Schneider 2 cells. Cells were maintained in Insect Xpress media (Lonza) 
by incubation at 28 oC in a controlled environment of 5% CO2 and 95% 
humidity (J ohansson, Drakenberg et al. 2007).  
 
Transfection was performed 24 hours following seeding 5x10 6 cells in a 
volume of 2.5 mls of Insect free Xpress Media with glutamine (Lonza) in 
one well of a 6 well plate (Immulons). The transfection reaction 
consisted of Fugene 6 transfection reagent (Roche) at a ratio of 3:2 ( 
Fugene µl : reporter DNA µg) according to manufacturer’s instructions, 
2 µg of reporter plasmid pMTE1E2, and 0 .1 µg of reporter plasmid 
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pCoBlast conferring resistance to the antibiotic Blasticidin per 
transfection reaction. After 48hours Blasticidin (Invitrogen) was added 
to the cells at a concentration of 25 µg/ ml and maintained for a period 
of 2 weeks to enable expansion of the Blasticidin resistant cell 
population. Following transfection, cells were maintained at all times at 
a concentration between 2x10 6 and 1x10 7 cells per ml of culture. 
 
Expression of soluble E2 was induced by incubating cells with 500  µM 
CuSO4 and continual shaking of cell cultures at ~105 rpm for a period of 
between 10  and 14 days. To recover expressed protein, culture 
supernatants were filtered through a 0 .2 µm membrane and then 
subjected to affinity chromatography using Strep-Trap columns (GE 
Healthcare), according to manufacturer’s instructions. Column fractions 
were assayed for total protein using the BCA assay (Thermo Scientific) 
and protein containing fractions were concentrated using 10  kDa size 
exclusion columns (Amicon) according to manufacturer’s instructions. 
The quality, conformation and purity of the protein produced were then 
verified by ELISA, gel electrophoresis followed by protein staining and 
Western blot. 
 
2 .4 . Protein quant ificat ion 
Two methods were used for protein quantification: the BCA assay 
(Thermo Scientific) and nano-drop spectrophotometer analysis. The 
BCA assay was performed according to manufacturer’s instructions, and 
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the test protein concentration in the sample was estimated by applying 
the resultant data to a regression equation produced from the values 
obtained for a set of protein standards. Regression analysis and 
estimations were performed using Excel (Microsoft Office 2007). To 
provide a second estimation of protein concentration, 2 µl of protein 
sample was quantified with a nano-drop spectrophotometer using the 
Beer-Lambert equation (absorbance value = extinction co-efficient x 
path length x analyte concentration). 
 
 
2 .5 . Ant ibodies 
Antibodies used in this study were human monoclonal antibodies A8, 
1:7 (J ohansson, Voisset et al. 2007) kindly provided by Mats Persson 
and the murine monoclonal antibodies AP33 and ALP98 provided by 
Arvind Patel (Owsianka, Tarr et al. 2005). The murine antibody H53 
was kindly provided by J ean Dubuisson (Cocquerel, Meunier et al. 
1998) and Mansun Law provided AR1A and AR3A (Law, Maruyama et 
al. 2008). Antibody specific to the strep-tag associated with the 
expressed E2, Anti-strep classic (IBA technology), was also used. 
All antibodies and their properties are summarised in Table 2.3.
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Table 2 .3  Sum m ary of all ant ibodies used in this study and 
inform at ion describing the epitopes. 
E2  ant ibodies and epitopes 
Ant ibody Epitope Neutra-
lising 
CD8 1  
com pe-
t it ion 
Broad 
act ing 
References 
Residues Form  
1 :7  523, 529, 
530, 535 
Confor-
m at ional 
Yes Yes Yes (Allander 2000;  
Johansson, Voisset  
et  al. 2007) 
A8  523, 529, 
530, 535 
Confor-
m at ional 
Yes Yes Yes (Allander 2000;  
Johansson, Voisset  
et  al. 2007) 
ALP9 8  644-651 Linear Yes No No (Owsianka, Clayton 
et  al. 2001;  
Clayton, Owsianka 
et  al. 2002) 
AP3 3  412-423 Linear Yes Yes Yes (Owsianka, Tarr et  
al. 2005) 
AR1 A 416-417, 
485, 538, 
540, 549 
Confor-
m at ional 
No No No (Law, Maruyam a et  
al. 2008) 
AR3 A 424, 436-
447, 523, 
530, 535, 
538, 540 
Confor-
m at ional 
Yes Yes Yes (Burton and Law 
2010) 
Ant i- tag St rep- tag Confor-
m at ional 
-  -  -  IBA 
H5 3  540-550 Confor-
m at ional 
No No No (Cocquerel, 
Meunier et  al. 
1998) 
 
2 .6 . SDS PAGE and W estern Blot  Analysis 
 To verify the size, stability and purity of the monomeric E2 proteins, ~ 5 
µg were run on a sodium dodecyl sulphate polyacrylamide 
electrophoresis gel (SDS-PAGE; NuPAGE NOVEX Bis Tris mini 10  % 
Gel, Invitrogen) for 60  minutes at 200  volts. The gels were either 
stained or used for Western blotting as described below. 
 
To visualise the E2 proteins and extrapolate size estimations relative to 
the marker ladder (Fermentas; Spectra Broad Range Protein ladder), 
Coomassie or silver staining was used. Silver staining was performed 
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using the reagents and protocols from Bio-Rad Silver Staining Kit. For 
the Coomassie Brilliant Blue Stain, the gel was shaken for 1 hour in  200  
mls of Coomassie Brilliant Blue stain made up as; 450  mls distilled 
water, 450  mls methanol, 100  mls glacial acetic acid and 2.5 grams of 
Brilliant Blue R 250 (Sigma), all filtered. Coomassie stain was replaced 
with destainer made up as 45% glacial acetic acid, 45 % distilled water 
and 10  % methanol and left for 1-2 hours changing destainer 3-5 times 
as necessary. 
 
For Western blot analysis, proteins present in PAGE gels were 
transferred on to a nitrocellulose membrane at 200  volts for 60  minutes 
in a Semi-dry conductor transfer cell (Bio-Rad). Following transfer, 
membranes were blocked on slow rock for 1 hour in 50  ml of 5% milk-
PBS Tween at room temperature. After 3 washes with 0 .05% PBS-
Tween, the membrane was probed with AP33 supernatant diluted in  
PBST 1/ 400 for 1 hour at room temperature. After 3 washes, 1/ 1000  
anti-mouse alkaline phosphatase (A2429, Sigma Aldrich), was added 
diluted in 0 .05% PBS-Tween and rocked for 1 hour at room 
temperature. The membrane was then washed thoroughly with PBS-
Tween and soaked in  BCIP/ NBT solution (Sigma FAST) for colour 
development on the membrane. 
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2 .7 . Enzym e Linked I m m uno- Sorbent  Assays 
2 .7 .1 .  GNA capture ELI SA 
Functional testing of the purified soluble E2 was achieved using a GNA 
capture enzyme immunoassay. Wells of a 96-well plate (Immulons) 
were coated with 100  ng/ well of Galanthus nivalis antigen  (GNA; 
Sigma), overnight at +4oC. Unbound GNA was removed and non 
specific binding sites were blocked for 2 hour with 200-300 µl of 5% 
milk-PBS Tween at room temperature. The plate was then washed 3 
times with PBS-Tween. Purified E2 sample was diluted 1:100  and 50  µl 
was added to each well of the plate, left at room temperature for 2 hours 
followed again by three washes in 0 .05% PBS-Tween. After washing, 
ǋORIǋJPOHLWKHU$DQG$3PRQRFORQDODQWLERG\GLOXWHGLQ
0.05% PBSTween was added to the wells for 1 hour at room 
WHPSHUDWXUH WKHQ ZDVKHG DV EHIRUH /DVWO\  ǋO RI DQWL-species 
immunoglobulin G (IgG)-Alkaline Phosphatase (Sigma) used at 1:5000  
diluted in 0 .05% PBS was added to the wells for 1 hours before 5 washes 
DQG DGGLWLRQ RI  ǋO RI %OXH-Phos microwell phosphalyse substrate 
system (KPL) and reading the plate with the micro-plate 
spectrophotometer at 620  nm (Molecular Devices V max plate reader). 
Protein samples that resulted in an OD reading of at least twice the 
negative control were considered positive. Depicted in Figure 2.2A. 
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2 .7 .2 .  CD8 1  binding assay 
The genotype 2B panel of soluble E2 constructs were tested to verify if 
they maintained the ability to bind CD81 protein. An ELISA 96 well 
plate (Immulons) was coated with 100  µl per well of 5 µg/ ml soluble E2 
protein diluted in carbonate bicarbonate buffer (Sigma) and left 
overnight at 4oC in a humidified box. The assay was continued as 
described in section 2.7.1 except the second incubation was with 
purified soluble CD81 LEL protein fused to a GST tag that had been 
added to the ELISA plate at 50  µl of 10  µg/ ml diluted in PBSTween . The 
plate was then covered and left at room temperature for 2 hours. All 
other steps were the same. Depicted in  Figure 2.3B. 
 
2 .7 .3 .  GNA capture t it rat ions 
Titrations of antibody or soluble E2 protein were performed in GNA 
(Galanthus Nivalis Antigen, Sigma) capture ELISA to assess the effect of 
HVR removal on epitope exposure. This assay was as described in  
section 2.7.1 and either the primary antibody or the E2 was titrated. E2 
titration consisted of concentrations starting at a sub-saturating 5 µg/ ml 
and titrated 3-5 fold for >5 dilutions. After washing the plate as 
described before 1-2 µg/ ml of test antibody was applied diluted in  
PBSTween for 1 hour. When the antibody was titrated, E2 was applied 
at 1 µg/ ml and the antibody was titrated from ~5µg/ ml in 3-5 fold for >5 
dilutions. All other details remained the same. 
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2 .7 .4 .  Point  m utant  binding com parison 
Point mutated soluble strain 1A20.8 E2 of residues G530 and D535 to 
alanine residues were compared in a set point ELISA. Briefly, 96 well 
ELISA plates (Immulons) were coated with 2 µg/ ml of soluble E2 
diluted in carbonate bicarbonate buffer (Sigma), covered and left over 
night at 4oC. All other steps were carried out as described in section 
2.7.1. Depicted in Figure 2.3C. 
  
2 .7 .5 .  Ant igenic test ing of pH effect  
To assess the temporal relevance of pH related effects in E2, the stage at 
which acidification of E2 occurred in  the ELISA was compared. In  one 
set up, 10  µl of soluble E2 protein was diluted in 90  µl of PBSTween of 
pH 7.5. Twenty µl of 0 .1 M sodium acetate buffer (Sigma) was added to 
reduce the pH to 5.5 and this solution was incubated at 37oC for 20  
minutes. Following this, the pH was raised back to 7.5 by addition of 20  
µl of 0 .1 M HEPES buffer (Sigma) before diluting the E2 in carbonate 
bicarbonate buffer to an appropriate volume and concentration for 
coating the ELISA plate. For this experimental set up, the primary 
antibody incubation was thus using antibody diluted in  PBSTween of 
pH 7.5 and continued accordingly. Alternatively the acidification 
occurred with the primary antibody incubation in which the binding 
event occurred in the presence of the acidic pH. The rest of the assay 
continued as described in section 2.7.1, as depicted in Figure 2.3C. 
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Figure 2 .3  Diagram m at ic representat ion of the com ponents of the 
var ious ELI SA set  ups. 
A)  GNA capture ELISA which was used for E2 and ant ibody t it rat ions against  
HVR deleted E2 in sect ion 4.2.2, B)  CD81 capture ELISA to t est  set  point  
relat ive binding of HVR deleted E2 panel to CD81 in sect ion 4.2.1, and C)  E2 
coated ELISA as used for com paring point  m utated and wild type E2 binding to 
ant ibodies, with or without  acid t reatm ent :  in sect ions 4.2.2, 4.2.3, 5.2 
respect ively. 
 
2 .8 . Stat ist ical analysis 
The statistical significance of the effect of transfection reagent to 
reporter DNA ratio in section 3.2.2, E2-antibody binding relative to wild 
type in section 4.2.2 and CD81 binding by HVR deleted 2B2.8 E2 
protein in section 4.2.1 was assessed by one way ANOVA analysis 
comparison of means with p<0.05. In section 4.2.2 EC50 values were 
derived from a curve regression analysis of sigmoidal dose type curves. 
Binding threshold (Ct) was determined as the x axis value (µg/ ml of 
titrated protein) at which the binding curve y axis value (OD) met twice 
the negative control signal value (OD). Linear regression analysis of the 
Ct values against the EC50 values used a two tailed Spearman rank test 
where alpha is 0 .05. Significance of the Ct values across the panel of 
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HVR deleted mutants was derived with one way ANOVA test comparing 
means with p<0.05. Analysis of the effect of sera in culture media on 
protein production in  section 3.2.4 was performed with a t test for 
paired 2 sample means. One way ANOVA was performed in Section 5.2 
assessing the effect of acidification of E2 on epitope exposure. All tests 
were performed with Graph pad Prism: version 5 software (Licensed by 
University of Nottingham). 
 
2 .9 . Phage display 
2 .9 .1 .  Affinity select ion 
The recombinant phage library screened in this project was created and 
previously used successfully with a different protocol to generate broad 
acting neutralising antibodies (Allander 2000). The biopanning process 
consisted of a cycle of input of purified phage in solution to a selection 
platform, enrichment of the phage and concentration to a purified 
solution (see Figure 2.4). The affinity selection allowed recognition of 
specific binding clones to be taken forward. Briefly, two 1.5 ml tubes 
containing 10  µl of streptavidin coated paramagnetic beads (DYNAL) 
and 500µl of PBS-0 .05% Tween 20  5% milk were rotated for 1 hour to 
allow thorough mixing of the beads and the blocking solution. One of 
the tubes was then placed on a magnetic rack to wash the beads three 
times with PBS to remove the blocking solution. In this tube 400  µl of 
1% BSA solution and 100  µl of phage solution was added to the beads 
and incubated at 37oC for 20  mins. The free solution was then removed 
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from the beads and mixed with 100  ng of soluble E2 protein (D535A 
mutant of genotype 1A 20 .8) and 10  µl of 5% BSA with 0 .05% Tween 20 , 
incubated on a rotation wheel for 2 hours at room temperature. Two 
test groups were designed for the affinity selection; one in  which the 
addition of the 1% BSA was of a pH 5.5 solution to maintain acidic pH 
throughout the selection, and the second group in which E2 was 
acidified in a volume of <100 µl for 20  mins at 37oC prior to dilution in  
the phage mix at pH 7.5. 
 
Specific binders were then recovered as follows. The second blocked 
tube of streptavidin coated magnetic beads was washed 3 times with 
PBS-0 .05% Tween 20  carefully and the phage-E2 mix added. The 
mixture was then incubated at 37 oC for 20  minutes and re-suspended 
twice to ensure thorough mixing. After placing the tube on a magnetic 
rack, the supernatant was carefully removed and the beads washed with 
500  µl of PBS-0 .05% Tween 20  5-10  times followed by a wash with PBS 
only then sterile water only. Bound phage were eluted from the beads by 
addition of 500  µl of elution buffer (0 .1 M HCl-glycine, pH 2.2, with 1 
mg BSA/ ml), re-suspension and incubation for 10  minutes. The tube 
was then placed on a magnetic rack and the supernatant removed, taken 
into a new tube and neutralised by addition of 50  µl of 2 M Tris-base. 
This final solution constituted the eluted phage mix (eluate). 
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Figure 2 .4  Schem at ic representat ion of enr ichm ent  of phage dur ing panning. 
Enrichm ent  of the phage populat ion here involves increasing the specificit y while decreasing the diversity of the expressed fab present .
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2 .9 .2 . Library expansion 
Following affinity selection, the eluted phage mix/ enriched library were 
expanded to minimize loss of rare target-binders during subsequent 
rounds. Amplification of the library was therefore carried out in the XL 
1 Blue bacteria, initiating a new round of panning with a 2 ml culture of 
~1.65 x 10 8 bacteria/ ml. The absorbance of this culture was read at 600  
nm and the concentration of bacteria estimated with the equation 1.0  
OD600nm=3.3x10 8 bacteria/ ml. The bacterial culture was infected with 
100  µl of eluted phage and left to infect for 15 minutes at room 
temperature in a 50  ml conical tube. Following this, 6 mls of warm SB 
media supplemented with 1.6 µl of 100  mg/ ml ampicillin were added to 
the culture and shaken at 250  rpm at 37oC for 1 hour, after which a 
further 2.4 µl of ampicillin were added and another hour incubation 
followed. Bacteria were then transferred to a sterile 500  ml culture flask 
containing 91 ml of SB media supplemented with 100  µg/ ml ampicillin 
in which bacteria were then super-infected with VCS M13 helper phage 
at a MOI of 30  before growing for  a further 1.5-2 hours shaking at 37oC. 
Finally, 50  µg/ ml kanamycin were added and the culture grown 
overnight (16 hours) at 37 oC. 
 
The following morning, bacteria were cleared from this culture by 
centrifugation at 4 000  x g for 15 minutes and the phage subsequently 
recovered from the supernatant by two rounds of precipitation as 
described in section 2.9.3. The concentration of phage expanded in  the 
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library was then determined by titration as described in section 2.9.4 
and ~1x10 12 phage subsequently used as the input to further rounds of 
affinity selection. 
 
2 .9 .3 . Phage precipitat ion 
To isolate phage from bacterial cultures, PEG-precipitation was used. 
Phage containing culture supernatants were recovered to remove 
bacteria and other debris by centrifugation at 4 000  x g for 15 minutes 
(Thermo: Heraeus Cryofuge). Phage were precipitated from the 
supernatant by addition of 1/ 5th volume of PEG (20  % [w/ v] 
polyethylene glycol-8000, 2.5 M sodium chloride) for 1 hour at 4 oC and 
collected by centrifugation at 15 000  x g for 15 minutes (Sorval). Phage 
pellets were then re-suspended in  0 .5-2 ml sterile PBS before a second 
precipitation with 1/ 5th volume of PEG, for 1 hour on ice. Phage were 
subsequently collected by centrifugation at 10  000  x g for 20  minutes 
(MSE Micro Centaur) and re-suspended in a final volume of 0 .2-2 mls 
1% BSA or sterile PBS (where phage precipitation began with smaller 
culture volumes of ~35 ml, the final re-suspension occurred at the 
smallest volume of 0 .2 mls). 
 
To remove any remaining bacterial debris the solution was separated by 
centrifugation at 10  000  x g for 5 minutes at 4 oC and the supernatant 
collected. The concentration of phage within the expanded/ enriched 
library was determined by titration as described in section 2.9.4, and 
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1x10 12 phage subsequently used as the input to further rounds of affinity 
selection. 
 
2 .9 .4 . Est im at ion of phage t iter  
To estimate the concentration of phage particles in  the preparations, 
phage solutions were diluted in sterile PBS and 10  µl added to 90  µl of 
mid log phase XL 1 Blue bacteria culture, left to infect at room 
temperature for 15 minutes before spreading onto agar plates 
containing 100  µg/ ml of ampicillin an grown overnight at 37 oC. The 
titer was then calculated as the number of colonies multiplied by 100 , 
then divided by the dilution factor expressed as phage particles (cfu) per 
ml. 
 
2 .9 .5 . I solat ion of phage clones 
Individual bacterial colonies were obtained by streaking bacteria on LB 
agar plates containing 100  µg/ ml ampicillin and grown overnight at 
37oC. Single colonies were then transferred to 3 ml of SB media 
containing 100  µg/ ml ampicillin and grown at 37 oC overnight again (16 
hours). Bacteria were recovered from this culture by centrifugation at 
10  000  x g for 3 minutes and either stored at -80 oC in media containing 
30% glycerol to make a glycerol stock, or the phagemid DNA was 
purified using a miniprep kit (Qiagen). Expansions from the glycerol 
stock of the bacterial culture were then performed as described in  
section 2.9.2 followed by PEG precipitation. Purified phage were then 
114 
 
reactivity tested in an ELISA format as described in section 2.9.6. 
Purified DNA was also used for sequence analysis and restriction 
enzyme digests. 
 
2 .9 .6 . Phage displayed pept ide ELI SA 
To determine whether phage clones enriched from the library directed 
specific binding to the selecting protein, reactivity was assessed by 
enzyme-linked immunosorbent assay (ELISA) in which the optimum 
concentration for these components was determined empirically (data 
not shown). Optimal sensitivity of this immunoassay was achieved by 
coating the ELISA plate with target molecule used in affinity selection at 
a concentration ~100µg/ ml diluted in carbonate bicarbonate buffer and 
loading 50  µl per well for overnight binding/ incubation at 4oC. The 
unbound well contents were then shaken out and replaced with 300  µl 
of PBS-0 .05% Tween 20  5% milk, covered and incubated for 4 hours at 
room temperature. Following blocking, wells were washed 3 times with 
PBS-0 .05% Tween 20  and approximately 1x10 11 phage particles were 
added to the wells, and then allowed to bind for 1 hour. The wells were 
washed  again with PBS0.05% Tween 20  and bound phage were 
subsequently detected by incubation with either anti-fd antibody 
(Sigma) or anti pIII antibody (Sigma), both diluted 1:1000 in PBST. The 
assay continued with appropriate secondary antibody and substrate as 
described in section 2.7.1 and the absorbance was measured as 
described. 
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2 .9 .7 . PCR screen of phagem id clones 
To be able to discriminate phagemid clones containing the correct sized 
gene inserts a PCR screen was designed using the primers described in 
Table 2.4 and illustrated in Figure 2.5. 
 
Table 2 .4 . Specificat ions of the pr im ers used for PCR screen and 
sequencing of phagem id clones. 
Com binat ions of prim ers were used to specifically am plify gene inserts 
individually or the whole segm ent  from  the light  up to and including the heavy 
chain. 
 
Prim er  Target  Direct ion Sequence 
SEQGb ~ 50 nucleot ides 
downst ream  of V 
region:  Heavy 
ant isense GTCGTTGACCAGGCAGCCCAG 
SEQLb ~ 50 nucleot ides 
downst ream  of V 
region:  Lam bda 
ant isense GAAGTCACTTATGAGACACAC 
SEQKb ~ 50 nucleot ides 
downst ream  of V 
region:  Kappa 
ant isense ATAGAAGTTGTTCAGCAGGCA 
Om pseq Om p leader:  
Light  
sense AAGACAGCTATCGCGATTGCA 
Pelseq Pel leader:  
Heavy 
sense ACCTATTGCCTACGGCAGCCG 
 
 
 
Figure 2 .5  Schem at ic representat ion of the linear coding region of the 
pCom b3 H phagem id gene inserts and associated am plificat ion 
prim ers. 
Om p and Pel leader sequences flag the beginning of each gene insert  allowing 
specific prim ers to am plify all inserts where these sequences are present . 
Likewise, prim ers were designed that  am plified from  the 3’ constant  region, 
also dist inguishing lam bda from  kappa light  chains. 
 
Amplification reactions were set up in 12.5 µl volumes containing 2.5 
pmol each of a combination of a sense and an anti-sense primer (see 
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Table 2.5) for a product ~600 bp, representing the individual Fab chain 
genes or a ~1200 bp product, containing both chain genes. The reaction 
also included 1 mM of dNTPs, 0 .3125 U of HotStarTaq DNA polymerase 
(Qiagen), and 1x PCR Buffer. Two µl of overnight culture diluted 1:100  
was used as reaction template. The PCR-cycling parameters were 15 
minutes at 95 oC followed by 40  cycles of 94 oC for 45 seconds, 61 oC for 
45 seconds, 72 oC for 3 minutes, subsequently followed by a terminal 
step of 72 oC for 10  mins. 
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3 . S2  Protein expression 
3 .1 . Expression system s 
Biopanning is a method for isolating favourable ligands such as specific 
antibodies based on chosen characteristics. The characteristics being 
targeted are imposed by the chosen target protein used to isolate the 
ligand/ antibodies. As such, the primary aim of this project was to 
generate a panel of possible target proteins to use for the enrichment of 
antibody libraries. In this project, HCV entry is the biological process 
that is being targeted and for this reason, conditions imposed on the 
chosen viral protein E2 during entry are to be considered. To perfectly 
mimic the behaviour of the protein in vivo, the functional 
characteristics of the potential target protein to be used in biopanning 
need to be assessed and verified. The expression system in which a 
protein is produced i.e. mammalian, bacterial or insect cell lines can 
impose different constraints on the final state and activity of the 
purified protein. Bacteria can be used to express high levels of protein 
but due to a lack of complex post translational modifications that occur 
in eukaryotic cell lines, the biological activity of the protein produced 
and correct folding can be problematic (Baneyx and Mujacic 2004). 
Given that during infection with HCV, the replication and assembly of 
progeny virus occurs in human cells via mammalian enzymatic 
pathways and using human cell specific molecular interactions, the viral 
proteins are thus produced with eukaryotic glycosylation and 
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chaperones. For this reason alone a eukaryotic expression system for 
viral proteins in  vitro is preferable. However, whilst mammalian cell 
lines are excellent for the production of membrane anchored and 
secreted proteins, the cell lines are largely inflexible as they are labour 
intensive, need a carefully controlled environment, show low expression 
levels, and require expensive media and time as it can take months to 
develop a stable cell line (Wurm 2004; Cha, Shin et al. 2005).  
 
 
Filamentous fungi and yeast cell lines can also be used to express 
recombinant proteins at high levels. However, membrane-anchored or 
secreted proteins like HCV E2 are produced at low levels compared to 
intracellular proteins (Gerngross 2004). Insect cell lines are also a 
prominent eukaryotic platform for protein expression as they can 
express virtually all types of heterologous recombinant protein (Douris, 
Swevers et al. 2006). Initial research demonstrated that the protein in 
question in this project- HCV E2, produced in insect cell lines using 
baculovirus or in yeast cell lines, did not reflect the functional 
characteristics that are known to occur in vivo (Rosa, Campagnoli et al. 
1996). However, the comparative E2 expressed by the mammalian cell 
line from the same study was able to retain functional characteristics. 
This observation was most likely due to different capabilities of the cell 
lines to glycosylate the proteins appropriately. 
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 In 2004, a new set of vectors for insect cell lines became available for 
producing recombinant proteins thus eliminating the need for the 
previous cumbersome method that required Baculovirus infection of the 
cells (Farrel, Swevers et al. 2005). An inherent problem with using a 
virus to transform a cell line by infection is an increased amount of 
proteolysis. The recovery of protein produced also requires cell lysis and 
therefore the maintenance of cell lines and continuity of protein 
production does not occur. With the pMT series of vectors for insect cell 
protein expression by Invitrogen (Hyung-Bae, Sun-Hong et al. 2002; 
Invitrogen 2012), there is full integrity of post translational 
modifications, a stable physiological environment and a high yield of 
secreted recombinant protein from serum-free media. The only 
limitations to insect cell protein expression systems lies in the type of 
post translational modifications and like all non-mammalian cell lines, 
correct folding. S2 cells, however, have been developed to maintain the 
ability to process complex glycans and thus correct formation of 
proteins that are suboptimal in other insect cell lines (Kim, Shin et al. 
2005). The insect cell line Drosophila Schneider 2 (S2) is well-adapted 
to post translational modifications such as N-glycosylation as it has 
folding machinery that promotes correct disulphide bonding in the ER. 
This makes it especially suitable for the expression of multi-domain 
glycoproteins such as HCV E2 and Fab molecules (Harrison and J arvis 
2006). Indeed multiple groups have used S2 cells successfully for the 
production of Fab and HCV E2 ((Kim, Shin et al. 2005; J ohansson, 
Drakenberg et al. 2007; Backovic, J ohnasson et al. 2009; Krey, d'Alayer 
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et al. 2010) also reviewed in (Douris, Swevers et al. 2006)) and the 
protocols developed by these groups have therefore been adopted and 
assessed in this project. 
 
The first aim of this project was to use the Drosophila S2 cell expression 
system outlined by J ohanssons group (J ohansson, Drakenberg et al. 
2007), to produce variations of the chosen target protein HCV E2 as 
soluble monomeric stable protein. However, before being used in  phage 
biopanning, it was important to validate the antigenicity and general 
characteristics of the expressed protein. 
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3 .2 . Results 
3 .2 .1 . Transient  Protein Product ion 
The first aim of this project was to verify that the glycoproteins 
produced in the S2 cell culture system were correctly folded. For this, 
transient test inductions were performed. A period of 24-48 hours for 
test protein expression was used in this project following the protocol 
outlined in a 2007 paper by J ohansson and his group (Johansson, 
Drakenberg et al. 2007). The test inductions performed in this project 
showed positive signals that were clearly distinguishable from the 
negative producing cell strains and controls and as such the cell strains 
that were expanded were confidently deemed to be producing high 
levels of protein that were verified to be correctly folded according to 
ELISA experiments with conformation sensitive antibodies. 
 
3 .2 .2 . Transfect ion Reagent  Rat io Effect  
To optimise the transfection process and consequently the protein 
yields, a variety of transfection conditions were assessed. The product 
instructions of the transfection reagent Fugene 6 suggest two 
transfection reagent: reporter DNA ratios, which are 3:2 and 6:1. 
Multiple transfections were performed with the constructs 1A20.8-
G530A and 1A20.8-D535A. The comparative variable between the 
various transfections was the amount of Fugene 6 reagent used in the 
reaction noted as the ratio of reagent relative to the 2 µg of reporter 
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plasmid DNA used. Forty eight hours post-transfection the 
supernatants were harvested and the amount of E2 protein produced 
was compared by ELISA using the monoclonal antibody AP33 (see 
Figure 3.1). 
 
 
Figure 3 .1  Effect  of the rat io of t ransfect ion reagent  to reporter  
plasm id on protein product ion. 
After 2 days of select ion and 24 hour test  induct ion with 500 µM copper 
sulphate solut ion. Tested via GNA coated ELISA detect ing E2 protein with AP33 
ant ibody followed by alkaline phosphatase conjugated ant i m ouse ant ibody and 
subst rate BCIP reading opt ical density at  620 nm . Asterisks indicate significant  
difference * p< 0.05 using a one way analysis of variance com parison of m eans.  
 
A Fugene to sample ratio of 3:2 produced more protein than the 6:1 
ratio, although this was only statistically significant for one of the E2 
constructs (G530A). Therefore, the suggested range of transfection 
ratios were deemed not to affect protein production to a great extent 
and the most economical ratio of 3:1 also provided in  the product 
instructions was kept for all further transfections. 
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3 .2 .3 . S2  cell Protein Expression  
Eleven different E2 constructs were transfected into S2 cells and the 
relative amount of protein produced was determined by BCA assay and 
nanodrop spectrophotometry. Protein yields varied from 0 .93 mg/ l-5.73 
mg/ l (see Table 3.1). This variation did not appear to fit any pattern 
relating to the constructs in question as the highest expressers were 
observed for both genotype groups regardless of the modification of 
each construct. 
 
Table 3 .1  Average yield of purif ied E2  for  each construct  produced of 
each genotypic st ra in. 
Protein was quant ified with a nanodrop spect rophotom eter and BCA assay. 
Protein yield is expressed as am ount  of pure protein collected per lit re of 
culture supernatant . E2 of st rain UKN1A20.8 contained different  m utat ional 
replacem ent  of residues to alanine whilst  the UKN2B2.8 st rain of E2 const ructs 
contained various com binat ions of delet ions of t he hypervariable regions HVR1, 
+95DQG+95ƩDQGUHVSHFWLYHO\ 
 
E2  construct : 
UKN1 A2 0 .8  
Am ount  of 
prote in 
( m g/ l)  
E2  construct : 
UKN2 B2 .8  
Am ount  of  
prote in 
( m g/ l)  
  W ild type 3.03 
W ild type 1.67 Ʃ 5.73 
G5 3 0 A 5.00 Ʃ 1.89 
D5 3 5 A 1.50 Ʃ 1.69 
G5 3 0 A- D5 3 5 A 
 
2.40 
 
Ʃ 
Ʃ 
0.93  
5.07 
  Ʃ 1.60 
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3 .2 .4 . Sera in S2  culture m edia 
To evaluate the impact of culturing the cells in serum free-media, two 
culture methods were compared. S2 cells, at a density of  5x10 6 cells / ml 
were split into two pools. One  pool was cultured using the standard 
serum free media whilst the second pool was grown supplemented with 
10% fetal bovine serum.  Cell density was recorded regularly with each 
passage occuring when cells reached a density of ~5x10 6 cells/ ml. 
Table 3 .2  Average grow th of cells per day of culture  expressed as cell 
density X 1 0 6  /  m l of culture / day of culture. 
Growth in serum - free m edia (SFM)  or with addit ion of 10%  foetal bovine serum  
over several passages was com pared. This process was repeated m ult iple t im es 
with passages occurring when cell cultures reached a density of ~ 5x106 
cells/ m l, and cells were seeded at  ~ 1x106 cells/ m l. Averages are recorded 
here. Two way ANOVA with Bonferroni post  t est  showed no significances with 
alpha as 0.05. 
 
Passage 
 
Cell grow th ( cells/ ( day x1 0 6 / m l) )  
Serum  Free Media  Media +  1 0 %  FBS 
average St . Dev. average St . Dev. 
1  0.499 0.053 0.712 0.096 
2  0.361 0.081 0.384 0.054 
3  0.688 0.068 0.408 0.065 
 
 
Table 3.2 shows that initially, cells receiving serum-containing medium 
grew more rapidly as the cell growth was almost 1.5 times greater for 
serum-treated cells compared to standard serum-free medium cells. By 
the time the third passage occured however, this trend had reversed as 
cell growth became almost twice as great for the serum free cells as for 
those receiving serum. Statistcial analyses of the data using a one way 
ANOVA test showed no significant differences  among the trends 
observed. So, whilst using FBS-containing medium for S2 cell culture 
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may initially improve cell growth, any increase in cell proliferation was 
short-lived. 
 
The impact of protein production on S2 serum-treated cells was 
subsequently assessed. Cell strains transfected with E2 constructs of 
genotype 1A or 2B were cultured in the presence or absence of 10% FBS 
throughout the selection period. Following selection, media were 
replaced with serum-free media only and a test induction was 
performed. The amount of protein produced was assessed by ELISA 
using the monoclonal antibody AP33 (see Figure 3.2). The amount of 
protein produced in the presence or absence of serum was similar, and 
paired t-tests for two sample means confirmed that there was no 
significant difference in protein yield between the two culture 
conditions. 
 
Table 3 .3  Num erical data and stat ist ical analysis of the com par ison 
betw een prote in expressions from  S2  cells receiving serum -
conta ining or  serum - free m edium . 
Assay form at  is GNA coated ELISA detect ing expressed E2 with ant i- st rep tag 
ant ibody and subst rate BCI P read at  OD 620 nm . The stat ist ical analysis was 
perform ed using a T test  for paired two sam ple m eans
 
   Protein product ion 
 ( OD 6 2 0  nm )  
 E2  st ra in 
  1 A  2 B  
  fbs  sfm  fbs sfm  
Average 1.62  1.78 0.54 0.75 
St  dev. 0.15  0.15 0.03 0.07 
p value 0.0319     0.0227    
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3 .2 .5 . Purified E2  Protein Panel 
Having defined optimal transfection and expression conditions, the S2 
expression system was utilised to produce a variety of target E2 proteins 
for subsequent use in  antibody biopanning experiments. The two E2 
constructs chosen as possible target candidates for biopanning were the 
hypervariable deleted E2 in the genotype 2B2.8, and E2 of genotype 
1A20.8 with mutagenesis of residues 530  and 535 (see Table 2.1). The 
E2 constructs were transfected into S2 cells, stable lines were 
established and then protein expression was induced with copper 
sulphate. Following 10-16 days of induction, supernatants were 
harvested, and run through affinity chromatography columns for 
purification and the amount of E2 protein yielded was analysed by 
Western blot and Coomassie gel staining (see Figure 3.3 & Figure 3.4 ). 
The purification of expressed soluble E2 successfully yielded 
monomeric, highly pure E2 protein. This panel of soluble E2 proteins 
were shown to be within a size range of 40-50  kDa with slight variations 
due to varying states of glycosylation. Deletion of the hypervariable 
regions contributed a maximum of about 8 kDa in line with the amount 
of genetic sequence excised from the protein coding gene. Inter-assay 
variation of the estimated size of E2 indicated sizes between 40  kDa and 
50  kDa. An estimated size of ~50kDa for S2 expressed soluble E2 has 
been shown elsewhere (Krey, d'Alayer et al. 2010) and so this is a 
satisfactory E2 protein. Correct fold of the E2 produced was confirmed 
with conformation-sensitive antibodies 1:7, A8 and the antibody AP33 
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that has conformational determinants, in ELISA format for each batch 
of protein produced. 
 
 
Figure 3 .2  W estern blot  ( A)  and Coom assie staining ( B)  of the 
delet ion m utant  E2  protein panel and the w ild type 2 B2 .8  isolate . 
A)  An ant ibody specific to the C term inus st reptavidin tag located on each E2 
was used to probe the blot  followed by species specific ant ibody conjugated 
with Alkaline Phosphatase for which the subst rate was BCIP/ NBT.  B)  2-5 µg of 
purified protein was run on an SDS-PAGE gel followed by protein staining with 
I nstant  Blue Coom assie stain. The panel of E2 proteins are wild type sequence 
as found in the clinical isolate, with variants containing delet ions of the 
hypervariable regions. The expected size of E2 is ~ 50 kDa, delet ion depending. 
 
Figure 3 .3  Panel of genotype 1 A2 0 .8  soluble  E2  prote ins in w estern 
blot  ( A)  and Coom assie sta ining ( B) . 
A)  An ant ibody specific to the C term inus st reptavidin tag located on each E2 
was used to probe the blot  followed by species specific ant ibody conjugated 
with Alkaline Phosphatase for which the subst rate was BCIP/ NBT.  Surrogate 
w ild type protein is of st rain 2B, with other proteins of st rain 1A. B)  2-5 µg of 
purified protein was run on an SDS-PAGE gel followed by protein staining with 
I nstant  Blue Coom assie stain. The panel of E2 proteins are wild t ype sequence 
as found in the clinical isolate, with variants containing alanine replacem ent  
m utagenesis of residues G530 and D535.  
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Smaller sized variants are visible for some of the E2 constructs (see 
Figure 3.4 & Figure 3.3 ). These variants were not consistently detected 
using reducing or non reducing SDS-PAGE and nor were any other 
variant sizes observed that would otherwise imply degradation of the 
protein preparations. Therefore, the size variants might possibly be due 
to variation in the glycosylation of the E2. Overall, the soluble protein 
produced can be considered homogeneous, and stably produced. It also 
proved technically difficult to demonstrate all proteins consistently on 
Coomassie staining and Western blots, possibly due to the low 
sensitivity of coomassie staining and the relatively low concentration of 
some of the protein samples. Assessment of the protein panel according 
to fold/ conformation was therefore next addressed and is discussed in 
section 4.
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3 .2 .6 . Deglycosylated purified E2  
In order to assess the degree and nature of glycosylation of the S2 
expressed soluble E2 protein in this project, glycosidase digestion 
experiments were performed (see Figure 3.5). Reduced and denatured 
wild type E2 showed a single band close to 50  kDa and thus the protein 
was stable and of the expected size. The single band shows that the 
protein was stable and not degraded. When the same protein 
preparation was also digested with pyrogenase F (NEB) to remove high 
mannose and complex N-linked glycans, two bands sized approximately 
~35 and ~40  kDa were produced (indicated by red arrows in the middle 
lane of Figure 3.5A) thus a loss of up to 15 kDa was observed when N-
linked glycan groups were removed. The remaining core E2 mass 
reflects E2 expressed in mammalian cells supporting that this protein is 
properly produced (Slater-Handshy, Droll et al. 2004). 
 
 
Figure 3 .4  SDS- PAGE analysis of glycan status of reduced and 
denatured S2  expressed E2  protein. 
Wild type genotype 1A20.8 soluble E2 m onom eric protein reduced and 
denatured ( left  hand lane)  or further t reatm ent  by either:  PNGase F (m iddle 
lane- red arrows) , or Endo H ( r ight  hand lane-  green arrows) .  
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Figure 3 .5  I llust rat ion of the different ial digest ion of PNGase F and 
Endo H. 
PNGase F is able to cleave between asparagines m oiet ies and proxim al N-
acetylglucosam ines providing there is no ɲ1,3 fucosylat ion. EndoH however 
cleaves between two N-acetylglucosam ine m oiet ies in the absence of any 
fucosylat ion. 
 
Glycosidases are enzymes that can cleave glycan moieties from proteins 
of which endoglycosidase H and pyrogenase F are two examples. Both 
enzymes cleave asparagine associated N-acetylglucosamine (GlcNAc) 
linkages but act at different points with varying activity. Figure 3.5  
shows that pyrogenase F targets the link between the asparagine residue 
and the proximal N-acetylglucosamine, except in the case of the latter 
being Į1-3 fucosylated. Endoglycosidase H however cleaves between 
two N-acetylglucosamines except when either of these moieties has been 
fucosylated. Human, insect and plant N-linked glycans most commonly 
contain Į1-6 rather than Į1-3 groups and so pyrogenase can be used to 
cleave a predominant portion of complex oligosaccharides (Varki, 
Cummings et al. 1999). The presence of 2 bands of similar sizes in  
Figure 3.4 following pyrogenase F treatment indicates two states of 
glycan digestion: almost complete and complete. Optimisation of the 
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pyrogenase treatment using more enzyme or a longer incubation period 
may be sufficient to complete digestion leaving a single band of only one 
protein species at ~35 kDa. The right hand lane of Figure 3.4 shows the 
size of the soluble E2 protein following digestion by Endoglycosidase H 
(NEB) with the bands marked by green arrows. Endoglycosidase H 
removes high mannose and hybrid oligosaccharides but cannot cleave 
fucosylated N-acetylgucosamines that therefore depicts complex 
oligosaccharides. Figure 3.5B & C show the different points at which 
endoglycosidase H and pyrogenase F cleave the main glycan groups. 
The use of endoglycosidase H and pyrogenase F thus distinguishes 
complex N-linked glycans from the other subtypes excluding the much 
less common Į1-3 fucosylated oligosaccharides which pyrogenase F 
cannot process. According to Figure 3.4, the mass specifically 
attributable to non complex N-linked glycans could be interpreted to be 
around 5 kDa. However, when analysing a pool of protein molecules it is 
not possible to distinguish between differentially glycosylated molecules 
or to be able to ascertain if specific glycans have been modified to the 
same extent on each molecule. The two bands in the endoglycosidase H 
treated lane are of size ~50 kDa and ~45 kDa showing some undigested 
protein along with digested protein in which only 5 kDa of glycan mass 
was cleaved. Taken together, these data show only partial digestion by 
endoglycosidase H, which could be improved by optimising the 
digestion protocol.  
Figure 3.3 shows the panel of genotype 1A E2 proteins, some with 
alanine replacements. Some of these proteins showed a fraction of 
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smaller sized variants indicating differential processing. Given the 
amount of post translational modifications required for E2 and the 
limited scope for this in the S2 cells the E2 was produced in, the size 
variation is likely a product of varying states of glycosylation. The 
double mutant (G530AD535A) the D535A E2 protein showed the least 
amount of this size variant, which was not consistently observed. Also, 
the wild type 1A E2 protein which did show a size variant in Figure 3.3  
showed normal core mass following glycosidase analysis. Therefore the 
G530A, D535A & G530AD535Asoluble E2 produced were taken to have 
a stable core though glycosidase analysis on all E2 samples would have 
been preferable for a more confident evaluation. 
 
Taken together, the E2 produced in this project is stable, highly pure, 
with a core mass of expected size and a glycan coat of ~15 kDa. The 
missing 10  kDa of glycan shield from the soluble E2 produced in S2 cells 
is likely due to limited post translational modifications that are 
otherwise present in mammalian cells. Glycan deletion has been shown 
to affect glycoprotein function whilst aiding epitope exposure (reviewed 
in (Helle and Dubuisson 2007)). Therefore, by having a thinner glycan 
coat that still retains the complex glycans, immunogenicity can be 
favoured hopefully with minimal effect on function. The production of 
stable, pure protein with a correct core mass and antigenicity thus 
supports that the E2 protein here closely reflects the viral protein as 
produced in vivo. 
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3 .3 . Discussion 
A study in Cryotechnology by Santos and her group (Santos, J orge et al. 
2007) tested the expression profile of S2 cells using the same protocol 
on a different reporter protein to allow fluorescent analysis of protein 
expression. S2 cells were observed to start producing detectable levels of 
the reporter protein as little as 5 hours post induction when induced 
with 500  µM CuSO4, showing up to 90% of cells present exhibiting 
expression by day five post induction (J ohansson, Drakenberg et al. 
2007). As an indicator of the expression pattern of S2 cells cultured 
using the same conditions, these data support that production of 
protein in S2 cells should be detectable by 24 hours and consequently 
that any production below detection level by this point could not be 
deemed an indicator of efficient expression. Given the clear separation 
between cell strains correctly producing E2 protein and those that did 
not, the cell strains expanded in this project were confidently deemed to 
be exhibiting efficient production of high levels of protein as reported 
elsewhere (J ohansson, Drakenberg et al. 2007; Gilmartin, Lamp et al. 
2012).  
 
In 3.2.2 the transfection ratio of the Fugene 6 reagent and reporter DNA 
was tested and the choice of ratio adopted was deemed to have no great 
effect on protein production. However, given that the ratios tested and 
the proteins produced in this project were of satisfactory amounts and 
within the ranges described by others using the same and similar 
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systems (reviewed in  (Douris, Swevers et al. 2006)), this does not 
discount the fact that greater differences could be observed using 
different proteins or constructs thereof. 
 
Cell culture based techniques can be replicated exactly and yet have 
varying output of the culture assays. Multiple groups have used S2 cells 
for expression of HCV E2 (J ohansson, Drakenberg et al. 2007; 
Backovic, J ohnasson et al. 2009; Gilmartin, Lamp et al. 2012) or other 
proteins (reviewed in  (Douris, Swevers et al. 2006)) with various 
reported outputs of protein from 0 .13 mg/ litre of supernatant to over 40  
mg/ litre (Gårdsvoll, Werner et al. 2004; Lim, Kim et al. 2004; Douris, 
Swevers et al. 2006; J ohansson, Drakenberg et al. 2007; Gilmartin, 
Lamp et al. 2012). Krey observed in a panel of E2 constructs that even 
different batches of the same cell strain had outputs that varied by up to 
20% (Krey, d'Alayer et al. 2010). Taken together, the variations in 
protein production observed here are in range of those observed by 
other groups. Thus, the S2 expression system here corresponds to its 
use by other groups. Variation in protein expression consequently 
cannot be considered an indicator of any hindrance to expression due to 
any of the particular constructs. 
 
The use of sera in media is a condition that has its benefits and 
disadvantages for different cell lines and purposes. Serum in cell culture 
media is generally considered to improve the survival of cell lines, 
growth and to increase protein expression. However, the inclusion of 
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animal-derived components in cell culture allows a potential risk of 
contamination by mycoplasma and prions (Kallel, J ouini et al. 2002). 
Mycoplasma contamination is very costly for loss of work, time and 
reagents along with sometimes being very hard to identify and then 
eliminate. The European Medicine Evaluation Agency (EMEA) and the 
Food and Drug Administration (FDA, USA) have consequently 
encouraged the elimination of the use of substances of animal origin 
(Castle and Robertson 1999; Batista, Moraes et al. 2009). The 
consequence of this is the development of cell culture methods that are 
serum free. For S2 cell culture, protein expression has been shown to be 
highly efficient without the use of serum (J ohansson, Drakenberg et al. 
2007; Gilmartin, Lamp et al. 2012) though some groups still choose to 
use serum for an improved yield (Backovic, J ohnasson et al. 2009). 
However, the presence of serum in the media not only affects the 
activity of the cells, but can also hinder the process of protein 
purification from supernatant by affinity chromatography. So, the data 
collected provides further evidence for there being no distinct advantage 
to the use of sera in S2 cell culture and protein production. 
 
A variety of studies have shown the influence of glycosylation on 
envelope proteins regarding fold and function (Fournillier, Wychowski 
et al. 2001; Slater-Handshy, Droll et al. 2004; Liu, Chen et al. 2007). 
One factor that can affect the glycan processing of viral proteins is the 
expression system used to produce them (Baneyx and Mujacic 2004; 
Gerngross 2004). As previously noted, different expression systems 
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have different capabilities for post translational modifications, and 
heavily glycosylated proteins like E1 and E2 can thus be very much 
affected by the system they are produced in. So far the soluble E2 
expressed in S2 cells here and by Krey in 2010 (Krey, d'Alayer et al. 
2010), differs from the majority literature describing E2 produced in  
mammalian cells and derived from cell lysates (Dubuisson, Hsu et al. 
1994; Fournillier, Wychowski et al. 2001; Op de Beeck, Cocquerel et al. 
2001; Slater-Handshy, Droll et al. 2004; Liu, Chen et al. 2007) 
according to one factor. This factor is the difference in size since E2 
purified from mammalian cells has been shown to have a mass of ~60  
kDa compared to ~50 kDa for S2 expressed E2. The 2004 paper by 
Slater-Handshy (Slater-Handshy, Droll et al. 2004) shows expressed E2 
protein derived from mammalian cell lines with an observable inter 
assay variability ranging from ~55 kDa to ~66kDa for the same E2 
construct. However, even at the smallest possible size of 55 kDa for the 
E2 protein truncated at residue 715, this is still larger than the soluble 
E2 protein also truncated at residue 715 from Kreys work in 2010, and 
this project which is closer to 50  kDa (see Figure 3.4). Inter-assay 
variability for determining the size of the soluble E2 within this project 
has given soluble E2 sizes from 45 to 55 kDa. The tag for affinity 
purification of the E2 protein used by Slater-Handshy(Slater-Handshy, 
Droll et al. 2004) is the c-myc/ His tag from the pcDNA3.1 vector 
(Invitrogen) and is detailed as adding 3 kDa to the recombinant protein 
size according to the manual. This project and Kreys (Krey, d'Alayer et 
al. 2010) used the pMT vector for expression in the S2 cells with the 
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given tag replaced with the Strep tag II (IBA) which will add a 
maximum of 1 kDa to a recombinant protein. This makes the difference 
of affinity tag insufficient to account for the size difference of E2 
produced from S2 cells and mammalian cells. Therefore, the main 
contributing factor for size differences observed in E2 produced here 
and elsewhere lies in the ability to produce the different post 
translational modifications of the chosen expression system. 
 
Slater-Handshys group (Slater-Handshy, Droll et al. 2004) 
demonstrated that the removal of all glycans from E2 caused a loss of 
around 20  kDa of mass by treatment with tunicamycin (Slater-
Handshy, Droll et al. 2004). The mass of their fully glycosylated E2 
protein was around 60  kDa, and the mass following complete glycan 
digestion became ~35 kDa as seen here. Thus a core mass of 
unglycosylated E2 being ~35 kDa is not significantly affected by the 
expression system and is correct in either mammalian cell lines or S2 
cells. So the differences in  mass observed in glycosylated E2 are 
confidently assigned to the glycan coat as the glycans produced in each 
cell line differs along with the actual mass of those glycans. Analysis of 
the glycosylation status of E2 expressed in mammalian cells showed a 
difference in size of 5-10  kDa between complete glycan digestion and 
non complex N-linked glycan digestion with endoglycosidase (Slater-
Handshy, Droll et al. 2004). The difference in size following the two 
digestions is therefore attributable to complex N-linked glycans and 
other glycans such as O-linked glycans. Similarly, a ~10  kDa size 
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difference was observed here between digestion with pyrogenase F and 
endoglycosidase, thus reflective of mass contributed by complex N-
linked glycans. The size difference contributed by non-complex N-
linked glycans on E2 protein expressed in mammalian cells is up to 20  
kDa (Slater-Handshy, Droll et al. 2004). In S2 cells, the core mass of E2 
matches that of mammalian expressed protein and the mass of non 
complex N-linked glycans is no more than ~5kDa. Therefore, whilst 
inter and intra-molecular differences in glycosylation limit the scope of 
these data and the consequential interpretation, this project clearly 
shows that in  S2 cells, a much smaller portion of the glycan coat on 
expressed E2 is made up of non complex N-linked glycans than in  
mammalian cell-expressed E2. 
 
Current literature has shown that mammalian cell-expressed E2 protein 
collected from medium was resistant to digestion with endoglycosidase 
H (Slater-Handshy, Droll et al. 2004). The same protein collected from 
cell lysates however was still susceptible to the same digestion 
indicating that late stages of protein production induce endoglycosidase 
resistance. The E2 protein produced here was collected from culture 
supernatants and thus could also have potentially incorporated 
resistance to endoglycosidase. Figure 3.5A shows two bands following 
endoglycosidase H digestion: the first band at the same size as 
undigested protein, possibly due to resistance to endoglycosidase and 
the second band 5 kDa smaller. Taken together, it is possible that the S2 
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expressed E2 protein produced here exhibited partial resistance to 
endoglycosidase digestion as observed elsewhere.  
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4 . Character isat ion of HCV E2  proteins: 
ident ifying possible targets for  
enrichm ent  of ant ibody libraries 
4 .1 . Preface 
 
In this project, a range of E2 target proteins were evaluated for use in  
biopanning against a phage antibody display library in order to isolate 
antibodies targeting novel epitopes. All of the constructs expressed good 
yields of E2 protein which, when analysed by PAGE and western blot, 
were shown to be predominantly monomeric and stable. These proteins 
were then subject to antigenic characterisation using a range of 
antibodies recognising linear and conformational epitopes, to identify 
which of these constructs would be most useful in the subsequent 
biopanning experiments. 
 
Figure 4 .1  Schem at ic representat ion of the linear form at  of E2  
m ark ing the various delet ions/ m utat ions m ade to create a panel of 
im m unogen candidates, HVR’s and CD8 1 binding sites: 
 The three hypervariable regions are m arked with green boxes, the two key 
CD81 binding residues G530 and D535 are m arked by dashed lines and CD81 
sites depicted with red boxes.  
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4 .2 . Results 
4 .2 .1 . HVR’s collect ively shield CD8 1  
binding sites 
Before testing hyper variable deleted E2 as a possible biopanning target, 
the ability to bind CD81 protein was tested as an indicator of 
conformation. CD81 protein interacts with E2 over 4 contact regions 
forming a conformation dependant interaction and this interaction is 
essential for cell mediated entry. 
 
Figure 4 .2  GST tagged soluble  hum an CD8 1  binding to E2 . 
Strain 2B2.8 wild type E2 and variants were tested in an ELISA with 5 µg/ m l of 
E2 probed with 10 µg/ m l of CD81-GST or GST alone followed by detect ion with 
m ouse ant i-hum an CD81 ant ibody conjugated with horse radish peroxidise 
(1/ 5000)  secondary ant ibody and BCI P/ NBT subst rate. Stat ist ical analysis using 
one-way analysis of variance (ANOVA)  com parison of m eans:  all bars relat ive 
to 2B Wild Type at  95%  confidence lim it  ( * , p< 0.05) .  
 
A simple ELISA assay was used to compare the effect of all 
combinations of variable region deletions in E2. Figure 4.2 shows the 
relative binding of soluble E2 with CD81 protein fused to a GST tag. 
Equal amounts of all E2 proteins were used so that the signal is 
comparable between the different E2 constructs. All the E2 protein 
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constructs tested bound the CD81 protein. Differences in overall 
binding affinity were evident and of these, the increased CD81 binding 
UHODWLYH WR WKH ZLOG W\SH REVHUYHG IRU WKH Ʃ+95 DQG WKH Ʃ+95	
constructs reached statistical significance. Only one E2 construct 
VKRZHG UHGXFHG &' ELQGLQJ Ʃ+95, 2&3), but this reduction was 
not significant. It should be noted that this construct also contained a 
deletion of the c-terminal region of the ectodomain, from c-terminal 
residues 645-715, which might have affected binding.  
 
4 .2 .2 . E2  ant igenic profile is HVR 
m odulated 
It is believed that the removal of specific variable loops in the HIV 
envelope protein gp120 better exposes conserved regions thought to be 
involved in receptor binding and neutralising antibody recognition 
(Wyatt, Sullivan et al. 1993; Gzyl, Bolesta et al. 2004). Without the 
crystallised structure of E2, conformational effects of specific deletions 
in the E2 protein cannot be determined. In  order to clarify how the 
HVR’s impact the structure and antigenicity of E2, we probed the 
various E2 constructs with a panel of well-characterised antibodies. 
Preliminary binding assays indicated that for some of the antibodies 
and constructs, binding saturation would not be possible (not shown). 
This precluded the use of the standard Scatchard analysis of binding 
affinities. Therefore, in order to be able to compare across constructs 
and antibodies, we utilised a method that compares binding threshold 
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values (Ct), i.e. the lowest antibody concentration that provides a 
positive signal in ELISA (McKeating, Zhang et al. 2004). 
 
Figure 4 .3  Tit rat ion curve for AR3 A against  E2  var iants. 
Full binding curves were achieved with AR3A ant ibody t it rated from  10 µg/ m l in 
5 fold dilut ions on a 96 well ELISA plate coated with 1 µg/ m l of genotype 2B2.8 
E2 variants. Bound AR3A was detected with goat  ant i hum an alkaline 
phosphatase secondary ant ibody (1/ 500) . A BCIP/NBT subst rate was applied 
and OD was read at  620 nm . Ct  values averaged at  0.2516 with SD 0.0363. 
 
To validate this approach, we compared the Ct value with the estimated 
EC50 value, for a sub-analysis using protein-antibody pairs that were 
able to reach saturation binding. An example of the full titration curve 
for antibody AR3A against a variety of proteins is shown in Figure 4.3. 
In a similar assay by McKeating and Zhang, the point of the curve which 
meets twice the amount of signal achieved by the negative control was 
used as the threshold for positive signal (McKeating, Zhang et al. 2004). 
To validate that this choice of comparison point among different data 
sets reflected the relationship given by EC50  comparison, a correlation 
of the EC50 versus the threshold value (Ct) according to McKeating and 
Zhang’s method was analysed. 
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Figure 4 .4  EC5 0 s of binding curves w ith AR3 A and a panel of E2  
var iants plot ted against  binding threshold values derived from  the 
sam e data. 
Stat ist ical analysis of this correlat ion was perform ed with Spearm an Rank test  
with significance level of 0.05 and the relat ionship was shown to be significant  
with a two tailed p value of 0.0046. This choice of threshold value has 
previously been used by McKeat ing and Zhang 2004 (McKeat ing, Zhang et  al. 
2004) . 
 
In the analyses of AR3A binding to a range of E2 constructs, there was a 
correlation between the Ct and EC50 (see Figure 4.4) and this 
correlation was significant in  a Spearman rank test (p<0.01). Having 
validated that the Ct represents a good surrogate for affinity, we utilised 
this approach to assess the binding of various antibodies to each of the 
E2 constructs. The amount of antibody and E2 protein available also 
posed another restriction on how to use the antibodies and purified E2 
at hand. A titration ELISA typically involves a set amount of target 
protein bound to a plate via a connector molecule such as GNA, 
followed by the application of varying concentrations of antibody from a 
very high dose to a very dilute dose, which allows a full binding curve to 
be attained. In this set up, only one step of the full assay is varied, this 
being the concentration of the primary antibody. With all other 
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components of the assay remaining constant, comparative 
interpretation of the data is possible. 
 
Restricted availability hampered the amount of some of the antibodies 
that could be used in  the assays. Therefore, to reduce the amount of 
antibody required, two different assay formats were compared: one 
whereby the E2 was captured and the antibody titrated, and the other 
capturing E2 dilutions and detecting this with a fixed amount of anti 
body. A hierarchy of E2 protein binding profiles was maintained in each 
titration. Calculation of the binding threshold in each data set was also 
maintained with a high correlation coefficient of 0 .9479 between the 
two sets of data supporting that the titration approach does not affect 
the hierarchy of binding among a given set of proteins (See Table 4.1). 
Thus with limited amounts of antibody, titrating the E2 protein would 
save the amount of antibody required. Therefore, where antibody was 
lacking, the format for which E2 was titrated was used in replacement. 
However, whilst both formats could be used to reflect binding 
differences between different proteins by each antibody, quantitative 
interpretation was consequently restricted to within each antibody-
format data set and not across the different formats. 
146 
 
 
Figure 4 .5  Tit rat ions of E2  test  prote in or prim ary ant ibody w ere 
perform ed in ELI SA to check  the relat ionship of binding for  each set  
up. 
The non- t it rated protein was used at  1 µg/ m l whilst  the t it rated protein was 
diluted. The prim ary ant ibody here is 1: 7 with E2 genotype 2B2.8 wild type, 
Ʃ+95	DQG Ʃ+95 1: 7 was t it rated from  20 µg/ m l in 5 fold dilut ions (A) , 
whereas E2 was t it rated from  10 µg/ m l in 3 fold dilut ions (B) . 
 
 
 
 
 
 
 
 
 
 
A 
B 
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Table 4 .1  Analysis of threshold values derived from  ELI SA t it rat ion 
com parison. 
Stat ist ical analysis of the correlat ion between the threshold values obtained 
according to each t it rat ion set  up was perform ed with a Pearson correlat ion 
test . Where E2 was t it rated, 1: 7 was applied at  1µg/ m l and where 1: 7 was 
t it rated, E2 was applied at  1µg/ m l. The t it rated protein is thus the variable from  
which the threshold value is derived. 
 
Threshold va lues for  binding ( µg/ m l)  
E2  const ruct   E2  1 :7  
2 B W ild Type  6.0843 8.1439 
Ʃ+95	  3.0693 1.4698 
Ʃ+95  0.5653 0.2318 
Pearson 
Correlat ion 
coefficient  
 0.9479  
 
 
Having established the optimal assay to be used, binding curves of 
neutralising antibodies AP33, A8 and AR3A were attained against the 
panel of purified soluble E2 constructs. These three antibodies 
represent epitopes located across the central domain I of the proposed 
structure of E2 (Owsianka, Tarr et al. 2005; J ohansson, Voisset et al. 
2007; Law, Maruyama et al. 2008). AP33 recognises a linear epitope 
located within a CD81 binding region within DI (Owsianka, Clayton et 
al. 2001; Owsianka, Tarr et al. 2005). The involvement of the residues 
in this area however has been disputed as having any direct involvement 
with CD81 binding (Rothwangl, Manicassamy et al. 2008) and so 
AP33’s competitive inhibition of CD81 binding (Owsianka, Clayton et al. 
2001) is possibly due to steric hindrance. A8 and AR3A recognise 
conformation-sensitive epitopes, which overlap with the CD81 binding 
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domain, and include residues 530-535 within DI (Johansson, Voisset et 
al. 2007; Law, Maruyama et al. 2008). The Ct values of each E2 
construct for the three antibodies have been plotted as a % relative to 
the wild type E2 protein of genotype 2B2.8 (see Figure 4.6). A higher Ct 
value, indicates a larger amount of titrated protein (AR3A was titrated 
whereas AP33 and A8 had E2 titrated) required to achieve a binding 
signal equal to twice the negative control. Unlike the CD81 binding, 
access/ exposure of each epitope varied widely over the panel of E2 
constructs. Constructs containing the HVR2 deletion demonstrated 
significantly improved binding to the CD81 binding site antibodies, as 
did the construct containing the triple deletion. These data did not 
provide a consistent reflection of that seen for the CD81 binding, 
however together they do indicate that the removal of HVR2 results in  
the increased exposure of the CD81 binding site, at least in  the context 
of soluble E2. 
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Figure 4 .6  Com parat ive binding of t it rated genotype 2 B2 .8  E2  var iants 
w ith 1  µg/ m l of AP3 3  and A8  ant ibody, and 1  µg/ m l of E2  for  t it rat ion 
of AR3 A ant ibody: 
AP33 (A) , A8 (B)  and AR3A (C) , detected with goat  ant i hum an/ m ouse alkaline 
phosphatase (1/ 5000)  and BCI P/ NBT subst rate. Stat ist ical analysis using one 
way analysis of variance (ANOVA)  of m ult iple com parisons:  all bars relat ive to 
2B Wild Type at  95%  confidence lim it  ( * , p< 0.05) . 
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The remaining deletions showed a variable effect on epitope exposure. 
However, the removal of HVR1 or 3 showed the strongest hindrance to 
the ability of antibodies to bind their epitopes. AP33 has an epitope 
most focused on an area near HVR1. The most detrimental effect on 
AR3A binding to its epitope was the removal of HVR3 alone. HVR3 
links two E2 domains that contain CD81 binding sites which are thought 
to also encompass at least part of the AR3A epitope. Site directed 
mutagenesis has identified specific residues within DI that are thought 
to be important for AR3A binding. The epitope for AR3A involves 
residues from multiple CD81 binding sites and thus changes in AR3A 
binding should be most reflective of the global form of E2. 
 
The only HVR that overlaps with the CD81 binding region is HVR2. 
Rather than hindering CD81 interaction with E2, the removal of HVR2 
allowed an improvement in binding by CD81 protein and the various 
antibodies examined here. Previous studies have shown that HVR1 and 
2 can modulate CD81 binding, although this relationship was in a strain 
specific manner (Roccasecca, Ansuini et al. 2003). There is also no 
current evidence that the antibodies used in this study recognise 
epitopes that encompass HVR2. HVR2 is located close to the putative 
fusion peptide proposed to lie at the uppermost region of Domain II 
according to Kreys model (Krey, d'Alayer et al. 2010). Other viruses 
including related flaviviruses have hydrophobic fusion peptides that are 
hidden from the aqueous solvent-accessible surface on the native 
proteins. These peptides become exposed following conformational 
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changes as a result of the binding process (Maeda, Kawasaki et al. 1981; 
Sattentau and Moore 1991; Smit, Moesker et al. 2011). Given the data 
shown here that HVR2 is most important for mediating access to 
conserved regions, should a fusion related conformational change in E2 
occur during entry, it would be of interest to see how HVR2 is affected 
or potentially involved. 
 
In practice, it has recently been shown that even with HVR2 only 
removed, HCV virus loses its ability to infect new cells (McCaffrey, 
Gouklani et al. 2011). Using pseudo particle virion and cell-cultured 
virus, the removal of any of the HVR’s abolished the ability to infect new 
cells. This may be a reflection of the HVR’s involvement in entry at 
some point downstream of binding. The loss of functionality in an 
immunogen, may not necessarily impact on the ability to induce 
antibodies to relevant epitopes, however it indicates a change in  the 
form of the protein that may equally cause a loss of local or global 
structural resemblance, beyond the scope of the analyses performed 
here, to the native form. Therefore, in  the aim of designing an 
immunologically relevant E2 immunogen that allows optimal access to 
conserved regions for identifying non-CD81 epitopes, a different 
approach than HVR deletion might be more successful. Also, the over-
exposure of the CD81 binding sites (which dominate the known 
neutralising epitopes on E2 so far) in  the HVR-deleted E2 means that as 
an antigen target in the biopanning process, the HVR deleted E2 as 
target would encourage rather than separate identification of epitopes 
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and antibodies equally afflicted with dependence on the CD81 binding 
sites. 
4 .2 .3 . G5 3 0  and D5 3 5  in CD8 1  epitopes 
CD81 binding sites have previously provided the focus of conserved 
neutralising epitopes. The main cross neutralising epitopes on E2 
identified so far have commonly been linked to residues G530  and D535 
(J ohansson, Voisset et al. 2007; Law, Maruyama et al. 2008; Perotti, 
Mancini et al. 2008; Mancini, Diotti et al. 2009). Evidence of cross-
neutralising non -CD81 binding site associated antibodies has been 
shown (Grollo, Torresi et al. 2006; Torresi, Fischer et al. 2007). More 
recently, different methodologies have isolated and characterised novel 
cross neutralising antibodies that do not involve CD81 residues; 
although one of these antibodies may target an epitope involving the 
first CD81 binding region and competes with CD81 binding possibly by 
steric hindrance (Sabo, Luca et al. 2011; Giang, Dorner et al. 2012). 
What these data confirm is the reality of finding novel non CD81/ G530-
D535 neutralising epitopes. As a result, the second approach adopted 
for design of an optimal biopanning immunogen target was to 
specifically mutate the residues G530 and D535 of the E2 protein. 
 
The first step in assessing point mutated E2 was to verify the effect on 
E2 conformation using the antibody H53 known to be broad-acting, 
conformation-sensitive and does not compete with CD81 (Cocquerel, 
Meunier et al. 1998). This antibody does not recognise E2 of genotype 2 
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and so the low signal observed in  Figure 4.7 against the wild type 2B E2 
confirms this and thus reflects background noise. Equally, the point 
mutations were performed in genotype 1A20.8 E2 which H53 does 
recognise. 
 
Figure 4 .7  Com parison of binding by non CD8 1  conform at ional m ouse 
ant ibody H5 3  to E2  of genotype 2 b and 1 a in w hich CD8 1  binding 
residues G5 3 0  and D5 3 5  have been point  m utated to alanine 
individually and together  ( G, D and GD respect ively) .  
GNA capture ELISA with 1 µg/ m l of soluble E2, probed with H53 supernatant  
1: 500 and detected with species specific alkaline phosphatase ant ibody with 
BCI P subst rate. Data plot ted relat ive to wild type 1A E2 protein. One way 
ANOVA was perform ed for each E2 const ruct  relat ive to 1A wild type with 
Bonferroni post  t est  with alpha as 0.05 ( * * * = p< 0.001, * * * * = p< 0.0001) .  
 
H53 demonstrated a consistent binding profile against the panel of 1A 
E2 constructs with no discernible difference among the single point 
mutations. The double mutation of G530 and D535 together did 
however cause a drop in binding, which indicates that changing both 
residues results in a loss of conformation. Therefore, of the choice 
between the three point-mutated versions of the E2 analysed, either of 
the single mutations would be preferable as a choice of target for 
biopanning as it retains native conformation. 
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Figure 4 .8  Com parison of binding by CD8 1  com pet ing ant ibodies to E2  of genotype 2 b and 1 a in w hich the key CD8 1  residues 
G5 3 0  and D5 3 5  had been point  m utated singly or  together to alanine. 
GNA capture ELISA with 1 µg/ m l of soluble E2, probed with prim ary ant ibody at  1 µg/ m l and detected with species specific alkaline 
phosphatase ant ibody with BCIP subst rate. Data plot ted relat ive to wild type 1A E2 protein.  One way ANOVA relat ive to 1A binding was 
perform ed for each E2 const ruct  with Bonferroni post  t est  at  alpha as 0.05 ( * = p< 0.05, * * = p< 0.01, * * * = p< 0.0001, * * * * = p< 0.00001) .  
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The dependence on residues G530 and D535 by known CD81 binding 
site epitopes was assessed in order to determine which E2 construct 
could abolish the known epitopes without compromising E2 
conformation. In a GNA-coated ELISA, the relative binding of each E2 
protein tested here was plotted against the wild type 1A. For all 
antibodies the more influential residue for maintaining the epitope was 
consistently D535 (see Figure 4.8). Binding to the epitopes for A8, 1:7 
and AR3A was almost completely abolished with the mutation of D535A 
whereas only a variable drop in binding was observed for G530A. AP33 
does not use G530 and D535 as contact residues for its epitope. The 
AP33 epitope does however overlap with the first CD81 binding site and 
so AP33 can exhibit competition with the CD81 molecule directly at this 
epitope. Any competition between AP33 and the CD81 protein at other 
CD81 binding sites could be due to steric hindrance. It is therefore 
interesting that D535A in the third CD81 binding site affected binding of 
multiple CD81 competing antibodies to their epitopes when G530A or 
G530A-D535A did not. Taken together, soluble E2-D535A is a 
promising target for biopanning or as a vaccine immunogen as it retains 
native form while abolishing many CD81 based epitopes. 
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4 .3 . Discussion 
Previous studies have shown that HVR1 occludes the first putative CD81 
binding site due to its proximity to this region and to an observed 
improvement in CD81 binding when HVR1 is removed (Bankwitz, 
Steinmann et al. 2010; Prentoe, J ensen et al. 2011). Roccassecca and 
McCaffreys papers both demonstrated that in the absence of all three 
HVR’s, soluble E2 showed improved CD81 binding (Roccasecca, 
Ansuini et al. 2003; McCaffrey, Boo et al. 2007). More recently 
however, McCaffrey further showed a contradictory loss of CD81 
binding with any deletion of HVR’s other than HVR1 (McCaffrey, 
Gouklani et al. 2011).  Contrary to previous results, these last data imply 
that HVR1 has no influence on CD81 binding and that the removal of 
HVR2 or 3 are predominantly detrimental to this function. An 
important difference in the latest data from McCaffreys group and the 
previous literature is the use of E1E2 whereas the previous data was 
based on E2 alone. This has functional significance as the production of 
the E1E2 heterodimer has been shown to have interdependence 
between E1 and E2 in a manner that does not appear to affect 
production of E2 alone (Choukhi, Wychoski et al. 1998; Bartosch, 
Dubuisson et al. 2003; Brazzoli, Helenius et al. 2005). So, the different 
relationships observed by McCaffrey in E2-CD81 binding when E1 is 
involved, may be showing an involvement of E1 in the final 
conformation of E2 that could also be impacting on CD81 binding. The 
full functional relationship between E1 and E2 still has many elements 
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that are not fully defined. So, to understand the antigenic relationship 
between E2 and the HVR’s, analysing E2 alone may result in some 
oversight of the full functional importance of parts of E2 with E1, but 
will allow a clearer interpretation of the effects specifically on E2 if E1 is 
not present. 
 
The data presented here are in line with Roccasecca and McCaffreys 
initial finding that improvement in CD81 binding occurs upon deletions 
of the HVR’s (Roccasecca, Ansuini et al. 2003; McCaffrey, Boo et al. 
2007). This implies that all hypervariable regions act to shield CD81 
binding sites. According to the E2 tertiary structure model proposed by 
Kreys group (Krey, d'Alayer et al. 2010), this can be envisaged for HVR1 
and HVR3/ IgVR as they lie close to the first putative CD81 binding site 
and between the last two CD81 binding sites respectively. HVR2 on the 
other hand does coincide with the second putative CD81 binding site 
causing a loss of some of the key residues in  this region. This makes it 
even more interesting that the removal of HVR2 should enhance CD81 
binding. What this means is that the removal of the HVR’s has caused 
secondary effects in the E2 protein. If HVR removal can cause improved 
access to regions that are elsewhere on E2, then there must be some 
degree of conformational shift to allow the antigenic exposure. Apart 
from the triple deleted E2 that had a different truncation, both E2 
constructs that had HVR2 deleted showed the best improvement in 
CD81 binding by more than 100%. Therefore, whereas previous groups 
have indicated that a triple HVR deleted E2 immunogen would provide 
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optimal epitope exposure, the data here show that HVR2 is the most 
influential of the three HVR’s for advocating exposure of the CD81 
binding-sites. 
 
The latest data from McCaffrey and her group also showed the 
functional importance of the HVR’s for HCV infectivity and replication 
(McCaffrey, Gouklani et al. 2011). Their data showed that without HVR2 
or 3, HCV lost the ability to infect by cell to cell transmission and also 
showed impaired ability to replicate efficiently. Deletion of HVR1 
however, hindered replication and entry though adaptive mutations 
allowed partial restoration of the ability to infect by the pseudo-particle 
in vitro assay. Whilst there are functional differences in the mode of 
infectivity for cell to cell and cell free infection, consequently affecting 
the role of E2 in  both processes, the possible loss of native structure 
from the observed loss of function of HCV E2 without HVR’s makes a 
vaccine/ immunogen virus model lacking HVR’s less favourable.  A 
functional factor that affects HVR2 and 3 but not HVR1 is the presence 
of glycans; HVR2 containing glycan 5 and HVR3 containing glycan 9, 
both having a moderate effect on in vitro infectivity, release from cells 
and sensitivity to neutralisation (reviewed in (Helle, Duverlie et al. 
2011). Taken together, the loss of the glycans within the HVR’s be partly 
responsible for the effects demonstrated in  McCaffreys most recent 
paper (McCaffrey, Gouklani et al. 2011). However, this would only be 
applicable to the deletion of HVR2 or 3, highlighting that other factors 
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are also involved in the detriment of viral function upon removal of the 
HVR’s. 
 
Infectivity assays using pseudo particle virions expressing E1E2 of 
various point mutations have shown that either G530 or D535 were 
crucial for entry as less than 5% infection was observed relative to wild 
type when these particular mutations were present. Likewise, CD81 
binding was almost completely abolished when either residue was 
replaced with an alanine (Owsianka, Timms et al. 2006). So, whilst 
these two residues are functionally essential for HCV, here we have 
shown that they are not essential for E2 conformation, which makes E2 
with either of these residues mutated acceptable as an immunogen in a 
vaccine model or as the antigen target in  biopanning. 
 
The S2 cell line has previously been used to produce HCV E2 protein for 
the purpose of modelling its structure (Krey, d'Alayer et al. 2010).  
Elsewhere and here, S2 expressed E2 has been deemed an acceptable 
surrogate for the in vivo protein. Biopanning allows the isolation of 
novel antibodies according to the choice of antigen target. Preliminary 
data has been provided by Prentoes group (Prentoe, J ensen et al. 2011) 
showing an obstructive role of E2 HVR1 in shielding the conserved and 
functional CD81 binding site. There has also been evidence from other 
groups that collectively show the HVR’s sterically hide epitopes 
(Roccasecca, Ansuini et al. 2003; McCaffrey, Boo et al. 2007). So far in 
this project, we have seen that deletion of the HVR’s allows optimal 
160 
 
exposure of the CD81 binding sites. To derive non-CD81 antibodies, the 
CD81 binding site focus of the E2 protein therefore needs to be 
counteracted. So the form of E2 to be used as antigen bait in biopanning 
to identify non-CD81 epitope accessibility should not be the HVR 
deleted model. 
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5 . Acidic environm ent  specifica lly 
m odulates E2  epitope exposure 
5 .1 . Preface 
 
As previously mentioned, the specificities of antibodies derived from 
biopanning can be shaped by the conditions imposed during the 
selection process (reviewed in (Bradbury, Sidhu et al. 2011)). Blocking 
of epitopes recognised by existing antibodies can direct the focus of 
antibody selection away from those antibodies acting at epitopes 
defined by the competing antibodies. Alternatively, specific mutagenesis 
of the target protein can eliminate binding of antibodies targeting 
dominant epitopes. Antibodies that bind to specific conformers of target 
proteins have been isolated from different methodologies without 
adopting specific constraints on the selection pool. Thompson and his 
group isolated their antibody that specifically binds to the fusion-active 
form of the West Nile virus envelope protein by immunisation of mice 
with an un-manipulated protein construct (Thompson 2009). Likewise, 
antibodies identified elsewhere that bind to post attachment forms of 
viral envelope proteins thus inhibiting fusion, were isolated from 
hybridomas that had been generated following immunisation with 
native viral protein (Imai, Sugimoto et al. 1998; Edwards and Dimmock 
2001). Taken together, if antibodies directed at fusion active forms of 
viral envelope proteins can be isolated for related viruses, and if 
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adapting selection conditions in biopanning can direct the specificity of 
antibodies to be isolated, it could be possible to derive antibodies 
against HCV E2 in its fusion active form to potentially act at a post 
attachment stage to inhibit fusion and thus entry. Indeed, functionally 
different conformers of caspase-1 protein have been used in phage 
display to specifically select antibodies targeting the active form of the 
protein (Gao, Sidhu et al. 2009). Therefore, to identify an antibody by 
biopanning that targets an entry intermediate of HCV E2, the 
conditions to be used in the biopanning process need to be defined such 
that the E2 target molecule can best represent the in vivo fusion active 
form. 
 
Current literature has shown pH to be a pivotal factor in HCV fusion 
(Lavillette, Bartosch et al. 2006; Tscherne, J ones et al. 2006; Haid, 
Pietschmann et al. 2009). There are also indications that E2 exhibits 
conformational changes (Keck, Op De Beeck et al. 2004; Op De Beeck, 
Voisset et al. 2004) during the entry process as occurs for other viruses 
(Maeda, Kawasaki et al. 1981; Sattentau and Moore 1991; Despres, 
Frenkiel et al. 1993; Lescar, Roussel et al. 2001). Antibody binding has 
been demonstrated to result in a subsequent change to the antigenic 
profile of E2 thereby providing indirect evidence of conformational 
changes in the E2 protein (Keck, Op De Beeck et al. 2004). Similarly, E2 
epitope exposure was also affected by redox status as the E2 
immunogenicity was distinctly improved upon mild reduction of the 
soluble protein (Fenouillet, Lavillette et al. 2008). The related Pestivirus 
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Bovine Viral Diarrhoea Virus (BVDV) was shown to be unaffected by 
exposure to reducing agents in a neutral pH environment and yet in an 
acidic environment, the reducing agents inactivated the virus (Krey, 
Thiel et al. 2005). It is therefore important to understand the complex 
interplay between various factors to induce functional changes in 
envelope proteins so that we can fully appreciate the role of 
conformation of envelope proteins during the entry process. 
 
Taken together, it is likely that E2 conformation and thus epitope 
exposure is affected by environmental conditions that facilitate entry/  
fusion in vivo. Therefore, given that acidic pH is a prerequisite for 
completion of fusion, and conformational changes in E2 are also likely 
to be involved, it is likely that changes in the E2 protein conformation 
during the entry process enable exposure of conserved sites as occurs 
for other acid-dependent conformation-responsive viruses (Sattentau 
and Moore 1991; Smit, Moesker et al. 2011). Therefore, the antigenic 
state of variably acidified E2 was investigated to decipher conditions for 
optimal mimicking of the fusion active state of E2 to be used as a 
biopanning target. 
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Figure 5 .1  Schem at ic representat ion of the E2  epitopes analysed for  
var iable exposure in acidic condit ions. 
Also m arked in red boxes are the highly conserved CD81 binding sites for which 
AP33, 1: 7, AR1A and AR3A epitopes overlap with. 
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5 .2 . Results 
5 .2 .1 . E2  rem ains stable under acidic incubat ion 
To assess the conformational effect of soluble E2 acidification, it was 
first necessary to verify that the protein remained stable under acidic 
conditions. An obstacle to this was the possibility that pH could affect 
the coating/ binding of the E2 protein to the microtiter plate, over the 
course of the assay, thus affecting the absolute amount of E2. So, the 
first assay was to look at the relative amount of E2 that remained 
present in the plate following incubations of various pH levels (see 
Figure 5.2). 
 
Figure 5 .2  The effect  on prote in coat ing w as looked at  using tw o 
different  st rains of E2  from  different  genotypic groups ( 2 B and 1 A) . 
Soluble E2 was coated in an ELISA with incubat ions of various pH levels probed 
with an ant ibody specific for the C- term inal st rep tag. The negat ive cont rol 
(neg)  had no E2 coated. One way ANOVA with Bonferroni post  test  relat ive to 
neut ral pH 7.5 stat ist ical analysis ( * * * =  p< 0.001, * * * * = p< 0.0001) . 
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Using an antibody specific to the tag associated with the soluble E2 
protein, a pH dependant loss of binding was observed. This data would 
indicate that the acidic pH proportionally affects the E2 protein and/ or 
the associated tag where the epitope lies. Equally this data did not 
distinguish whether the apparent loss of binding was due to an effect on 
the protein affecting binding, an effect on the antibody affecting binding 
to the epitope or if it indicated a loss of absolute E2 present in the assay. 
Therefore, the same assay was repeated with an antibody that 
recognises a linear epitope at the C terminus of the E2 protein shortly 
before the junction to the strep-tag (see Figure 5.3). 
 
Figure 5 .3  St rep- tag dependant  and independent  detect ion of soluble  
E2  over a range of pH  levels. 
Acidic incubat ions were perform ed in ELISA form at  to assess the effect  of pH on 
uncoat ing of an ELISA plate when coated with soluble E2. ALP98 recognises a 
linear epitope at  residues 644-651. One way ANOVA with Bonferroni post  test  
relat ive to neut ral pH was perform ed for ALP98 data ( * * = p< 0.01)  
 
ALP98 is a murine antibody that potently binds a linear epitope at the C 
terminus of the E2 protein (Owsianka, Clayton et al. 2001). However, 
this antibody does not recognise genotype 2 and so was only compared 
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to the anti-strep tag binding for genotype 1 soluble E2. Figure 5.3 shows 
that the pH-dependant loss of binding by the anti-strep antibody is 
restricted to that antibody and not a universal effect. The signal derived 
by ALP98 remains centred around 100% up to pH 4.5, after which there 
is a 20% loss of signal at pH 3.5. Binding effects on the ALP98 antibody 
due to pH are therefore less prominent than for the anti-tag antibody, or 
possibly compensated by additional effects that improve binding 
kinetics. The loss of signal at pH 3.5 is possibly due to some un-coating 
of E2 from the plate or an effect on E2 itself. So, if ALP98 binding 
activity is un-/ minimally affected by pH, from pH 7.5 to 4.5, the soluble 
E2 remains coated to the ELISA plate. 
 
 
Figure 5 .4  St rep- tag dependant  and independent  detect ion of soluble  
E2  1 A2 0 .8  over  a  range of pH  levels. 
Acidic incubat ions were perform ed in ELISA form at  to assess the effect  of pH on 
E2 conform at ion. H53 recognises a CD81 binding site independent  and 
conform at ion-dependant  epitope with contact  residues 540 and 550 in dom ain 
I .  One way ANOVA was perform ed relat ive to neut ral pH with Bonferroni post  
test  alpha as 0.05 ( * = p< 0.05) .  
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Having shown that acidification of E2 does not appear to cause 
significant loss of protein from the assay, the relative stability of the E2 
protein in the acidic environment was tested with the conformation 
sensitive murine antibody H53 (see Figure 5.4). Indeed, there was no 
loss of binding by the antibody H53 over the various acidifications. The 
loss of binding shown by the anti-tag antibody indicates that there was 
indeed a lowering of pH and so taken together, if the antibodies used 
here are not subject to changes in binding activity due to acidification, 
no loss of conformation in E2 has been observed. Such pH related 
effects on antibody binding would need to be determined before a final 
conclusion. However, as the pH was reduced, an improvement of 
binding by antibody H53 occurred peaking at around pH 5.5, indicating 
a possible effect in binding kinetics. Unlike ALP98, H53 did not show 
any loss of binding at pH 3.5. So, either the implied loss of E2 by ALP98 
at pH 3.5 does not affect H53 or the favourable binding kinetics 
demonstrated with H53 compensates for loss of E2 present at the lower 
pH. 
 
5 .2 .2 .  Acid exposure induces perm anent  effects 
To assess the conformational effects on E2 due to acid exposure, any 
trends observed need to be a true reflection of E2 associated changes 
and not an indication of factors such as effects on the probing antibody. 
In order to clarify this, the effect on binding kinetics was compared 
when E2 was acidified then neutralised prior to coating onto an ELISA 
plate versus acidification during the incubation with primary (probing) 
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antibody (see Figure 5.5). Equal amounts of protein were coated onto 
the plate from each set-up in which acidification was at pH 5.5 known to 
be crucial for HCV entry and thus most likely to induce any functionally 
important conformational shifts in the E2 protein. 
 
Figure 5 .5  Binding of soluble E2  1 A2 0 .8  in different  ELI SA set - ups. 
E2 either rem ained at  neut ral pH throughout  the assay (neut ral;  blue bars) , 
acidified at  pH 5.5 then neut ralised prior t o coat ing (pre-acid;  red bars)  or 
acidified to pH 5.5 during the ant ibody incubat ion (ab-acid;  green bars)  and 
detected with either the conform at ion sensit ive ant ibody H53 or an ant ibody 
target ing the at tached tag. Stat ist ical significance was tested with a one way 
ANOVA with Bonferroni post  t est  analysis ( * , p< 0.05, * * * * ,  p< 0.0001) .  
 
In Figure 5.2, Figure 5.3 and Figure 5.4 there was an evident loss of 
binding with anti-tag specific antibody following incubation at pH 5.5 
compared to no acidification/ neutral conditions (pH 7.5). Figure 5.5 
shows that whilst up to 50% loss of binding can be observed by the anti-
tag antibody in the presence of acidic pH 5.5, only ~20% of this effect is 
in a permanent antibody-independent manner. The E2 itself however, 
may not necessarily exhibit the same effect in the two acidification set 
ups as the attached tag. Therefore, the conformation dependant 
antibody H53 was used to see if the observed effect on binding is 
retained when E2 is acidified prior to coating, and thus a permanent 
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effect on E2. Figure 5.4 shows that there was an increase in binding 
signal of around 15% for H53 when the antibody incubation occurred at 
pH 5.5. This increased binding however was not reflected with 
acidification prior to coating as seen in Figure 5.5, therefore indicating 
that change in binding of up to 15% is either due to a transient pH effect 
on E2 and thus the epitope, or effects on the H53 antibody and/ or 
binding kinetics. Literature looking at the stability and biological 
activity of murine (Matikainen 1984; J iskoot, Beuvery et al. 1990; 
Vemeer and Norde 2000) and human antibodies (Castle, Karp et al. 
2002; Ejima, Tsumoto et al. 2007) has consistently shown a lack of 
conformational or binding effects above pH 4, requiring lower pH and 
long incubations of at least 16 hours or temperatures above 50 oC to see 
significant changes. Therefore, in the pH range 7.5-4.5, effects observed 
in the assays performed in this project can confidently be attributed to 
be a product of changes in E2 before the antibody (though the 
antibodies used will still be susceptible to effects due to the pH to an 
undetermined and individually varying degree). The data in  Figure 5.5 
indicates that a significant portion of the acid induced effects on E2 are 
transient as they were not fully retained following acidification prior to 
E2 being coated on to the ELISA plate. Therefore to test conformation 
effects on E2 due to acidic pH, the effect on antibody binding needs to 
be tested in  the presence of acidic pH (when any such conformation 
effects are most likely to be present).Lastly, the acidification of E2 with 
the incubation of the probing antibody was logistically much less 
difficult to automate over a range of pH levels and so taken together, 
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acidification with antibody incubation was used as the test assay format 
over acidification prior to coating. 
 
 
 
5 .2 .3 . Ant igenicity of E2  is a ltered by pH- induced 
effects in a  st ra in specific m anner 
 
Conformational changes in HCV E2 have so far been assumed to occur 
during the entry process. In the absence of being able to crystallise the 
E2 protein, there is a lack of structural appreciation of conformational 
differences between its pre and post-fusion form. To try and clarify what 
conformational changes may occur, the antigenic profile of soluble E2 
was assessed with four antibodies recognizing epitopes of a 
conformational and linear nature. The first two antibodies AP33 and 
1:7, target epitopes focused on the first and third CD81 binding sites 
respectively. The second pair of antibodies, AR1A and AR3A, are broad 
acting and target discontinuous epitopes that overlap with two or more 
of the highly conserved CD81 binding sites; the former being non 
neutralising and the latter potently neutralising. The binding signal 
achieved with each antibody was plotted relative to incubation at 
neutral pH (Figure 5.6 & Figure 5.7). 
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Figure 5 .6  Ant ibody detect ion of E2  of tw o st rains ( 1 A2 0 .8  in red bars 
and 2 B2 .8  in blue bars)  over  a range of pH level incubat ions. 
A)  AP33 is a neut ralising ant ibody that  has an epitope focused on the first  CD81 
binding site. B)  1: 7 is a neut ralising ant ibody with an epitope focused on the 
third CD81 binding site. Stat ist ical test ing is by one way ANOVA all relat ive to 
neut ral pH 7.5 ( * =  p< 0.05, * *  P< 0.01, * * * =  p< 0.001, * * * * =  p< 0.0001) .  
 
Figure 5.6 show the epitope exposure over a pH scale from 7.5 to 3.5 for 
soluble E2 of genotypic strain 1A20.8 and 2B2.8 with antibodies AP33 
and 1:7. What is immediately evident for AP33 is a difference in pattern 
between the two strains as the pH is decreased. Epitope exposure for 
AP33 showed a different profile for the two strains of E2: E2 of strain 1a 
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showed a peak epitope exposure at pH 5.5 then returning close to 100% 
at the lowest pH, whilst strain 2b showed an improvement in epitope 
exposure proportional to the increase in acidity. This has two 
consequences. Firstly, the antigenic state of E2 is pH-affected and 
secondly such trends are also strain  specific. However, the epitope for 
1:7 however showed no significant changes in epitope exposure over the 
pH range tested here. 
 
The second pair of epitopes examined were discontinuous epitopes 
overlapping with multiple CD81 binding sites, but with only one of them 
being neutralizing; neutralising antibody AR3A and AR1A as non-
neutralizing (see Figure 5.7). Given that parts of these epitopes overlap, 
there is some degree of competition between these two antibodies (Law, 
Maruyama et al. 2008), however the differences between these epitopes 
denote that the antibodies have differing phenotypes. The antigenic 
profile of E2 using these antibodies, like 1:7, did not show a significant 
pattern over the pH range, or a distinctly different profile from the two 
strains of E2 tested. However, AR1A did show a significant drop in  
epitope exposure at the lowest pH tested for both E2 strains. 
 
Taken together, the data here support that acidic pH induces changes in  
the antigenic profile in  a strain and epitope-specific manner. Given that 
pH 5.5 has been shown to be the optimal pH for fusion to occur in the 
endosome, a pH of 5.5 was taken forward as a promotive factor to 
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induce a fusion active state in  the soluble E2 for biopanning to select 
fusion related antibodies. 
 
 
Figure 5 .7  Ant igenic test ing over a  pH range of 7 .5 - 3 .5  w ith 
ant ibodies recognising discont inuous epitopes. 
A)  Conform at ion-sensit ive neut ralising ant ibody AR3A, which has a 
discont inuous epitope spanning the cent ral dom ain I  and residues near the first  
and third CD81 binding sites. B)  Non-neut ralising conform at ion sensit ive 
ant ibody AR1A has a discont inuous epitope that  coincides with the first  and 
second CD81 binding site with other contact  residues close to the third. 
Stat ist ical significance is from  a one way ANOVA relat ive to neut ral pH 7.5 for 
each st rain ( * * =  p< 0.01, * * * p< 0.001) .  
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5 .3 . Discussion 
The strep tag attached to the E2 molecule consisted of 8  amino acids, 
one of which is a histidine. The consequence of this amino acid is that as 
the pH level lowered, there was protonation of the histidine which could 
sterically affect the ability of the anti-tag antibody to recognise its 
epitope. Therefore, the pH-dependant loss of binding by the anti-tag 
antibody over a pH range did not truly reflect a loss of absolute strep-
tag associated E2 in the assay but instead indicated the degree of 
acidification as the more acidic the environment, the greater the 
proportion of histidine residues in the pool of E2-tag molecules present 
became protonated. Figure 5.5 shows that effects of protonation of the 
E2 and associated tag were only partly retained following acidification 
prior to coating compared to acidification in the presence of the anti-tag 
antibody, and thus the acid related effects observed are either partly 
reversible or partly a reflection of effects on the antibody itself, if not 
both. For the E2 conformation sensitive antibody H53, there was no 
apparent difference in  binding between the neutral E2 control and the 
E2 acidified prior to coating E2. This indicates that either any E2 effects 
due to acidification were reversible, or any changes did not affect H53 
binding its epitope. When acidification occurred in the presence of the 
antibody, however, a 13% difference was observed therefore indicating 
that up to 13% of binding is affected by transient changes in epitope or 
that an acidic environment affects binding kinetics by up to 13%. Figure 
5.5 shows that for the anti-tag antibody, a minimum of 12% difference 
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in binding could be attributed to permanent changes in its epitope on 
E2. However, given the differences in individual antibody-epitope 
binding in response to pH effects, a universal standard is not 
appropriate for the panel of antibodies. 
 
The question of monoclonal antibody stability in pH varying 
environments has been addressed previously with a consistent outcome. 
Preliminary studies by Matikainens group showed that in ELISA format, 
murine antibodies retained significant binding even after incubation at 
pH 4-9 for over 16 hours (Matikainen 1984). Further to this a multitude 
of assays were used to assess antibody activity and stability following 32 
days incubation at pH3-10  followed by neutralisation (J iskoot, Beuvery 
et al. 1990). Collectively, ELISA, flow cytometry, gel permeation 
chromatography, fluorescence polarisation and quenching, IEF and 
western blot analysis showed only loss of antibody activity from 
incubation at the extreme pHs. Fluorescence spectroscopy, ultraviolet 
CD, birefringence, and calorimetric methods showed significant 
changes in  conformation of murine monoclonal antibodies only at pH 
below 3.5 with temperatures above 50 oC (J iskoot, Beuvery et al. 1990; 
Vemeer and Norde 2000). This data from murine antibody analysis 
suggests that pH effects observed in this project are likely due to E2 
epitope related changes, however differences between individual 
antibodies and species differences cannot be ignored. Indeed, one 
analysis of human monoclonal antibodies showed no change in stability 
or binding following incubations at pH 4 or above (Castle, Karp et al. 
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2002). Only after 24 hours of incubation at pH 3.5 was blocking activity 
affected or antigen binding seen to be reduced by more than 40%. 
Circular dichroism (CD), differential scanning calorimetry (DSC), and 
sedimentation velocity have also been used to assess stability and 
conformation of human monoclonal antibodies exposed to pH 2.7-3.9 
as can occur during purification process (Ejima, Tsumoto et al. 2007). 
Overall no gross conformation changes were observed, and following 24 
hours of incubation at acidic pH in 4 oC near UV CD-spectra showed the 
acid conformation was stable. Taken together, the literature is 
consistent with the view that antibodies undergo limited conformational 
change and so support pH effects observed here to be attributable to 
changes in the E2 epitopes. 
 
The entry process of flaviviruses such as dengue virus and West Nile 
virus are known to include conformational changes in the envelope 
proteins that facilitate fusion. The data presented here show that E2 
firstly remains stable and secondly exhibits changes in epitope exposure 
in a locally restricted manner as an effect of exposure to an acidic 
environment. Therefore, as related virus envelope proteins expose 
conserved sites specifically during the entry-fusion process, HCV E2 is 
also likely to do so in response to a lowering of pH in the endosome or 
linked with other factors/ aspects of the entry. The proposed fusion 
peptide of HCV E2 is located in domain II close to the second CD81 
binding site (Krey, d'Alayer et al. 2010). The only antibody tested here 
with an epitope involving residues in this region was AR1A which only 
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showed an effect at the lowest pH where upon residues other than 
histidine can become protonated. Continuing this analysis with 
antibodies that target epitopes in the vicinity of the fusion loop would 
give a better indication of how the locality of the fusion loop may change 
its exposure during the entry process.  
 
Figure 5 .8  Schem at ic representat ion of the locat ion of hist idine 
residues in the linear E2  form  for  E2  st rains 1 A 2 0 .8  ( A)  and 2 B2 .8  
( B) .  
Red boxes m ark the locat ion of the four putat ive CD81 binding sites, purple 
dashed lines the hist idine residues and the coloured boxes the act ive epitopes 
for  each st rain. 
 
Figure 5.8 shows the relative positioning of all histidine residues, CD81 
binding sites and epitopes examined in this study. Between pH 7.5 and 
4.5, the only amino acid that would become protonated in this range is 
histidine and only the AP33 epitope for strain 2B2.8 was significantly 
acid affected in this pH range. There are multiple examples of histidine 
protonation causing low pH associated structural changes (Lazar, 
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Marshall et al. 2003; Nordlund 2003), even within the endosome and 
so this event is thought to play a critical role for viral fusion (Chen, Lee 
et al. 1998; Bressanali, Stiasny et al. 2004; Da Poian, Carneiro et al. 
2005; Roussel, Lescar et al. 2006). A difference in the location of the 
histidine residues between the two strains of E2 is that a histidine at 
residue 384 in strain 2B2.8 is not present in strain 1A20.8. According to 
the proposed tertiary structure of E2  (Krey, d'Alayer et al. 2010), 
residue 384 is in closer proximity to the AP33 epitope than the two 
histidines of strain 1A20.8 at residues 444 and 445, which are buried 
deep in the centre of domain I. Taken together, it is possible that the 
acid related effect of the AP33 epitope exposure in strain 2B2.8  is a 
secondary consequence of the protonation of the histidine at residue 
384. To further investigate this, specific mutagenesis of this residue to 
another polar amino acid such as glutamic acid or aspartic acid and also 
to a non-polar amino acid such as glycine to repeat the antigenic testing 
would elucidate how protonation of specific residues affects exposure of 
certain epitopes. 
 
Genotypic differences in HCV E2 function have been observed 
elsewhere (Prentoe, J ensen et al. 2011; Tarr, Urbanowicz et al. 2011). 
Likewise, as an assessment of function, binding to CD81 protein also 
varied over the various genotypic strains looked at (Albecka, Montserret 
et al. 2011). Taken together, the inter-strain difference in binding profile 
observed here is thus likely to be a real effect and not solely an artefact 
of the assay. 
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6 . A phage display select ion m ethod 
using a novel target  
6 .1 .  Preface 
 
Biopanning is an in vitro display technology for isolating novel ligands 
for a given peptide. Such a ligand may be in  the form of an antibody or 
conversely in the form of an epitope that a given antibody recognizes. 
Phage display is the most popular biopanning format and has indeed 
been used to isolate the main broad acting neutralizing antibodies 
targeting HCV E2 known to date. Various vectors exist to create 
libraries for use in biopanning; though all the E2-antibodies derived 
from phage display mentioned here came from libraries of the same 
vector (J ohansson, Voisset et al. 2007; Law, Maruyama et al. 2008; 
Perotti, Mancini et al. 2008; Mancini, Diotti et al. 2009; Giang, Dorner 
et al. 2012). In 1991 a new phagemid system was published that allowed 
the creation of combinatorial Fab libraries on the surface of the M13 
phage particle (Barbas, Kang et al. 1991). Monovalent display of the Fab 
molecules fused to pIII capsid protein along with the use of VCSM13 
helper phage is the basis of the type 3+3 library formats that have 
generated anti-E2 antibodies. In this vector, the light chain and heavy 
chain are produced separately and come together associated to the 
protein product of gene III to which the heavy chain is fused (see Figure 
6.1 and Figure 6.2) 
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Figure 6 .1  Linear sequence form at  of the pCom b 3 H vector w ith gene 
inserts for  Fab com binatorial library of 3 + 3  form at  as used here and 
elsew here ( Barbas and W agner 1 9 9 5 ) . 
 
 
 
Figure  6 .2   pCom b 3 H phagem id vector layout .  
Depicted are gene inserts, rest r ict ion sites, leader sequences, prom oter and 
linker ( fusing the heavy chain to the gene I I I  protein product )  as in Figure 6.1. 
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In recent years novel antibodies have been identified targeting envelope 
proteins of related and similar viruses to HCV. West Nile virus is related 
to HCV and has envelope proteins that undergo conformational changes 
during the entry process exposing key epitopes that can be targeted to 
block fusion and completion of the entry process (Thompson 2009). 
Similarly, antibodies that target cryptic epitopes found on envelope 
proteins only exposed after the initiation of the entry process have been 
isolated for HIV (Zwick, Labrijn et al. 2001). As discussed earlier, 
should HCV E2 also undergo conformational changes during entry, 
there is the potential to uncover novel epitopes that can be targeted as 
an antiviral strategy. Earlier discussion has elaborated the current data 
on E2 and the evidence for conformational responses to factors such as 
pH. In section 5 we saw that the exposure of conserved epitopes that 
overlap with CD81 binding sites was positively affected by an acidic 
environment. Indeed the CD81 binding sites are highly conserved and 
most importantly, the first and third site looked at most closely are 
centrally located in the E2 protein according to the current model (Krey, 
d'Alayer et al. 2010). Therefore, the evidence so far suggests that in a 
fashion similar to viral breathing described elsewhere (Dowd 2009), 
HCV E2 also shows temporally improved exposure of central and 
conserved regions, however, in specific response to prolonged pH 
exposure. Therefore, novel epitopes might also be exposed with this 
antigenic effect. To increase the chances of targeting a novel epitope in 
the biopanning format, conditions to induce the exposure of such 
epitopes need to be defined. Given the data, here and elsewhere, 
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acidification of E2 was taken as a prerequisite condition of the antigen 
target for the biopanning process. Also, to improve the likelihood of 
identifying a novel epitope that is not dependent on the CD81 binding 
sites seen so far to dominate the E2 broadly neutralising epitopes, the 
D535A E2 was chosen to be the antigen target. 
 
Figure 6 .3  I llust rat ion of the select ion process as a cycle of steps. 
 The start ing point  1 pre-m ade library of phage part icles each expressing a 
different  Fab clone associated with the gene I I I  product .  The select ion cycle 
begins with infect ion of a bacterial culture such as XL1-blue by the 
bacteriophage and am plificat ion by growth of the phage producing-bacteria 
depicted as stage 3. Phage part icles are isolated from  the bacterial culture to 
apply to the panning process in step 4-6. This m ay be in the form  of ant igen-
coated ELISA wells or as m agnet ic beads. After  incubat ion to allow adhesion 
between the ant igen capture and the phage part icle, wells are washed to 
rem ove the unbound phage leaving only specifically bound phage part icles in 
step 5. Finally, the pool of specific phage is eluted in step 6 and is ready to 
direct ly infect  a new bacterial culture to init iate a new round of panning. 
 
The phage display protocol in this project included a two-hour 
incubation of the antigen target and the Fab- expressing phage particles. 
The binding event between the phage-displayed Fab molecule and the 
E2 target was in the acidic environment of pH 5.5. To counteract any 
possible secondary effects on the phage and Fab due to the acid 
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environment, a second group in which the E2 target was acidified prior 
to mixing with phage-Fab was panned at neutral pH. 
6 .2 . Results 
6 .2 .1 . Phage infect ivity is not  affected by acidity 
The phage display process designed in  this project involved a prolonged 
incubation of phage in an acidic environment. To verify that this 
incubation would not impair function of the phage particle, infectivity of 
the phage with or without incubation at pH 5.5 (as used in the panning 
process) was compared with all other parameters matched between the 
two test groups for both libraries panned. 
Table 6 .1  Com par ison of phage infect ivit y follow ing test  incubat ions. 
 Library phage were incubated for 2-3 hours at  pH 5.5 or pH 7.5 (non- t reated)  
before infect ing XL1-Blue bacteria at  MOI  > 30 to plate on 1.5%  agar plates 
supplem ented with 50-100 µg/ m l of select ion ant ibiot ic am picillin. Titers were 
derived in duplicate and averages recorded. Unpaired t - test  com parison of 
m eans produced non-significant  p value of 0.3099 for the lam bda library and 
0.688 for the kappa library.   
 Phage t iter  ( cfu/ m l)  
Lam bda Kappa 
Acidif ied neutra l Acidif ied Neutral 
Average 2.098x1010 7.635x1010 2.1x109 1.8x109 
P value 0.3099 0.688 
 
 
The recovered titer of bacteria infected with equimolar aliquots of 
phage, were found to be in the same log range for both libraries showing 
no significant difference according to the unpaired t-test comparison of 
means. The phage were thus concluded not to be functionally impaired 
by the acidic incubation. Any further difference to be observed between 
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the two test groups in the biopanning process could then be attributed 
to effects on the expressed Fab particles themselves. 
 
6 .2 .2 . Titers show  rest r ict ion and enrichm ent  
Four to five rounds of biopanning were performed in which the two test 
groups showed a restriction in titers followed by a further expansion, 
thus indicating enrichment (see Figure 6.4). Though this was much less 
pronounced for the kappa library panning, the recovery of titer in  the 
final panning within the acid group still occurred. However, the neutral 
test group of the kappa library panning had a titer reduced to zero at 
pan 3 and thus a fourth panning did not occur.  
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Figure 6 .4  Biopanning eluate phage t iters after each round of 
select ion recorded in t r iplicate  show n here  as averages.  
Five rounds of panning were perform ed against  the lam bda library (A)  and four 
with the kappa (B) , with the select ion event  occurring in two form ats:  either in 
the presence of pH 5.5 (acid;  red line) , or  at  neut ral pH (7.5;  purple bar)  
where the E2 target  protein had been exposed to pH 5.5 for 20 m inutes then 
neut ralisat ion before applicat ion to the panning to dist inguish perm anent  over 
tem poral acid induced E2 effects.
A 
B 
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6 .2 .3 . Screening by cell lysate ELI SA does not  
dist inguish erroneous clones  
Screening of phage eluates following the biopanning can be performed 
with multiple assay formats. A popular method is to use the bacterial 
cell lysates following overnight culture growth of the phage-producing 
bacteria as the source of expressed Fab in an ELISA. In this format the 
capture can be the same antigen target used in the panning or a 
molecule specific for the phage particle or Fab, such as anti-pIII or 
anti– fd antibody respectively. Using the antigen target as a capture 
allows verification of the specificity of the selected Fab, and the anti-fd 
antibody as a capture allows an assessment of the relative amount of 
Fab/ phage molecules present (given that the cell lysate is a crude 
sample and so has a variable amount of Fab/ phage molecules). With 
these data, the ratio between the signals derived from the different 
captures can be calculated to assess the relative affinities between 
different Fabs. 
Table 6 .2  Calculat ion of relat ive aff init y of Fab m olecules from  a 
select ion of test  bacterial ce ll lysates. 
Clone D5 3 5 A ant igen ( ag)  Ant i fd capture  ( cap)  Rat io 
( ag/ cap)  Average  
( OD 620 nm )  
St . Dev. Average 
 ( OD 620 nm )  
St . Dev. 
N4  0.4175 0.0276 0.4075 0.0389 1.0245 
N1 0  0.4000 0.1414 0.4875 0.0148 0.8205 
A1  0.2735 0.0134 0.2765 0.0063 0.989 
A6  0.8375 0.1732 0.7450 0.0693 1.124 
1 :7  3.9380 0 4.0655 0.0686 0.968 
A ratio greater than 1 was taken as an acceptable affinity of the Fab 
molecule for the antigen as the relative specific binding would be 
greater than the binding signal reflecting amount of phage present. 
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The control clone was the Fab molecule of 1:7 shown in section 4.2.3 to 
have minimal affinity for E2 D535A used here as the antigen target. 
Therefore, given the low expected affinity of 1:7 to D535A, the fact that 
1:7 showed a ratio of less than 1 supported the cut-off level for the ratio 
of binding to distinguish non/ low-binders being not too low. Four 
plasmid DNA test clones were picked out using this analysis: 2 from 
each test group (acidic and neutral incubation). One from each group 
was considered a possible specific binder according to the ratios 
calculated (see Table 6.2). To subsequently assess this method of 
screening, these four clones were separated on an agarose gel following 
digestion with Sac I to verify that they were the correct size. According 
to the vector sequence illustrated in Figure 6.2, there should be a single 
Sac I site that should produce a size of ~4.7 kb. Two of the clones, A6 
and N10, showed a size difference between the digested and undigested 
groups indicating presence of the Sac I site. N4, however, did not appear 
to be digested by Sac I indicating that the phagemid is erroneous though 
the size could be correct at around 5 kb. However, if the phagemid was 
not digested, the inferred size seen in  Figure 6.5 cannot be taken as true. 
On the other hand, clones A6 and N10  that did appear to be digested by 
Sac I showed a resultant size of around 3.5 kb and 4 kb respectively, 
both of which were far short of the expected size.  
 
Figure 6 .5  Sac I  rest r ict ion digest  of three phagem id clones that  w ere 
selected by cell lysate ELI SA binding rat io calculat ion. 
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According to Table 6.2, clones A6 and N4 were possible specific binders 
and yet the restriction digest showed grave errors in these phagemids. 
The test sample in the ELISA was the cell lysate from the bacteria in  
which these phagemids were expressed and therefore also contained 
many other proteins, malformed and otherwise. Therefore, the 
crudeness of the sample could affect the clarity of the assay. 
 
A PCR-based screen was designed to test for the presence of intact 
phagemid clones using two sets of primers that could identify the 
presence of the light chain, heavy chain and the full segment of light 
chain and heavy chain together (see Table 2.5 and Figure 6.1). This 
would produce bands of around 700 base pairs for the individual chains 
and a band around of 1,200  base pairs for the full segment containing 
both chains.  
 
Figure 6 .6  PCR screening of three phagem id clones to ver ify presence 
and correct  size of gene inserts.  
Heavy and light  chain gene inserts were am plified for  t est  clones were A6, N4 
and N10, from  the lam bda library panning with posit ive size cont rols 1: 7 and 
K03 from  the kappa library. 
 
Two control clones were used: 1:7 and a non-E2 binding clone also of 
the same vector named K03. The PCR screen showed that all three 
clones tested proved erroneous whereby they either lacked a gene insert 
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or showed an incorrect size for both genes together. The control clones 
were of kappa lineage and so for the light chain showed no amplification 
due to the use of a lambda-specific primer. This indicates an absence of 
cross-contamination that could produce false positives. Taken together, 
the PCR screen can discriminate erroneous clones that are not complete 
or deletion containing, which would make a beneficial means of initial 
screening before more defined analysis of specific Fab reactivity. 
 
6 .2 .4 . PCR screening of panning eluates 
Bacterial cultures of the panning eluates, which represented a mixed 
population of phagemid, were applied to the PCR screen devised (see 
Figure 6.6). The final three pans from the lambda library panning were 
tested; acid group pan 3, 4 and 5 (A3, A4, and A5 respectively), along 
with neutral group pan 3, 4 and 5 (N3, N4, and N5 respectively). 
Primers specific to either the kappa or lambda light chains were used for 
screening this distinguishing between the two. The control clones 1:7 
and K03 however, contained kappa light chains and so the PCR screen 
using lambda light chain primers for the test clones did not specifically 
amplify their light chains though these clones had been tested elsewhere 
with the correct primer to know that the correct pair did work and that 
the control clones were correct. Use of the lambda light chain primer 
with the kappa controls provided a control for contamination of samples 
thus indicating their purity. PCR screening of panning eluates from the 
kappa library panning was also performed using all eluates available.  
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Figure 6 .7  PCR screen of panning round e luates ( 1 - 5 )  from  the Kappa ( A)  and Lam bda ( B)  library, acid and neut ral panning 
condit ion groups ( A/ N) .   
Am plificat ions of the heavy and light  chain gene inserts were perform ed with the 1: 7 (kappa)  clone as a posit ive cont rol for insert  size.
A B 
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Figure 6.7 A and B shows that the control clones 1:7 and K03 were of 
expected sizes for the heavy and light with heavy chain segment 
amplification (~600 base pairs and ~1,200  base pairs respectively), 
along with no contamination for the lambda light chain amplification. 
The eluates of the neutral pH biopanning group showed a lack of intact 
clones across the 3 pans analysed from both libraries as no light chains 
were amplified from the lambda library, along with a lack of correct 
heavy with light chain in both libraries. For this reason, the neutral pH 
panning groups were discarded from further screening. From the acid 
group pans of the lambda library, pan 5 lacked light chains and the band 
for the amplification of light with heavy chain being very faint implied a 
very low number of phagemid vectors containing the full correct insert. 
Pan 3 and 4, however, distinctly showed the correct size bands for all 3 
PCR amplifications. Only the amplification of both the light and heavy 
chain showed surplus bands matching the size of a single chain, possibly 
a product of non-specific binding as it was fainter, or equally indicating 
the presence of a smaller proportion of vectors containing a deletion in 
the insert. The panning eluates A4 and A3 of the lambda panning acid 
group were thus taken forward as candidate samples for further 
screening. Presence of correct clones throughout the screen of the kappa 
library acid panning eluates supported the final pan (A4) to also be 
taken forward for further screening. Taken together, the PCR screen 
provides a satisfactory method of vetting a mixed population of 
phagemid clones for intact and correctly sized inserts of both Fab genes. 
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6 .2 .5 . Evidence of enr ichm ent  of specific clones 
Given the presence of incorrect clones being found after panning, 
enrichment of correct clones was then tested to complement the titers 
recorded. Figure 6.8 shows the PCR screen applied in section 6.2.3 to 
the lambda and kappa phage library pre-panning (pan 0) as an 
indication of the frequency of intact clones in the starting libraries.  
Thirty individual clones from each library were initially tested using the 
PCR screen to verify the presence of chain segments of the correct size 
in the phagemid vectors. From the Lambda library, only 2 of the 30  
clones showed correct segments for the heavy, light and both chains 
together. This gave a surprisingly low rate of ~7 % intact clones in the 
starting library. The Kappa library showed a higher quality with 30  % 
intact clones for heavy, light and both genes together. To know that the 
biopanning resulted in  enrichment of intact clones, a higher percentage 
of intact clones would be need to be present after panning. 
 
Individual clones from the panning eluates of the Lambda acid group 
pan A3 and A4, along with the Kappa acid group A4 were also tested 
with the PCR screen of the heavy and light chain together (see Figure 
6.9 and Figure 6.10). Lambda Pan 3 showed 70  % intact segments with 
varying strength of the visible band and some lanes showing surplus 
bands of smaller sizes. Looking only at the lanes that contained a single 
band of the correct size, the proportion is lowered to 25 %. However, 
this is still over three times that of the initial proportion found in the 
un-panned library shown in Figure 6.8. At pan four, however, there are 
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no visible bands of the correct size. Given the presence of the correct-
sized band when looking at the pan eluate as a whole in Figure 6.7, the 
result is thus more likely to be showing that the proportion of intact 
clones in A4 was reduced to less than 1 in 20/  5% and so would not be 
showing any enrichment of intact clones. Taken together, the acid group 
pan A3 showed an enrichment of intact clones and so was taken forward 
as the eluate to be screened for specific reactivity against the antigen 
target. 
 
 
 
 
Figure 6 .8  PCR screen of 3 0  individual phagem id clones from  the 
Kappa ( A)  and Lam bda ( B)  library phagem id pool pre- panning.  
Clones 1: 7 and K03 act  as posit ive cont rols for  insert  size.  
A 
B 
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Figure 6 .9  PCR screening of phagem id clones from  the final tw o 
panning rounds of the lam bda library. 
Heavy with light  chain gene inserts for 20 individual phagemid clones from  pan 
group A3 and A4 of the Lam bda library panning were com pared to the posit ive 
cont rol 1: 7. 
 
Analysis of the final panning output from the kappa library panning is 
shown in Figure 6.10 .  Out of twenty clones, 50% were shown to have 
intact light chain, heavy chain and both genes together of a correct size. 
This is a 20% improvement, which is much less than seen for the 
lambda library even though the initial kappa library contained a higher 
proportion of correct clones. Overall, however, enrichment of correct 
clones was evident for the acid test panning groups from both libraries. 
  
Figure  6 .1 0  PCR screening of kappa library phagem id clones. 
Am plifying the heavy, light  and heavy with light  chain gene segm ents of 
selected clones from  panning group Acid-4, with 1: 7 as posit ive cont rol clone. 
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6 .2 .6 . React ivity of panning eluates by ELI SA 
Panning eluate purified phage were tested in ELISA to verify specific 
reactivity against E2. One eluate from the lambda neutral panning 
group was included for comparison and the Fab clone 1:7 acted as the 
positive control. Figure 6.11A shows that of the lambda panning, neutral 
panning group 5 (N5) and acid panning group 4 (A4) had significantly 
less specific reactivity than 1:7 clone, unlike acid panning group 3 
according to a one way ANOVA. This data thus supports the decision to 
screen the eluate from panning 3 of the lambda acid panning group for 
E2-specific clones. The final panning from the Kappa library showed 
improved reactivity to E2 over the previous panning compared to 
background binding and was therefore also screened further (see Figure 
6.11B).  
Figure 6 .1 1  ELI SA test ing the react ivity of the Lam bda ( A)  and Kappa 
( B)  library panning eluates against  E2  1 A2 0 .8 .  
Stat ist ical significance was tested with a one way ANOVA with Bonferroni post  
test  analysis ( * * =  p< 0.01) . 
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6 .2 .7 . I ndividual selected clones show  posit ive 
react ivity against  E2  in ELI SA 
PCR analysis of phage clones showed 7 phage clones from the lambda 
library panning correctly containing intact heavy and light chain gene 
inserts (see Figure 6.9). Reactivity was tested in ELISA format against 
wild-type E2 of genotype 1a against which the positive control 1:7 shows 
optimal binding, against D535A E2 as used in the panning process, and 
also against blocked wells to indicate non-specific binding. The positive 
control, known to lose binding ability where residue D535 is mutated, 
showed an expected loss of binding against D535A that matched the 
non-specific binding to the blocked well (See Figure 6.12). The clone 
K03 is a non-E2 binding clone and so indicates non-specific binding. 
Test clones 9, 12, 14 and 15 showed significant differences binding to 
wild-type E2 compared to the non-specific binding to the blocked wells 
and D535A E2. Along with the crudeness for the assay possibly masking 
the full extent of such relationships, these data were taken as indicative 
of potential for greater reactivity in the form of IgG and therefore, it  was 
concluded that all clones analysed here were possible candidates for 
subcloning into a mammalian expression system to be produced as IgG 
for further reactivity and specificity testing. 
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Figure 6 .1 2  React ivit y of selected phage Lam bda clones to E2  w ild-
type protein or D5 3 5 A target  protein in ELI SA. 
1: 7 binding to wild- type E2 provided the posit ive cont rol set  at  100%  with 
blocked wells indicat ing non-specific binding m arking the baseline 0% . All other 
data are plot ted relat ive to 1: 7. Stat ist ical significance was tested with a one 
way ANOVA with Bonferroni post  t est  analysis ( * ,= p< 0.05, * * = p< 0.01, 
* * * = p< 0.0001, * * * * =  p< 0.0001)  
 
Figure 6.13 shows the ELISA testing of the kappa library panning 
clones. The positive control 1:7 in this assay showed a significantly 
higher binding to the wild type E2 than to the panning target D535A, 
though binding to D535A was still much higher than the non-specific 
binding observed by the negative wells. Inter-assay variability was thus 
taken to be a large factor in the difference in  binding pattern observed 
by the 1:7 control clone in Figure 6.13 and Figure 6.12. However, looking 
at the test clones from the kappa group, an increased level of binding to 
the target E2 protein can be seen over the wild-type E2 protein, 
indicating preferential binding for a majority of the clones tested. A high 
degree of variability can be seen in these data by the large error bars 
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although binding to both E2 proteins was consistently greater than to 
the negative wells with some tests reaching statistical significance. 
Taken together, no kappa clones analysed were discounted from being 
possible candidates for specific reactivity in the IgG format. 
 
Figure 6 .1 3  React ivit y of selected phage kappa clones to E2  w ild- type 
prote in or  D5 3 5 A target  prote in in ELI SA. 
Data calculated and plot ted relat ive 1: 7 as in Figure 6.12. 
 
6 .2 .8 . Selected clones show  preferent ia l binding at  
acidic pH in ELI SA 
Section 6.2.7 showed that the selected phage from both library pannings 
contained significant reactivity to the E2 molecule; wild type for 4 of the 
lambda clones and/ or the D535A target used in the biopanning process 
for kappa 2 of the clones. Binding in  acid or neutral pH was compared 
in order to clarify how much of this mixed reactivity was dependent on 
the acidic environment. Firstly, the binding of the mixed population 
phage panning eluates were tested. Figure 6.14 shows the lambda 
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library eluates with a preferential binding to the target E2 D535A in 
neutral pH over acidic with significance for pan group A4, whereas the 
panning eluates from the kappa library panning showed a preferential 
binding to the target protein in acidic pH for both eluates tested, also 
significantly for the second pan group tested (see Figure 6.14). However, 
a mixed population could mask the binding activity of the minority of 
preferred clones and so the final clones from each library panning 
experiment were also tested for acid-dependent binding. 
 
Figure 6 .1 4  React ivit y of the fina l tw o panning e luates to the target  
prote in D5 3 5 A E2  in acidic and neut ral binding environm ent  for the 
lam bda ( A)  and kappa ( B)  library. 
For each panning eluate, binding in acidic condit ions as per the panning process 
was set  at  100% . Stat ist ical test ing with one way ANOVA ( * = p< 0.05)  
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Figure 6.15 shows the relative binding of the final clones from each 
library panning to the target D535A E2 protein in acidic pH 5.5 as used 
in the biopanning set up (set as 100% for each clone), compared to 
neutral pH 7.5 or non-specific binding to blocked ELISA wells. The 
lambda clones showed consistently preferred binding to E2 in an acidic 
environment of pH 5.5 although the high variability of the data limits 
the scope of this effect. The kappa library clones also showed variability 
in binding though a preferential binding to acidic E2 could be 
determined for a a majority of the panel. Taken together, though low 
reactivity and high variability clouded a pattern in binding of the phage-
expressed Fab clones to D535A E2 in the different pH environments, 
there was still evidence of preferential binding at acidic pH. This 
therefore indicated that the biopanning set up adopted in this project 
enabled enrichment of Fab clones with improved binding at acidic pH. 
Time permitting, subcloning of these clones into expression vectors to 
be produced in an IgG format for further testing would be a great 
addition to the validation of this project. 
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Figure 6 .1 5  React ivity of selected phage clones to the target  E2  
prote in D5 3 5 A in acidic condit ion or neut ra l pH: 
A- lam bda library clones and B-kappa library clones, where acidic binding 
represents 100%  for each clone. Stat ist ical test ing was perform ed with one 
way ANOVA ( * = p< 0.05, * * = p< 0.01) .  
 
6 .2 .9 . Sequence analysis of the selected paratopes 
Sequence analysis can be used to verify the diversity of a given phage 
display antibody pool or as a means of selection (Spear, Breakfield et al. 
2001; Wang, Zhang et al. 2004; Ballard, Holm et al. 2006; Cheng, Zhou 
et al. 2009). As the libraries had previously been panned using another 
form of the E2 target protein (Allander 2000), the sequences derived 
here and previously were compared in Table 6.4. Likewise, given that 
A 
B 
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the aim of the  protocol used in this project was to isolate Fab clones 
with preferential binding in the acidic environment, a greater degree of 
hydrophobicity in the paratope could be expected and parameters of 
hydrophobicity were therefore described (see Table 6.3). Unlike the 
germline encoded and cross reactive 1st and 2nd complementarity region 
(CDR), CDR3 is considered to be the key determinent of specificity in 
the B cell receptor and therefore antibody derived antigen recognition. 
In fact the CDR3 of the variable heavy chain is sufficient to allow 
otherwise identical IgM molecules to identify one antigen from another 
(Xu and Davis 2000). Analysis of the sequences of the CDR3 of a 
sample of the selected clones and those previously identified (Allander 
2000) showed no immediate difference in  isoelectric points or net 
charge at pH 7  was observed as the ranges of the parameters 
overlapped for all clones. 
 
Table 6 .3  Hydrophobicity param eters for  a  select ion of phage clones. 
Clones Kappa 11-18, & 3, and Lam bda 4, 12 were isolated from  the current  
project  whereas L1, 1: 7 and A8 are clones previously isolated and descr ibed by 
(Allander 2000) . 
 
 
Fab heavy 
CDR3  
I soelect r ic 
point  ( pH)  
Net  charge 
at  pH 7  
Kappa 1 1 - 1 8  3.1 -1 
Kappa 3  9.43 1 
Lam bda 4 , 1 2  7.65 0.1 
L1  4.26 -1 
1 :7  7.65 0.1 
A8  3.88 -1 
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       Table 6 .4  Sequence com plem entar ity of clones der ived from  phage display panning of lam bda and kappa libraries. 
Fab clone CDR3  sequence Proport ion 
hydrophobic 
residues Light  chain  Heavy chain 
Lam bda I ncorrect  
clones 
P QSFDSNNLV  -   
Q NSRDTSGNNNYV DGPEENMLI PAAIRYYFDS 
W QSYDISLSGNV DGPEENMLI PAAIRYYFDS 
New 
panning 
4 QSYDRNFGGWV VVIPNAIRHTMGYYFDY 0.53 
7 QSYDRNFGGWV  -   
12 QSYDRNFGGWV VVIPNAIRHTMGYYFDY 
14 QSYDRNFGGWV  -   
15  -  DASMWFAP 
Kappa Allander 
2000 
L1 QQYGSPPYT EVLFGSIKGRYYLEN 0.38 
A8 QQSYTTPRT SPIKMVQGMMLDAFDI  
1: 7 QQRSDWVT VVIPNAIRHTMGYYFDY 
1: 11 QQYGSSPRT KDPPRFCSGGNCYPGFFQQ 
L3 QHYSTWPLT TEGSPFGSIKGRYLEN 
A12 QQYGTPRT MPYPKHCSRGSCWGWFDP 
1: 5 QLYGNSRWT RDPPRYCSAGRCYPGF 
New 
panning 
3 HHYVSSSRT VRVGRLLVRGYYDYFMDV 0.47 
11 QQYFASPRT ATGWMLDS 
13 QQYFASPRT ATGWMLDS 
18 QQYFASPRT ATGWMLDS 
205 
 
Sequencing of the phagemid clones showed a low level of diversity (see 
Table 6.4). Dominant clones were seen among the kappa and lambda 
sequences, alongside some clones for which full sequences proved 
difficult to attain. This may be due to the quality of the samples, loss of 
primer binding sites or sub-optimal amplification parameters for the 
type of sample used (e.g. bacterial culture or colony, or  purified DNA). 
Table 6.4 shows the proportion of hydrophobic residues present in  the 
heavy chain CDR3 sequence among the different sequences presented. 
For the newly panned groups this variable is close to or above 0 .5 
meaning there is an average of 50% hydrophobic residues in these 
sequences. Among the heavy chain CDR3 sequences from the previously 
panned group, this rate drops to 0 .38 which indicates that  less than 
40% of these sequences are hydrophobic residues. It is possible that 
whilst the hydrophobicity of the selected CDR3 regions may not differ 
from the sequences derived without using acidic conditions, the 
propensity to have hydrophobic residues in  the CDR3 regions in  the 
newly selected clones may be an effect of panning in acidic conditions. 
However, hydrophobic residues have been shown to be pivotal for the 
binding affinity and structural integrity of antibody paratopes where 
tyrosine plays a unique role in antigen recognition (Fellouse 2006). 
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6 .3 . Discussion 
One of the conditions used in the biopanning protocol adopted in this 
project involved a prolonged incubation of Fab-expressing phage and 
E2 protein in an acidic pH. In section 5.2.1, it was shown that the HCV-
fusion pH of 5.5 did not destabilise the E2 protein. However, the phage 
particle and the expressed Fab were also exposed to acidity and so 
equally at risk of acid-induced effects. Analysis of a group of structural 
environmental bacteriophage (actinophage) showed that in acidic 
habitats, a minimum of phage could be isolated from conditions below 
pH 6, whereas the same host species and phage from neutral pH 
environments contained high levels of natural phage (Sykes and 
Williams 1981). A more detailed analysis, however, showed that 
infectivity and adsorption were not hindered at acidic pH but that it was 
replication that was greatly reduced. Whilst there is a modest amount of 
literature detailing the activity and stability of phage proteins/ enzymes 
at various pH levels, there is a limited emphasis on the stability/ life 
cycle of the phage particle. The exposure of the phage particle to acidic 
pH in this project thus relies on the ability of the phage to remain 
infective following acidic incubation. Table 6.1 shows no difference in  
phage titer derived from infecting bacteria following incubation at acidic 
or neutral pH, and thus the phage in this project were not deemed 
functionally compromised by the conditions used. 
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Another possible consequence of this biopanning set up was acid-
induced effects on the surface-expressed Fab molecule. Section 5 
showed acid-related effects in antibody-antigen binding and so from 
this data, such effects could equally be present in the panning process. 
Indeed, full human monoclonal antibodies have previously shown 
improved antigen binding ability at acidic pH, sometimes despite there 
being almost no binding activity observed at neutral pH (Kumar and 
Saxena 1992; Raghavan, Bonagura et al. 1995; Lopez, Trevani et al. 
1999).  Analysing the stability and function of human IgG showed that 
an exposure to pH 4 or lower for more than 24 hours was necessary for 
any effects to occur (Castle, Karp et al. 2002). The Fab molecule, 
however, is likely to be less stable than a full IgG molecule. The fusion-
active Fab identified to neutralise West Nile Virus (Thompson 2009) 
was shown to be functionally indifferent to the pH it was exposed to, 
thus supporting the notion that the acidic conditions imposed in  the 
biopanning procedure in this project would not hinder the ability of the 
phage-expressed Fab to bind to the antigen. 
 
Initial screening of the phage clones was performed using bacterial cell 
lysates as described elsewhere (Barbas and Wagner 1995). This 
approach, however, did not distinguish clones that contained deletions 
as illustrated in  Table 6.2/ Figure 6.5. A PCR-based screening of the 
library and/ or the clones derived has been used elsewhere either to 
verify the quality of the enrichment after the biopanning process or to 
screen clones based on gene size before testing for specificity (Spear, 
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Breakfield et al. 2001; Gnanasekar, Rao et al. 2004; Wang, Zhang et al. 
2004; Ballard, Holm et al. 2006; Cheng, Zhou et al. 2009). Therefore, 
the same approach was adopted here to assess phage clones containing 
the correct sized genes before testing reactivity. Figure 6.8, Figure 6.9 
and Figure 6.10  together show that enrichment of clones containing the 
correct sized inserts occurred between the initial libraries and the final 
panning groups analysed. The proportion of correct clones found in  
both libraries was low, however enrichment was observed for both 
panning experiments. The maximum proportion of correct clones after 
panning was estimated to be up to 70%. Ideally, the final proportion 
would be above 90% and so the panning experiments performed could 
be deemed suboptimal. Factors affecting this low rate could include the 
low proportion in the original library and low stringency during the 
panning process. The proportion of correct clones in the starting library 
is a product of the efficiency of the sub-cloning performed in  the 
creation of the library and so can be highly variable. Likewise, the 
stringency adopted during the panning process is a product of human 
input and cannot easily be assessed in a quantifiable manner, especially 
as we were applying a novel panning protocol (acidic condition). Taken 
together, the biopanning experiments analysed here showed enrichment 
and selection of specific clones, though in future, the biopanning 
protocol used in this project could benefit from optimisation.  
 
Sequence analysis of the final clones showed repeated CDR3 sequences 
indicating related clones originating from the same B cell. Differences in  
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the binding behaviour could therefore be attributed to elements outside 
of the region analysed such as the framework sequences. These 
differences, such as in the form of mutations, may exert changes in  
binding behaviour of the Fab molecule due to differences in the global 
structure of the molecule. However, true differences in  the binding 
pattern of the clones analysed in this project could be better determined 
in the format of IgG molecules and testing in vitro binding or 
neutralisation in cell culture. A vector for the expression of human IgG 
in mammalian cells that could be used is the pDCOrig huIgI1 (Scancell 
Ltd, Nottingham, UK). For this, subcloning of the individual heavy and 
light chains currently in the pCOMB 3H vector into pDCOrig vector is 
followed by transfection of a mammalian cell line whereupon transient 
expression of the whole IgG molecule can occur. Such data would be 
able to provide validation of the method used in  this study and indeed 
further work is aimed at achieving this. 
 
The final clones analysed from both libraries were panned in an acidic 
environment.  A total of 9 clones out of 17 analysed showed specific 
reactivity to E2, 1 of which also showed preferential binding at pH 5.5 
(see Figure 6.12, Figure 6.13 & Figure 6.15). Comparison of binding to 
the E2 target protein D535A and the wild type E2 protein revealed that 
of the 9 clones that showed specific reactivity to E2, 8  had preferential 
binding to the wild type E2 rather than the D535A E2 which was used as 
the target molecule during selection. This data was not the expected 
outcome; however the data do not discount the preferential binding to 
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either E2 protein by the Fab clones over background non-specific 
binding. The single clone that did show specific reactivity to E2 with 
higher binding to D535A and in acidic conditions was however a novel 
sequence and so, the method used in this project successfully allowed 
isolation of a novel fab clone with desired characteristics. Only further 
experimentation in the IgG format will reveal if these qualities are 
upheld in the full antibody form. 
 
Analysis of the paratope sequence (see Table 6.4) and hydrophobicity 
(Table 6.3) did not show any particular differences between the selected 
clones and the previously isolated antibodies from the same kappa 
library panned (Allander 2000). The likely effect of the panning 
protocol adopted here would be to select for paratopes with an 
increased proportion of hydrophobic residues to interact with the 
cryptic epitopes on E2 likely to become unshielded upon acidification. 
Indeed, cryptic epitopes as seen in HIV and related viruses are often 
hydrophobic in nature (Oss 1995) or have a greater tendency to contain 
hydrophobic residues (David, Borza et al. 2001). Whilst a hydrophobic 
epitope will bind more strongly to a hydrophobic paratope, an 
interaction with a non-hydrophobic paratope would be 2-3 times 
weaker, which is still a functionally important interaction (Oss 1995). In 
the absence of a hydrophobic paratope being able to interact with its 
epitope, it is conceivable that the paratope would be likely to form a 
weak non-specific interaction to evade the aqueous hydrophilic 
environment. This model could partly explain the relatively low specific 
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binding by the phage clones as a product of higher non-specific binding 
seen in Figure 6.11-Figure 6.14. As this project is the first phage display 
set up to pan specifically in an acidic environment for the selection of 
acid-dependent Fab clones, it is therefore not possible to easily gauge 
the realistic impact of the specific and non-specific binding affinity of 
selected clones as affected by the pH environment.  
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7 . Fina l discussion 
 
In just over two decades HCV has been isolated, sequenced, cultured 
and investigated in a multitude of ways. Despite these efforts however, 
an effective vaccine still evades us and the virus continues to triumph 
over the natural immune response. Many antibodies that target HCV E2 
have been isolated over the last decade, almost all of which target 
epitopes overlapping with CD81 binding sites. In the early part of this 
project a panel of soluble E2 constructs were produced in S2 cells. 
Characterisation of these proteins revealed expected sizes for this cell 
line although glycosylation was variable and not complete compared to 
E2 expressed elsewhere in mammalian cells (Dubuisson, Hsu et al. 
1994; Fournillier, Wychowski et al. 2001; Op de Beeck, Cocquerel et al. 
2001; Slater-Handshy, Droll et al. 2004; Liu, Chen et al. 2007; 
McCaffrey, Boo et al. 2007). High five and sf9 are two insect cell lines 
that have been used extensively for the production of several eukaryotic 
proteins successfully and so could be used for the expression of HCV E2 
protein (Li, Brown et al. 2001; Morias and Costa 2003; Andronopoulou, 
Labropoulou et al. 2006; Douris, Swevers et al. 2006; Munster, 
Ziegelmuller et al. 2006). Like S2 cells, culturing of this cell line is 
significantly less time consuming, labour expensive, allows greater 
yields of highly pure protein and uses cheaper reagents than 
mammalian cell culture for protein production. As insect derived cell 
lines, the same issues of glycosylation observed in this project with S2 
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cells will likely also apply to sf9 and high five cell lines. Therefore, 
testing the expressed E2 protein from these cell lines would allow 
evaluation of whether these cell lines are appropriate to use for the 
production of functionally competent or structurally intact, soluble, 
secreted HCV E2 protein as a replacement or improvement to S2 cells. 
Previously, production of HCV E2 in insect cells relied on the 
baculovirus system which was not able to overcome the need to lyse 
cells to extract the proteins (Lanford, Notvall et al. 1993; Zhao, Liao et 
al. 2003). Using this system however it was observed that there could be 
variation in the glycosylation status of the envelope proteins thus 
producing variable molecular weight proteins as seen in this project 
(Lanford, Notvall et al. 1993). Otherwise Zhaos group was able to 
produce the mammalian standard sized 66 kDa soluble E2 protein in 
insect cells (Zhao, Liao et al. 2003) thus confirming that it is possible to 
produce HCV E2 as seen in mammalian cells. Taken together, 
advancements in  expression vectors and cell culture techniques might 
eventually allow for stable, inducible expression of HCV E2 in insect 
cells conferring the practical advantages seen so far, matched to the 
protein characteristics observed when expressed in mammalian cells 
and ultimately in vivo. For now however, the S2 cell line allows 
production of soluble HCV E2 protein of an acceptable standard for 
basic experimentation and interpretation. 
 
S2 expressed soluble HCV E2 protein was purified and characterised in  
section 3 and 4. Antibodies targeting epitopes with conformational 
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determinants were used in ELISA and Western blot assays to assess the 
structural integrity of the purified E2 protein. SDS-PAGE analysis was 
also used to verify size and stability. The glycosylation status of the E2 
protein was seen to vary though the overall size of all E2 constructs 
produced was deemed satisfactory (section 3.2.5). Assessment of the 
conformational state of the HVR deleted E2 constructs was confirmed 
with CD81 binding as CD81 has a conformational binding domain on E2 
spanning 4 discrete regions (Owsianka, Timms et al. 2006; Rothwangl, 
Manicassamy et al. 2008). Due to the nature of D535A and G530A 
being key CD81 binding determinants (Owsianka, Timms et al. 2006), 
binding to the conformational antibody H53, which cannot recognise E2 
of genotype 2 (in which the HVR deletion panel was created) but can 
recognise genotype 1 (Cocquerel, Meunier et al. 1998), was used instead. 
Only the double mutant G530A-D535A lost conformation (see Figure 
4.7) thus excluding it as a candidate target protein for biopanning. 
Ideally, more extensive characterisation would be performed in this 
analysis, such as a greater array of assays or a wider choice of antibodies 
to further support the conclusion that these E2 constructs retained 
conformational structure. The literature has shown that both HVR 
deleted E2 along with G530A and D535A E2 does not retain  consistent 
binding and entry capabilities in cell culture or pseudo particle assays 
(Owsianka, Timms et al. 2006; McCaffrey, Gouklani et al. 2011) thus 
hampering the choice of assays applicable. Two such assays that would 
allow a more accurate interpretation however would be the use of 
Isothermal Titration Calorimetry (ITC) (O'Brien, Ladbury et al. 2000), 
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and Surface Plasmon Resonance Immunoassay (SPRI) (Liedberg, 
Nylander et al. 1983; Rich and Myszka 2007). Using these assays, the 
binding parameters between E2 and a test antibody can be accurately 
analysed. Thus comparison between binding efficiency of each E2-
antibody pair can be made. The choice of conformational antibodies for 
these analyses could also be greater, such as the use of the inclusion of 
the CBH antibodies: some of which are CD81 independent (Hadlock, 
Lanford et al. 2000). Likewise, the epitope analysis performed in  
section 4.2.2 and 4.2.3 could be extended by comparing the same 
deletions/ mutations in multiple genotypes. Indeed, it has been shown 
certain characteristics of HCV differ among the various genotypes 
(Lavillette, Tarr et al. 2005) and so exploring these differences further 
to better understand the structural consequences in such a genetically 
diverse virus would still be valuable in determining the universal 
characteristics of HCV. 
 
Section 5 looked at the effects of pH environment on HCV E2-antibody 
binding. The E2 protein tested was seen to remain stable in the acidic 
conditions known to occur during the entry process (see section 5.2.1). 
Looking more closely at the transiency of these epitope effects in E2, it 
was hard to form a definitive interpretation. A non-significant portion 
of acid-induced binding effects appeared to be retained after 
neutralisation of E2 when looking at the antibody targeting the strep-
tag, whereas a significant effect in antibody binding was observed in the 
presence of pH 5.5 for this antibody and H53 (section 5.2.2). Inability to 
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differentiate how much of the acid-induced conformational effect on E2 
is permanent or transient led to the choice to analyse epitope binding in  
the presence of acidic pH along with the design of a panning group in 
section 6 where the interaction between E2 and Fab expressing phage 
was in  the presence of acid pH 5.5. Given the limited data available on 
the extent of pH induced conformational effects on HCV glycoproteins 
and their duration, a valuable preliminary investigation was initiated 
here that with further work could go towards defining in  further detail 
the events of entry and fusion for E2 from a structural biology 
perspective. The data gathered in  section 5.2.2 would have greatly 
benefited from expansion to include the full pH and antibody range 
available when looking at the transiency of conformational E2 effects. 
Also, more antibodies available targeting epitopes of a conformational 
nature, neutralising preferably though not necessarily CD81 binding site 
located, would have improved the possible interpretation. As previously 
mentioned, the panel of CBH antibodies from the Foung lab would have 
been applicable (Hadlock, Lanford et al. 2000). The use of ITC or SPRI 
could also be applied to the analysis of pH induced conformational 
effects on E2. Using pH as a constant or variable in each E2-antibody 
pair, it would be possible to more accurately analyse the effect of pre-
acidified then neutralised E2 (thus permanent effects only), as well as 
binding in the presence of various acidic pH levels. Another valuable 
extension of this work would be to compare these data across genotypic 
groups. It has already been shown that there are subtle differences in 
pH dependency during entry across different genotypic groups 
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(Lavillette, Tarr et al. 2005), and so there is potential for more 
pronounced differences in the binding behaviour of E2 across the pH 
range. Such differences may be variances in the threshold of sensitivity 
to pH or the extent of the binding kinetic effects observed. 
 
Biopanning of a combinatorial phage display library in the pComb3H 
vector was described in section 6. During this process, difficulties in  
attaining high titers, efficient screening of the selected clones, as well as 
testing of these clones was seen. Assessment of the library pre-panning 
showed a low proportion of intact phagemid clones though this did not 
prevent earlier use of the library to successfully isolate novel 
neutralising antibodies (Allander 2000 ; J ohansson, Voisset et al. 2007) 
(section 6.2.4). Screening methodologies were developed leading to a 
final pool of potential clones (see section 6.2.3 to 6.2.5). Higher titres of 
purified phage would have allowed more flexibility in the analysis of the 
test clones derived such as titration assays for binding affinities. Issues 
also arose in the sequencing of these clones limiting the interpretation 
of the diversity of the final panel analysed. Unlike the previous sections, 
in which affinity was the characteristic that would have benefitted from 
more accurate experimental assessment, in this final section, 
determining the specificity of each fab clone to the target E2 protein was 
equally hard to clearly define. Relatively small differences were 
observed in binding of the fab clones to the D535A E2 construct used as 
the target in biopanning compared to the wild type protein and non-
specific binding. Comparison of the acidic environment as in  the 
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panning for fab-E2 binding also did not show great differences to 
binding in neutral pH with only 2 out of 17 clones showing significant 
preferential binding in acidic conditions. The biopanning method 
employed in this project would have benefitted from more panning 
groups to better compare the selection of clones derived from various 
conditions. The advantage to that would be the ability to discriminate 
fab clones that can be isolated from binding in acidic and neutral 
binding conditions or clones that are only isolated in acidic conditions 
for example. Subtractive selection like this has been used elsewhere to 
define clones according to sequence or selective characteristics 
(Gnanasekar, Rao et al. 2004; Hof, Cheung et al. 2006). A subtractive 
selection panning group for this biopanning project could adopt an 
exhaustive set up as effectively demonstrated by Giang and his group. 
This could be panning enrichment/ selection with an acidic pH 5.5, 
followed by selection at neutral pH in which the unbound phage is 
retained and reused for a further selection at acidic pH. The reversal of 
pH conditions, could also be performed i.e., selection at neutral pH 
followed by selection at pH 5.5 where unbound phage is retained to use 
in one more selection event once more at neutral pH. The first group 
containing fab clones that can only bind E2 in a pH 5.5 environment, 
and the second group containing fab clones that can only bind E2 in 
neutral pH conditions would then theoretically contain two distinct 
pools of fab clones that could be verified by sequence analysis. 
Alternatively, fab clones that are able to bind their target at neutral and 
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acidic pH may be the desired product and thus alternate selection 
conditions could be used in the same panning group. 
 
Research aimed at finding novel, broadly neutralising antibodies to 
HIV, influenza virus, flaviviruses, and other viruses has not only 
produced useful antibodies but also made novel methodologies available 
for producing novel HCV antibodies. The project described in  this 
dissertation and other projects that produced the main anti-HCV 
broadly neutralising antibodies used phage display to isolate the desired 
antibodies. Recent research on antibodies targeting influenza virus used 
phage display followed by cell-based screening to find the C05 antibody, 
which has an epitope on the stem of the crucial viral Haemaglutinin 
envelope protein. The C05 antibody neutralises several virus groups, 
protecting mice from viral challenge (Ekiert, Kashyap et al. 2012). 
 
RT-PCR using single-plasma-cell extracts and plasma-cell monoculture 
methods were recently used to isolate novel influenza-neutralising 
antibodies (Corti, Voss et al. 2011; Whittle, Zhang et al. 2011). Advances 
in phage-display technologies in the 1990s led to an explosion of 
research aimed at identifying novel antibodies. Recent growth in 
techniques based on flow cytometry and cell sorting allowed antibody-
producing cells to be systematically isolated. Corti (2011) used cell 
sorting to isolate more than 10 5 plasma cells in single-cell cultures, 
which they subsequently screened for desired antibodies (Corti, Voss et 
al. 2011), identifying the F16 antibody several times in the same donor. 
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The F16 antibody recognises a conserved epitope and neutralises 
multiple virus groups by blocking the conformational changes necessary 
for viral envelope fusion with the cellular membrane. 
 
HIV research has also benefited from recent methodological advances. 
Walker (2009) screened 1800 donors using a novel, single-B-cell 
microneutralisation method and isolated two novel antibodies with 
quaternery structure-dependant conformational epitopes. The 
neutralising antibodies were about an order of magnitude more potent 
than other known HIV antibodies and had the same or greater target 
breadth. Wu (2010) used cell sorting and RT-PCR, along with cell 
staining and cell-based, single-B-cell capture-screen isolation of 
antibody-producing cells, to identify novel, broadly neutralising HIV 
antibodies. They used a resurfaced viral glycoprotein (gp120) to isolate 
memory B cells specific for the host CD4-binding site. They then used 
the isolated B cells to identify the VRC01 antibody, a highly potent 
antibody that neutralised more than 90% of the HIV isolates tested. 
Another novel approach to HIV research using an alternative sorting 
strategy based on capturing single B cells that recognise the viral Env 
protein expressed on the surface of transfected cells (Klein, Gaebler et 
al. 2012) identified a novel epitope that is not displayed on the soluble 
form of the Env protein. 
 
The continuing methodological advances for isolating and screening 
antibody-producing cells have proven fruitful for HIV and influenza 
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research. The same advances can be used to expand the available pool of 
broadly neutralising anti-HCV antibodies. For now, phage display is the 
most productive method used in HCV research and will likely continue 
to be productive as our understanding of the virus grows. The choice of 
methodology will always depend on the properties of the virus that we 
wish to manipulate, however; so the broader research on HCV host-cell 
entry and infectivity, which is currently far behind the research on HIV 
and influenza host-cell entry and infectivity, remains crucial to our 
efforts to identify novel, broadly neutralising anti-HCV antibodies. 
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8 . Fina l conclusions 
 
This project aimed to isolate novel antibodies targeting HCV E2 non-
CD81 epitopes that would retain binding ability during entry and fusion. 
Characterisation of various E2 constructs revealed novel aspects of E2 
epitope exposure and binding following targeted deletion/ mutation 
such that HVR2 is the most influential HVR in improving exposure of 
the CD81 binding domain. Also HCV E2 is able to maintain stable 
conformation with G530 or D535 mutated but not both together. A brief 
analysis of epitope exposure in varying pH environments also revealed 
potential for genotype and epitope specific conformational changes in  
response to acidic environment. Fusion binding antibodies have been 
isolated for viruses other than HCV as discussed earlier providing proof 
of principle that such a model of an antibody for HCV can be achieved. 
Equally, antibodies to non-CD81 epitopes have recently been isolated by 
multiple groups also using tailored phage display methodologies. The 
same target E2 construct D535A as used here successfully generated 
non CD81 binding epitopes thereby supporting the notion of such 
antibodies to be found (Keck, Xia et al. 2012). Also recently, the use of 
competitive inhibition of the target molecule (E1E2) to occlude sites of 
known epitopes has been used to isolate novel antibodies binding to 
“new” areas of the envelope protein (Giang, Dorner et al. 2012). Like 
these recent studies, this project has used a phage display approach, 
with the same phagemid vector, using a defined set of conditions to 
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select for specific qualities of the Fab clone isolated to encourage 
functional ability in the full antibody format for effectivity during the 
entry process of HCV, Fab clones isolated in this project showed initial 
promise for preferential binding to the D535A E2 construct, along with 
clones showing enhanced binding in acidic conditions. Only one of the 
isolated Fab clones however significantly showed both characteristics. 
Taken together, the biopanning setup used here, can potentially allow 
isolation of antibodies targeting epitopes on HCV E2, optimally exposed 
during the entry process. 
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